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Abstract
Epstein-Barr virus (EBV) specific T cells control EBV-driven proliferation o f infected 
B cells in vivo. Deficient EBV immunity predisposes to post-transplant 
lymphoproliferative disease (PTLD) and EBV-positive Hodgkin’s disease (HD). 
Treatment for PTLD is reduction in immunosuppression (RIS) allowing EBV immune 
recovery. Current methods o f monitoring RIS include immunophenotyping for 
increases in MHC Class II CD8 T cells, but this is not a specific measure o f EBV 
immunity. A method was developed for enumerating functional EBV-specific T cells 
using an intracellular cytokine staining (ICS) assay to measure interferon-y (IFN-y) 
production after brief in vitro stimulation with EBV antigens.
Analysis o f EBV-positive PTLD patients showed a temporal relationship between 
emergence o f EBV-specific IFN-y'CD8^ T cells and PTLD regression in response to 
RIS. The increase paralleled the rise in MHC class I IC D 8 4 T cells. Analysis of 
tum our infiltrating lymphocytes (TILs) from EBV-positive HD patients showed 
presence o f EBV-specific IFN-y+CD4^ and IFN-y4CD8+ T cells. Although this result 
indicates EBV-positive HD is not a consequence o f deficient EBV immunity, the 
observed accumulation o f CD4+ T cells may represent immune suppressive cells.
The ICS assay was demonstrated as a rapid and reliable method for detecting 
functional EBV immunity, but requirement for several million PBMCs can limit 
utility. Quantitative RT-PCR (qRT-PCR) was used to measure IFN-y gene 
transcription by T cells stimulated with EBV antigen and showed comparable results 
to ICS using fewer cells.
Clinical assessment o f EBV status o f tumours is hampered by lack o f a single 
monoclonal antibody able to detect all EBV antigens. A novel monoclonal antibody, 
RFD3, was used to stain EBV-positive tissue and detected all forms o f EBV latency. 
Results correlated with current diagnostic techniques..
In summary, this thesis describes development and evaluation o f novel approaches for 
detecting EBV and measuring EBV-specific T cell immunity that have potential for 
clinical and research applications.
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Introduction
1.1 Epstein-Barr virus
Epstein-Barr virus (EBV; HHV-4) is a member of the ancient and highly successful 
y herpes virus family and is ubiquitous amongst the adult population worldwide. The 
virus probably evolved from a nonhuman-primate virus as EBV shares sequences and 
a genetic organization similar to the EBV-like virus o f the rhesus monkey and both 
viruses maintain persistent infection in the oropharynx and B cells (Moghaddam et 
al., 1997). Through millions o f years o f co-evolving with its human host, EBV has 
developed supreme survival strategies to establish a cycle o f lifelong latent infection 
o f memory B lymphocytes with intermittent reactivation and productive (lytic) 
phases, to ensure spread to other susceptible hosts. This process ordinarily has little 
impact on the health o f the majority o f the infected population, however the latent 
genes of EBV have oncogenic potential as shown by their ability to immortalise B 
lymphocytes (Pope et al., 1968).
EBV was originally discovered in a B cell line cultured from Burkitt’s lymphoma 
cells (Epstein et al., 1964), and is now known to be present in greater than 95% of all 
African Burkitt’s lymphomas (Magrath, 1990). Subsequent studies have shown that 
EBV is also associated with a variety o f other human tumours including Hodgkin’s 
disease (HD) (Weiss et al., 1989), post transplant lymphoproliferative disease (PTLD) 
(Crawford et al., 1980), nasal T/ natural killer (NK) cell lymphoma (Jones et al., 
1988; Kanavaros et al., 1993; Tsuchiyama et al., 1998), leiomyosarcoma in 
immunocompromised patients (McClain et al., 1995) and epithelial cancers such as 
nasopharyngeal carcinoma (zur Hausen et al., 1970) and gastric carcinoma (Rowlands 
et al., 1993; Shibata and Weiss, 1992).
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All o f these tumours are characterised by the presence o f extrachromosomal copies o f 
the circular viral genome in the cancer cells and the expression o f the EBV-encoded 
latent genes, which appear to contribute to the malignant phenotype (Rickinson and 
Kieff, 2001).
1.1.1 The molecular Biology of EBV
The EBV genome was the first o f the herpes viruses to be completely cloned and 
sequenced (Baer et al., 1984) and is composed o f linear double-stranded 
deoxyribonucleic acid (DNA) o f approximately 172 kilobase pairs (kb) in length. The 
genome exists in linear form in viral particles, however, after infection o f B cells, the 
virus circularises and persists as an episome in the nucleus (Figure 1.1), thereby 
establishing a latent infection. Periodically, the virus reactivates, switching to a lytic 
cycle where it can proliferate and release new viral particles. Latently infected B cells 
express a range o f EBV-encoded proteins consisting o f the EBV nuclear antigens, 
EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-LP and the latent 
membrane proteins LMP1, LMP2A and LMP2B. The pattern o f expression o f these 
latent proteins differs between normal and malignant B cells and is associated with 
different types o f EBV-malignancies (as discussed later). In addition to the latent 
proteins, two types o f EBV-encoded non-translated ribonucleic acid (RNA) are also 
transcribed in latency; EBV-encoded RNAs (EBERs) and BamHIA  rightward 
transcripts (BARTs). Each o f these products o f EBV infection are intrinsically 
associated with oncogenesis by interacting with, or exhibiting homology with, a 
variety o f anti-apoptotic molecules, cytokines and signal transducers and are further 
described below and in Table 1.1.
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Figure 1.1: The Epstein-Barr virus genome
Viral replication proceeds from the origin of plasmid replication (oriP) in a clockwise direction. The 
black arrows indicate the position of the coding exons for each of the latent proteins; the six nuclear 
antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and the three latent membrane proteins (LMPs 
1, 2A, 2B). EBNA-LP is transcribed from variable numbers of repetitive exons. LMP2A and LMP2B 
are composed of multiple exons located either side of the terminal repeat (TR) region, which is formed 
during the circularisation of the linear DNA to produce the viral episome. The outer red clockwise 
arrow represents EBV transcription during a form of latency known as latency III where all the EBNAs 
are transcribed from either the Cp or Wp promoter. The inner blue clockwise arrow represents 
transcription of EBNA1 which originates from the Qp promoter during latency I and II.
Figure adapted from (Young and Murray, 2003).
EBNA1: EBNA1 is vital to the maintenance and replication of the episomal EBV 
genome (Yates et al., 1985). It exerts its function by binding to the plasmid origin of 
viral replication (OriP, Figure 1.1) and is able to interact with viral promoters up-
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regulating transcription o f other EBNA proteins and LMP1. A series o f Gly-Ala 
repeats within its sequence interferes with antigen processing and major 
histocompatibility (MHC) class I-restricted presentation (Levitskaya et a l., 1995), and 
it was previously thought that EBV-infected cells that express EBNA1 alone were 
unable to be recognised by EBV-specific CD8' T cells. However a recent study has 
challenged this and shown that EBNA-1 is able to be presented to CDS' T cells via 
the MHC class I pathway but reactive cells produce interferon-y (IFN-y) rather than 
lytic activity (Lee et al., 2004)
EBNA2: EBNA2 is one o f the first viral proteins to be expressed after infection of B 
cells in vitro and is essential for cell immortalisation (Cohen et al., 1989). It is able to 
indirectly activate the transcription o f both cellular genes such as c-myc (a cellular 
proto-oncogene) and CD23 (a B cell surface activation antigen) as well as LMP1 and 
LMP2A (Zimber-Strobl and Strobl, 2001) by binding to transcription factors such as 
the viral Cp binding factor. EBNA2 has been shown to interact with other 
transcription factors involved in the Notch signalling pathway (Jic-recombination- 
binding protein, RBP-Jk (Grossman et al., 1994; Hsieh and Hayward, 1995)) which 
has been implicated in oncogenesis (reviewed by (Lefort and Dotto, 2004).
EBNA 3A, 3B and 3C: These gene products are all transcriptional regulators and also 
able to interact with Cp binding factor 1 involved in the notch signalling pathway. 
EBNA 3A and EBNA 3C are thought to be crucial in the transformation o f B cells in 
vitro, whereas EBNA 3B is not. EBNA 3C is thought to achieve this by disrupting the 
cell-cycle cell points mediated by the retinoblastoma (rb) tumour suppressor gene 
products (Parker et al., 1996).
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EBNA-LP: Together with EBNA2, this protein is also produced early after infection 
o f B cells. EBNA-LP interacts with HBNA2 and together bind and inactivate p53  and 
rb, forcing the resting B cells into the G1 phase o f the cell cycle (Szekely et al., 
1993). EBNA-LP also interacts with transcription factors involved in the notch 
signalling pathway.
LMP1: LMP1 is the main transforming protein o f EBV. It is able to exert its
oncogenic effects by acting as a functional homologue o f CD40, a receptor on 
germinal centre B cells. CD40 is also a member of the tumour necrosis factor receptor 
(TNFR) superfamily and activation via LMP1 or T helper cells results in the 
expression o f B-cell adhesion molecules, B cell activation markers (CD23, CD39, 
CD44 and MHC class II) (Wang et al., 1990) as well as the anti-apoptotic molecules 
bcl-2 and A20 (Laherty et al., 1992; Eliopoulos et al., 1997). LMP1 is therefore able 
to drive B cell proliferation and rescue B cells from apoptosis.
LMP2A and LMP2B: The LMP2 proteins are not essential for EBV transformation 
o f B cells, but are able to promote the latency o f the virus in B cells by modifying B 
cell development. LMP2A contains immunoglobulin tyrosine-based activation motifs 
(Alber et al., 1993) that are also present in the B cell co-receptors CD79A and 
CD79B. LMP2A is able to inhibit B cell receptor (BCR) signalling by binding and 
sequestering tyrosine kinases involved in signalling pathway (M iller et al., 1995). 
This then prevents unwanted antigen-induced activation o f EBV infected B cells that 
would cause reactivation and entry into the lytic cycle. LMP2A is able to transform 
epithelial cells in vitro (Scholle et al., 2000), and is implicated in the pathogenesis of 
NPC and gastric carcinoma.
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Table 1.1: Products of EBV during latent infection
(Adapted from (Thompson and Kurzrock, 2004).
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EBER1 and EBER 2: EBERs are thought to promote persistence o f the virus by 
inhibiting the anti-viral effects of IFNs by binding to the IFN-inducible, double 
stranded-RNA-dependant protein kinase, PKR (Takada and Nanbo, 2001; Nanbo et 
al., 2002). EBERs have also been implicated in the suppression o f EBV-specific 
cytotoxic T cells by increasing the secretion of IL-10 thus inhibiting the ThI 
response(Kitagawa et al., 2000; Ruf et al., 2000)
1.1.2 Patterns of EBV gene expression
EBV infected B cells in vivo express different patterns o f latent gene expression. 
Memory B cells obtained from healthy individuals express only EBER and LMP2 and 
possibly EBNA1, however the expression in patients with EBV-associated diseases 
varies and has been classified in to three latency programmes (Table 1.2). 
EBV-transformed B cells proliferating in vitro express latency programme III
(Rickinson and Kieff, 2001).
Latency
Programme
EBNA1 EBNA2 EBNA3 LMP1 LMP2 EBER Disease
Type I + - - - - + Burkitt’s lymphoma 
PTLD-BL type.
Type II + + + + NPC, HD, peripheral 
T-cell lymphoma, 
PTLD-HD type.
Type III + + + + + + PTLD-DLBC type, 
X-linked
lymphoproliferative 
disease, Infectious 
m ononucleosis
Type 0 +/- - - - +/- +/- Healthy individuals
Table 1.2: Expression of EBV latent genes in disease
+ -  positive expression, - = negative expression, +/- = possible expression, PTLD = post transplant 
lymphoproliferative disease, BL = Burkitt’s lymphoma, HD = Hodgkin’s disease, DLBC = Diffuse 
large B cell.
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1.1.3 EBV epidemiology
EBV is unable to cross the placenta and infects individuals from birth onwards, 
leading to a cumulative incidence o f over 90% of the world’s population. Infected 
individuals shed virus either intermittently or continuously into their saliva (Yao et 
al., 1985; Niederman et al., 1976) and primary infection typically occurs during early 
childhood from close contact between family members (Gratama et al., 1990; Fleisher 
et al., 1981). Primary infection in young children is usually a subclinical illness 
(Fleisher et al., 1979) and occurs at an early age in communities with poor standards 
o f hygiene (Biggar et al., 1978), however, in areas of higher standards o f living, 
primary infection is often delayed until early adulthood where it causes infectious 
mononucleosis (IM). Early studies showed that IM occurred in 50-74% of young 
adults (Hallee et al., 1974; Niederman et al., 1970; Sawyer et al., 1971), however, a 
recent prospective study amongst university students showed that IM developed in 
only 25% (Crawford et al., 2006).
It is widely assumed that primary infection in adolescence occurs through the saliva 
shared through kissing, however, the virus has been detected in both female (Sixbey 
et al., 1986) and male (Israele et al., 1991) genital secretions raising the possibility o f 
sexual transmission. In addition, correlations have been made between both EBV 
seropositivity and history o f IM, with high numbers o f sexual partners in university 
students (Crawford et al., 2002).
EBV can also be transmitted via blood and organ donation through the receipt of 
latently infected B lymphocytes (Alfieri et al., 1996; Cen et al., 1991). Seronegative
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organ recipients from a seropositive donor are estimated to have an 80% risk of 
primary EBV infection in the first year following transplant (Ho et al., 1988).
1.1.4 EBV infection of B cells
EBV is able to infect B cells through the interaction of the major viral envelope 
glycoprotein gp350 with the complement receptor CD21 on the surface o f B cells 
(Nemerow et al., 1985). Following this a second envelope glycoprotein, gp42 binds 
to MHC class II molecules (Li et al., 1997) and the virus is able to enter the cell.
In healthy individuals, EBV infected B cells are confined to the memory compartment 
however the precise route by which the virus accesses these cells remains 
controversial. Two mechanisms have been proposed (Figure 1.2). The first based on 
detailed analysis o f tonsillar B cells suggest that EBV predominantly infects the naive 
B cells and mimics the physiological process o f antigen-driven memory cell 
development in the germinal centres o f lymphoid tissues, detailed in Figure 1.3 
(Babcock et al., 2000; Babcock and Thorley-Lawson, 2000; Joseph et al., 2000). This 
model suggests that EBV switches on a growth programme causing newly infected 
naive B cells to proliferate and express all o f the latent viral genes. Proliferation is 
then terminated by EBV down-regulating viral expression to EBNA1, LMP1 and 
LMP2 (latency programme II). LMP1 and LMP2A ensure selection and survival of 
EBV-infected B cells in the germinal centres by functioning as a CD40 homologue 
(LMP1) and by mimicking BCR engagement (LMP2A). Infected B cells then 
differentiate into memory B cells and exit into the peripheral circulation. This model, 
however, is unable to explain why immunohistochemical and in situ hybridisation 
studies in tonsils o f patients with IM showed localisation o f EBV-infected B cells in
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Figure 1.2: Proposed models of primary and persistent infection of B cells by EBV
EBV viral particles establish a primary focus of lytic replication in the oropharynx (A) with possible 
involvement of the epithelial cells. Infection then spreads to B cells populating the lymphoid tissues. 
Two models have been proposed for how memory B cells become infected. The first (B) suggests that 
EBV directly infects the memory B cells population of the lymphoid tissues. EBV switches on viral 
genes associated with latency III resulting in widespread proliferation. Eventually proliferation is 
terminated by the down regulation of all or most of the EBV latent genes and memory B cells exit into 
the peripheral circulation. The second model (C) suggests that EBV predominantly targets naive B 
cells population and enters the memory B cell reservoir by exploiting the physiological antigen-induced 
selection of memory B cells that occurs in the germinal centres (Figure 1.3). Following proliferation of 
the naive B cells driven by EBV expressing the latency III programme, EBV down-regulates latent 
gene expression during transit through the germinal centres before differentiation into memory B cells. 
Persistent infection (D) and completion of the EBV life cycle occurs during antigen-driven activation 
of B cells. This recruits memory B cells into the germinal centres where activation of viral latency 
programmes may occur. Memory B cells may differentiate into plasma cells, with resultant activation 
of the lytic cycle and production of viral particles (E). These particles can be shed into the saliva and 
infect a second host. Alternatively viral particles can directly infect the naive (F) or memory B cells 
(G). Memory B cells may also exit the germinal centres and re-enter the peripheral circulation, 
replenishing the EBV reservoir (H).
= EBV viral particle
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Figure 1.3: B cell development
Naive B cells expressing a functional BCR are released into the peripheral circulation from the bone 
marrow. On encountering cognate antigen and activated T-helper cells, B cells become activated and 
migrate to the dark zone of the germinal centres within secondary lymphoid organs (A). The activated 
B cells then reduce expression of their surface immunoglobulin and undergo rapid cell division and 
mutation of their rearranged immunoglobulin (Ig) genes (B). This process is termed somatic 
hypermutation and creates B cells with BCRs of different affinities for a particular antigen. B cell 
proliferation eventually stops and surface expression of Ig is increased. B cells then migrate to the light 
zone of the germinal centre where they must interact with follicular dendritic cells and T-helper cells in 
order to survive. B cells compete for binding of the antigen presented by the follicular dendritic cells 
and are selected according to the binding affinity of the membrane Ig (C). B cells expressing the high- 
affinity Ig pass this selection process and receive a second survival signal from the T-helper cells via 
the CD40/CD40 ligand interaction (E). This prompts the selected B cells to undergo further repeated 
rounds of proliferation. At this stage the immunoglobulin genes of many of the selected B cells are 
remodelled by class-switching (F). This process alters the Ig heavy-chain constant region resulting in a 
switch of Ig isotype from IgM/IgD to IgG, IgA or IgE without altering antigen specificity. Selected 
germinal centre B cells then differentiate in to memory B cells or plasma cells, leave the germinal 
centres and enter the peripheral circulation (G). B cells expressing Ig with lower binding affinities fail 
to pass the selection process and die by apoptosis (D).
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the extra-follicular areas and rarely in the germinal centres (Niedobitek et al., 1992; 
Meru et a l., 2001; Araujo et a l., 1999).
In addition naive and memory B cells show the same susceptibility to EBV infection 
in vitro (Ehlin-Henriksson et al., 2003), and therefore it is difficult to understand why 
memory B cells in the germinal centres would be excluded from infection in vivo.
An alternative model therefore proposed that EBV directly infects the memory B cell 
population (Kurth et al., 2000; Kurth et al., 2003), however while this is consistent 
with the IM studies above it fails to explain the existence of the infected naive B cells 
expressing the latency III programme in the germinal centres (Babcock et al., 2000; 
Joseph et al., 2000).
Exit from the germinal centres induces a latency programme in which few or no latent 
genes are expressed (Table 1.2). Memory B cells therefore evade immune recognition 
and elimination by EBV-specific T cells and provide a life-long reservoir o f EBV- 
infected cells. The EBV life cycle is completed by memory B cells reactivating and 
infecting new hosts. The details of this process are unclear, however it is possible that 
antigen-induced activation o f B cells recruits memory B cells into the germinal 
centres o f the tonsil and drives differentiation into plasma cells, a process which has 
been linked to activation o f the viral lytic genes (Crawford and Ando, 1986). EBV 
particles are then produced and can be either shed into the saliva or used to replenish 
the EBV reservoir by infecting co-resident naive B cells.
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1.2 Immune responses to EBV and evasion strategies employed by 
the virus
1.2.1 General immune responses to viruses
The immune response to a pathogen involves both innate and adaptive immunity. The 
innate immune response represents the initial line o f host defences and consists of 
anatomical barriers such as the skin and mucous membranes, the complement 
cascade, phagocytic cells such as macrophages and neutrophils, natural enzymes such 
as lysozyme, type I IFNs and NK cells. Most components o f the innate immune 
response are present prior to exposure with the antigen and are not specific to a 
particular pathogen. Re-exposure with the same pathogen instigates an identical 
cascade of disease-resistant mechanisms which is uniform across all members o f the 
same species. Upon contact with an antigen, macrophages secrete a series o f factors 
that promote the inflammatory response and the elimination o f pathogens. These 
include the cytokines interleukin-1 (IL-1), interleukin-6 (IL-6), IFN-a and tumour 
necrosis factor a  (TNF-a) as well as complement proteins and hydrolytic enzymes.
The innate response to a viral infection is primarily through the induction o f type I 
IFNs (IFN-a and IFN-P) and the activation o f NK cells. Type I IFNs are secreted by 
infected cells and dendritic cells (via their pattem-recognition receptors, PRRs) in 
response to double-stranded RNA produced during the viral life cycle. IFN-a and 
IFN-p mediate an anti-viral response by binding to the IFN a/p receptor and 
activating the JAK-STAT pathway. This in turn up-regulates transcription o f several 
host genes, including the enzyme 2 ’-3’oligo-adenylate synthetase [2-5(A) synthetase] 
which activates a ribonuclease that degrades viral RNA. Other genes activated by
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IFN-a and IFN-P include dsRNA-dependent protein kinase (PKR) which prevents 
further viral replication by inactivating protein synthesis. Type I IFNs can also induce 
the adaptive immune response to a viral infection by increasing expression of 
costimulatory molecules such as CD80, CD86 and CD40 on the surface of dendritic 
cells. This in turn facilitates antigen presentation and activation o f antigen-specific T 
cell responses. IFN-a and IFN-P in conjunction with IL-12 also bind to and activate 
NK cells inducing lytic activity and enhancing their capacity as cytotoxic cells.
The adaptive immune response represents an evolutionary high level o f defence 
which is able to provide specificity, diversity, memory and recognition o f self/non 
self. In contrast to the innate immune response, the adaptive immune response only 
starts after exposure to an antigen and is able to change its response following re­
exposure with the same antigen. The main effectors o f this response are antigen- 
induced T and B cells which are reliant on professional APC for activation.
Activation o f naive T cells requires two stimulatory signals. The first involves binding 
o f the T cell receptor (TCR) to antigen that has been processed and presented on the 
surface o f a MHC molecule as a peptide. The second signal is mediated by binding of 
costimulatory molecules found on the surface o f all APC such as the glycoprotein B7- 
1 to CD28 on the surface o f T cells. The presence o f both signals initiates T cell 
activation, secretion of IL-2 and expression o f the IL-2 receptor. Without a 
costimulatory signal, naive T cells are unable to be fully activated and either become 
anergic or die by apoptosis.
Antigens are processed and presented by the MHC molecules on the surface o f APCs 
according to the route by which they enter the cell (Morrison et al., 1986). 
Endogenous antigens are produced from within the host cell and include viral proteins
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from virally infected cells or unique tumour proteins (Figure 1.4). This form of 
antigen is degraded by the proteasome into peptides 8-10 amino acids long which are 
then transported into the endoplasmic reticulum (ER) by the protein transporters 
TAPI and TAP2 (Powis et al., 1991). Inside the ER MHC class I molecules are 
synthesised and stabilised by binding o f P2 microglobulin, which in turn facilitates the 
binding o f the antigen peptide to the MHC class I peptide cleft and exit from the ER. 
Peptide.MHC class 1 complexes are then transported to the cell surface via the Golgi 
apparatus. The MHC-peptide complex is recognised by T cells expressing the CDS 
molecule.
MHC class II molecules are also synthesised in the ER where they associate with an 
invariant chain protein (Figure 1.4). MHC class II molecules are then transported 
through the endocytic compartments where the invariant chain is degraded leaving a 
shorter fragment known as CLIP (class Il-associated invariant chain peptide) within 
the peptide cleft. These mechanisms inhibit the possibly undesirable binding o f 
endogenous peptide fragments.
Exogenous antigen, produced outside the host cell enters by phagocytosis and enters 
the endocytic compartments. Here the antigen is degraded into peptide fragments. 
Expression o f a non-classical MHC class II molecule, HLA-DM mediates the 
exchange o f  CLIP with the peptide fragment into the binding cleft o f the MHC class 
II molecule (Denzin and Cresswell, 1995; Sloan et al., 1995). The peptideiMHC class 
11 complex is then exported to the surface o f the APC where it is recognised by T cells 
expressing the CD4 molecule.
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Figure 1.4: Antigen presentation via the endogenous and exogenous pathways
Endogenous pathway: Endogenous antigen (1) is processed by the proteasome and degraded into 
peptide fragments. The peptides are then transported into the ER via TAPI and TAP2 molecules (2). 
The peptide binds to the cleft present on the surface of a MHC class I molecule bound to B2 
microglobulin and exits the ER into the Golgi apparatus (3). The peptide:MHC class I molecule is then 
transported to the surface of the APC (4).
Exogenous pathway: MHC class II molecules are synthesised within the ER and bound to an invariant 
chain protein (1) which inhibit binding of the peptides. The MHC class II + invariant chain are then 
transported to the Golgi apparatus (2) and into the endocytic compartments. Here the invariant chain 
dissociates (3) leaving a short fragment called CLIP. HLA-DM, a non-classical MHC class II molecule 
expressed in the endocytic compartments mediates the exchange of CLIP for peptide fragments (4) 
degraded from exogenous antigen (5). The peptides bind to the open cleft of the MHC class II molecule 
and are transported to the surface of the APC (6).
Figure adapted from (Goldsby et al., 2003)
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Evidence, however, has suggested that this model of antigen presentation is over- 
simplistic and that professional APC are also able to present exogenous antigen via 
MHC class I molecules in a process referred to as cross-presentation (Norbury and 
Sigal, 2003). Recent mouse studies have also suggested that this is the main 
mechanism by which primary viral CD8* T cell responses are generated (Mueller et 
al., 2002; Gold et a l , 2002).
The effector functions o f the adaptive immune response can be tailored according to 
the invading pathogen, the microenvironment created by the infection and the means 
o f antigen presentation. Activated CD4f T-helper (TM) cells are involved in this 
process by modulating their cytokine profile in response to the antigen. Two polarised 
responses have been described (ThI and Th2 responses), although it is thought that 
most pathogens require a mixture o f both for effective eradication.
The ThI response describes the secretion o f IFN-y, TNF-P and IL-2 by activated Th 
cells in response to a pathogen such as an intracellular virus that requires eradication 
by cell mediated cytotoxicity. These cytokines activate CD8+ T cells and drive the 
proliferation o f cytotoxic T lymphocytes (CTLs). CTLs kill virally infected cells by 
the release o f cytotoxic granules containing perforin and granzymes or via the Fas-Fas 
ligand pathway resulting in apoptosis. The ThI cytokine profile also activates 
macrophages and induces antibody-class switching to IgG antibodies that support 
phagocytosis and complement fixation.
In contrast, the Th2 response describes the secretion o f IL-4, IL-10 and IL-13 from 
activated Th cells in response to a pathogen such as a soluble bacterial toxin that 
requires neutralisation by antibodies. These cytokines provide B cell help by 
promoting B cell differentiation and secretion o f antibodies.
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B cell development and activation has been described previously (Figure 1.3). The 
net result o f this process is the production o f antibodies specific for an antigen. 
Antibodies bind to antigen through their variable regions, however, the effector 
functions are mediated through the constant region domains. Opsonisation, 
complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC) 
are all mediated by the antibody:antigen complex binding to the Fc or C3b receptors 
on phagocytes, macrophages or NK cells. Neutralisation o f viruses is mediated by 
antibodies binding to viral epitopes that facilitate either viral attachment to the 
receptors on the target cell used for cellular entry or fusion o f the viral envelope with 
the plasma membrane. If the latter occurs, the antibody is able to mediate complement 
driven lysis o f the enveloped viral particle. Antibodies or complement may also 
agglutinate viral particles resulting in opsonisation and phagocytosis.
1.2.2 Innate response to EBV
Recent studies from patients with the X-linked lymphoproliferative (XLP) disease 
have demonstrated the role o f NK cells in controlling primary EBV infection. Young 
males with the genetic disposition to XLP are clinically well until primary EBV 
infection when 50% develop fulminant IM, 20% develop B cell lymphomas and 30% 
develop dys-gammaglobulinaemia (Howie et al., 2000; Hamilton et al., 1980). All 
three phenotypes have been shown to be secondary to a deregulated EBV-specific T 
cell response and uncontrolled B cell proliferation. The genetic defect in XLP is an 
absence of the signalling lymphocytic activation molecule (SLAM) associated protein 
(SAP) (Coffey et al., 1998; Sayos et al., 1998; Nichols et al., 1998), a protein which 
is thought to control NK activation by interacting with the NK costimulatory receptor
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2B4/CD244. This receptor is constitutively expressed on NK cells (Nakajima et al., 
2000) and has been shown in vitro to bind to CD48 (Brown et al., 1998), a molecule 
highly expressed on B cells shortly after infection with EBV (Thorley-Lawson et al., 
1993). It has therefore been postulated that NK cells recognise EBV through the 
CD244/CD48 interaction and that abnormal signalling in XLP due to the absence of 
SAP leads to failure of NK cell control of primary EBV infection.
1.2.3 B cell responses to EBV
EBV stimulates a strong antibody response during primary infection. Early in the 
diagnosis of IM, IgM and IgG responses to the nucleocapsid and envelope proteins 
are evident. This is typically followed by IgG responses to the lytic proteins as well as 
EBNA2 and EBNA1 (Nikoskelainen and Hanninen, 1975). Neutralising antibodies to 
gp350 (the point o f entry for EBV into the B cells) arise late in the course o f IM, and 
therefore do not play an important role in the control o f the virus.
1.2.4 T cell responses to EBV
The cell-mediated response to EBV has been well documented and shown to play a 
critical role in the control o f primary and persistent EBV infection and prevention o f 
uncontrolled EBV-driven B cell proliferation. CD8+ T cell and CD4+ T cell responses 
are considered below.
1.2.4.1 CD8+ T cell responses
Primary EBV infection is associated with large clonal expansions o f CD8+ T cells 
(Callan et al., 1996; Maini et al., 2000) that are predominately directed to the lytic 
EBV antigens (Callan et al., 1998b; Hislop et a l,  2002). Studies with fluorochrome
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labelled recombinant HLA class I:peptide complexes, known as tetramers, to detect 
EBV specific T cell in patients with IM showed that up to 12% of circulating CD8 T 
cells were specific for an HLA-A2 restricted epitope (GLCTLVAML) from the lytic 
antigen BMLF1, and up to 45% were specific for an HLA-B8 restricted epitope 
(RAKFKQLL) from the intermediate early lytic antigen BZLF1. In contrast, the 
magnitude o f the CD8f T cell response to latent EBV antigens is considerably smaller 
and typically comprises o f 2.5% of the peripheral CD8^ T cell population (Callan et 
al., 1998b; Callan et al., 1998b; Hislop et al., 2002). Explanations for why primary 
CD8+ T cell responses should be directed towards lytic EBV antigens during primary 
infection are unclear, however a recent study suggested that the efficiency o f antigen 
presentation may be responsible (Pudney et al., 2005).
Functional studies on the clonally expanded CD8* T cells have indicated their 
protective role in primary EBV infection. EBV-specific CD8+ T cells express a 
variety o f activation markers (Callan et al., 1998b; Hislop et al., 2002) and have been 
shown to demonstrate efficient cytolytic activity in vitro (Callan et al., 2000; Steven 
et al., 1996). In addition, on stimulation with HLA-restricted peptides, a proportion of 
EBV-specific CD8+ T cells will produce IFN-y (Hoshino et al., 1999).
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Figure 1.5: The dynamics of T cell responses to EBV
Following the large primary burst of responses towards lytic antigens in primary 
infection and smaller response to latent antigens, T cell responses are down regulated 
(Figure 1.5). Evidence has shown that EBV-specific CD8+ T cells die in vitro by 
apoptosis pathways independent of Fas-ligand or TRAIL, and that they express low 
levels of Bcl-2, an intracellular molecule that protects against apoptosis mediated by 
cytochrome c (Callan et al., 2000). This suggests therefore that EBV-specific CD8+ T 
cells are programmed for cell death and will die after clonal expansion in the absence 
of survival signals.
The mechanisms involved in the selection of which T cells from the primary clonal 
response survive and are represented in the memory T cell population, and which T 
cell clones die by apoptosis are poorly understood. Initial evidence analysing the TCR
CD8* T cell response to 
lytic antigens
CD8+ T cell response to 
latent antigens *
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usage of latent antigen CDS' T cells in primary and persistent EBV infection 
supported the linear model of T cell differentiation (Opferman et al., 1999) and that 
the repertoire o f EBV-specific memory CDS T cells reflected those seen in the 
primary T cell response (Callan et al., 1998a; Silins et al., 1996). However, analysis 
o f TCR usage from clones specific for lytic antigens showed that patterns o f response 
changed over time (Annels et al., 2000; Callan et al., 2000) with rapidly proliferating 
clones from the primary response being poorly represented or even absent from the 
memory T cell response. Further studies have suggested that this heterogeneity may 
arise from clonal senescence (Davenport et al., 2002).
The function o f EBV-specific T cells also changes during down-regulation (Catalina 
et al., 2001; Hislop et al., 2002). Expression o f the activation marker CD38 is 
typically lost, while expression o f CD62L (L-selectin) and the chemokine receptor, 
CCR7 increase, changes which reflect maturation o f the immune response.
Persistent EBV infection evokes a similar pattern o f T cell responses to that seen in 
primary EBV infection with lytic antigen-specific T cells dominating over latent 
antigen responses. Together both lytic and latent CD8+ T cells responses account for 
1-3% of the circulating CD8+ pool in healthy EBV sero-positive individuals (Tan et 
al., 1999); a relatively high frequency which reflects the response to intermittent viral 
reactivation. Studies have shown however that not all o f these cells appear to be 
functionally equivalent, as demonstrated by the frequency of IFN-y producing EBV 
peptide-specific CD8+ T cells representing 20-40% of the epitope-specific CD8+ T 
cells measured by HLA tetramer staining for the same epitope (Tan et al., 1999). A 
second study also illustrated functional heterogeneity in persistent infection by 
showing that IFN-y producing lytic peptide-specific CD8+ T cells do not always
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express the activation marker CD28 or the CD45RO isotype consistent with the 
classical model of central memory differentiation (Hislop et al., 2001). Recent 
evidence however suggests that a proportion of memory EBV-specific CDS' T cells 
that produce IFN-y in response to peptide stimulation and are cytolytic in vitro also 
re-express the CD45RA isoform (Dunne et al., 2002). These cells are resistant to 
apoptosis due to increased expression o f bcl-2 and therefore may represent a 
subpopulation of memory T cells that are crucial in preserving the long-term 
immunity o f EBV.
1.2.4.2 CD4+ T cell responses
Analysis o f the CD4+ T cell response to EBV has lagged behind that of the CD84 
response, primarily due to restricted knowledge of epitopes binding to the MHC class 
II molecule, and the limited availability o f class II HLA tetramers.
Despite this, several studies have used PBMCs stimulated with lysates from EBV- 
transformed lymphoblastoid cell lines (LCLs) or fusion proteins to stimulate a CD4+ 
response from patients with primary infection. The first study showed that up to 5.2% 
(mean o f 1.4%) o f circulating CD4+ T cells responded to EBV antigen by producing 
IFN-y (Amyes et al., 2003). The second study, however, demonstrated lower 
frequencies of IFN-y producing CD4+ T cells after stimulation with fusion proteins 
containing both lytic and latent EBV proteins (Precopio et al., 2003). CD4+ T cell 
responses were directed to the BZLF1 and BMLF1 lytic proteins and EBNA1 latent 
proteins, with little response to EBNA 3A. In both studies, responses had fallen to 
undetectable levels by 1 year, suggesting that CD4+ T response to EBV in primary
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infection is characterised by a small clonal burst followed by a period of 
downregulation (Figure 1.5).
Phenotypic analyses of CD4' T cells from patients with persistent infection have 
shown that functional heterogeneity also exists in this population as well as the CDS' 
memory T cells (Amyes et al., 2005; Harari et al., 2005). Results showed that EBV- 
specific CD4* T cells could be compartmentalised according to their expression of 
CCR7, CD27 and CD28 as well as their ability to produce the cytolytic mediators, 
perforin and granzyme and the cytokines IFN-y, TNF-a and IL-2. These studies 
therefore provide insights into CD4+ T cell differentiation following exposure to 
antigen.
1.2.5 EBV immune evasion strategies 
1. 2.5.1 Latent gene down regulation
The main immune evasion mechanism that EBV employs during latent infection is 
down regulation o f latent antigen expression. Infected memory B cells express no or 
little EBV antigens (Latency programme 0, Table 1.2) (Babcock et al., 1998; 
Hochberg and Thorley-Lawson, 2005b) therefore limiting the number o f targets that 
EBV-specific CD8+ T cells are able to recognise. In contrast, EBV infected B cells 
that enter the lytic cycle for viral replication, express all the latent antigens (latency 
programme III). These antigens prompt vigorous CD8+ T cell responses and cell 
mediated killing (Rickinson and Moss, 1997). This therefore ensures that EBV-driven 
proliferation o f B cells is controlled and that persistent EBV infection remains a 
benign event for the host.
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1.2.5.2 Inhibition o f  antigen processing by Gly-Ala repeat
As previously discussed the Gly-Ala repeat domain found in EBNA1 is able to inhibit 
antigen presentation to CD8' T cells by inhibiting proteasomal processing (Levitskaya 
et al., 1995). Therefore EBV-associated malignancies such as Burkitt’s lymphoma 
that express EBNA1 alone and proliferating memory B cells in healthy individuals 
avoid recognition by EBV-specific CD 81 T cells and are rendered immunologically 
invisible. Recent studies however, have challenged this, showing that EBNA1 -derived 
epitopes derived from defective proteins that are prematurely truncated during 
translation or incorrectly folded after translation (defective ribosomal products, 
DRiPs) can be presented successfully to CD8^ T cells by MHC class I molecules 
(Voo et al., 2004; Tellam et al., 2004; Lee et al., 2004).
1.2.5.3 Inhibition o f Protein Kinase (PKR)
EBERs are the most abundant o f all the latent EBV gene products and found in all 
EBV-associated malignancies (Table 1.2). EBV utilises this protein in immune 
avoidance by inhibiting PKR (Nanbo et al., 2002). This enzyme is activated by type I 
IFNs binding to the IFN a/p receptor and in conjunction with 2-5(A) synthetase 
prevents protein synthesis, thereby effectively blocking viral replication. EBERs 
however, promote EBV persistence by directly blocking PKR activity.
1.2.5.4 Suppression o f  innate and adaptive immunity
Several o f the EBV gene products share both sequence and functional homology with 
host proteins. EBV can therefore mimic the activity o f these proteins and modulate 
the immune response to the virus.
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BARF1, a gene expressed early in EBV replication neutralises colony-stimulating 
factor-1 (CSF-1). This cytokine is responsible for both inducing monocyte
proliferation as well as up regulating monocyte secretion of IFN-a (Cohen and 
Lekstrom, 1999). Therefore EBV can interfere with the anti-viral effects of innate 
immunity and delay immune responses that are dependent on monocyte proliferation 
and differentiation.
The EBV induced gene 3 (EBB) is expressed at high levels by EBV-transformed B 
cells and has homology with the p40 subunit of IL-12 (Devergne et al., 1997). IL-12 
is essential for NK cell activation and when released from professional APCs 
polarises specific T cell responses towards a Tul phenotype. It has therefore been 
proposed that EBB acts as an immunomodulator as well as an inhibitor o f NK cell 
activation (Devergne et al., 2001).
BCRF1 is expressed early in EBV replication and shares 85% homology with IL-10 
(Hsu et al., 1990). This gene is therefore able to suppress T cell responses directly by 
reducing IL-2 and IFN-y production and indirectly by regulating MHC class I and II 
expression and suppressing professional APC migration to regional LNs. EBERs 
present in both lytic and latent EBV infection have also been shown to exert the same 
effects by up regulating IL-10 production (Nanbo et al., 2002).
BHRF1 shares 25% sequence homology with the human bcl-2 proto-oncogene 
(Henderson et al., 1993) and has been shown to inhibit apoptosis by interfering with 
granzyme mediated cell killing by CTLs (Davis et al., 2000).
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1.3 EBV associated malignancies: The role of EBV in pathogenesis
EBV is associated with both lymphoid and epithelial malignancies. However, despite 
EBV infecting 90% of the world-wide population, it is only responsible for an 
estimated 1-2% of malignancies. EBV-related malignancy is also often confined to 
geographical areas. This therefore suggests that although EBV is involved in tumour 
development, additional cofactors are also required. The following sections outline 
the proposed pathogenesis o f both lymphoid and epithelial EBV-associated 
malignancies by describing their cell phenotype and how this relates to the role of 
EBV in persistent infection o f healthy individuals detailed previously.
1.3.1 EBV-associated lymphoid malignancies
EBV is associated with B-cell as well as T and NK cell lymphomas. Each express 
different patterns of latent genes (Table 1.2) and originate from different cell 
phenotypes within the differentiation pathways. Individual sets o f cofactors also 
appear to be vital for the pathogenesis of each type o f lymphoma.
1.3.1.1 B u rk itt’s Lym phom a
B urkitf s lymphoma (BL) exists in two forms. The endemic form was originally 
described as a tumour o f the jaw  affecting children in equatorial Africa and New 
Guinea where malaria is holoendemic (BURKITT, 1958), and is associated with EBV 
in all cases. The endemic form o f BL has a high incidence and accounts for 16% of all 
childhood cancers in these geographical areas (Lavu et al., 2005). The sporadic form 
however, has a much lower incidence and by definition occurs outside equatorial 
Africa. In this form EBV is only found in 15% of cases (Rickinson and Kieff, 2001).
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BL typically develops in extra-nodal sites such as the jaw, ovary, breast, liver and 
kidneys. However, histologically BL cells resemble germinal centre B cells, sharing 
the same phenotypic markers (CD 10, CD77, BCL6) and showing evidence o f ongoing 
somatic hypermutation.
Irrespective o f EBV association or geographical location, BL cells share similar 
genetic abnormalities and it is thought that this is a crucial cofactor in the 
development o f BL. The hallmark of BL is one o f three chromosomal translocations 
which places the c-myc cellular oncogene on chromosome 8 under the control o f the 
Ig heavy chain or light chain genes resulting in its constitutive expression and 
uncontrolled proliferation (Zech et al., 1976). BL is also associated with mutations in 
tumour suppressor genes such as p53 (Bhatia et al., 1992; Gaidano et al., 1991) and 
retinoblastoma-like 2 (RB2) (Cinti et al., 2000).
The role of EBV in the pathogenesis o f BL is less certain. EBV-positive BL cells only 
express EBNA1, a latent gene that is primarily involved in the maintenance of the 
viral genome (Yates et al., 1985) and with questionable oncogenic potential. It is 
therefore possible that BL arises from EBV-infected germinal centre B cells that are 
destined to becoming a memory B cell but that c-myc expression occurring as an error 
o f somatic hypermutation prevents differentiation and promotes proliferation o f B 
cells expressing the restricted latency type I pattern o f EBV antigens. This model is 
illustrated in Figure 1.6 and suggests that EBV has no role in the oncogenesis o f BL 
and is present solely by chance. Alternatively it is possible that the non-coding EBER 
RNAs contribute to BL pathogenesis by inducing the anti-apoptosis gene bcl-2 and 
promoting cell survival. Recent evidence has shown that EBER RNA expression is up 
regulated by c-myc (Niller et al., 2003) and therefore sustained EBER expression by
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BL cells may counteract the pro-apoptotic function of c-myc and allow c-myc-driven 
proliferation.
\ \ / /  SHM
BCR SHMSHM
Latency Type I
EBNA 1
SHMNaive B 
cell
SHMMyc-\
trans
Burkitt’s 
lymphoma cell
Germinal centre
Figure 1.6: Bystander pathogenesis model of Burkitt’s lymphoma
EBV infected naive B cells proliferate within the germinal centre where they undergo somatic 
hypermutation (SHM). During this process B cells that were destined to become memory B cells are 
vulnerable to translocation of the proto-oncogene, Myc into the immunoglobulin loci (Afyc-Ig 
translocation), resulting in uncontrolled proliferation.
99Br EBV viral particle
Another option is that EBV initiates oncogenesis by transforming germinal centre B 
cells that are then targets of c-myc translocations. These cells would therefore initially 
express all latent genes, however subsequent selection forces down regulation of EBV 
genes to latency type I expression. Evidence from this model comes from a recent 
study showing deletion of the growth promoting EBNA2 gene in several cases of BL 
(Kelly et al., 2002). Whether this selection pressure results from the incompatibility
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that exists in vitro between EBV latency type Ill-driven and c-myc-driven growth 
programmes in B cells (Pajic et al., 2001), or a need to down regulate immunogenic 
EBV proteins in immuno-competent hosts, or the expression o f another as yet 
undetermined cofactor, is unclear.
Both malaria and human immunodeficiency virus (HIV) are associated with an 
increased incidence o f BL, suggesting their role as additional cofactors. These 
infections are known to cause polyclonal B cell activation (Greenwood and Vick, 
1975; Lane et al., 1983) and recruitment o f EBV-infected B cells into the germinal 
centres. Although the precise mechanisms have yet to be determined this activity has 
potential for increasing the risk o f c-myc translocations and thus BL.
1.3.1.2 H odgkin’s Disease
Hodgkin’s disease (HD) represents approximately 20% of all lymphomas in the 
western world and has a rising incidence. The role o f EBV in the pathogenesis of HD 
is unclear, however, EBV clonal DNA is found in the R-S cells o f approximately 40- 
50% of HD tumours.
The characteristic histopathological features o f HD are small numbers of the 
malignant multi-nucleated Reed-Stemberg (R-S) cells and Hodgkin cells surrounded 
by large populations of mononuclear cells. It is this infiltrate that is used to classify 
HD into two histological groups: Classical HD (lymphocyte-depleted HD; nodular 
sclerosing HD; mixed cellularity HD and lymphocyte-rich HD) and Non-classical HD 
or nodular lymphocyte predominant HD (Harris et al., 1994).
The cellular origins o f R-S cells in classical HD have long been debated, however, 
recent molecular analyses have identified them as germinal centre B cells that contain
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functional immunoglobulin rearrangements but with nonsense mutations or deletions 
resulting in defective Ig transcription (Kuppers, 2002; Kanzler et a l., 1996; Marafioti 
et al., 2000). These mutations would ordinarily ensure elimination by apoptosis in the 
germinal centres (Figure 1.7) suggesting that HD results from these atypical cells 
being rescued by a transforming agent. EBV-positive R-S cells express LMP1 and 
LMP2 in addition to EBNA1 (Latency pattern II). Both LMP genes are able to rescue 
B cells from apoptosis by activating the CD40 and BCR signalling pathways as 
discussed previously and therefore indicate a probable role for EBV in the 
pathogenesis of EBV-positive tumours. Whether EBV is involved in the established 
R-S cell clone in HD is unclear, particularly as there are no latency type II expressing 
EBV-positive HD cell lines available for study. R-S cells have lost several 
downstream components o f the BCR signalling pathway (Schwering et al., 2003) and 
therefore LMP2 is unlikely to function in the established tumour, at least through the 
recognised pathways. In contrast, LMP1 continues to exert its effects through the 
activation o f NF-kB. Similar deregulation of NF-kB function is also seen in EBV- 
negative R-S cells, with inhibition of the main NF-kB regulator (Kuppers, 2002) 
indicating the importance o f this pathway in the pathogenesis in both EBV-positive 
and negative HD.
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Figure 1.7: Pathogenesis of EBV-positive HD
The malignant R-S cells of HD originate from germinal centre B cells with destructive Ig variable gene 
mutations. These cells normally are eliminated by apoptosis but are thought to be rescued by survival 
signals from the EBV latent genes LMP1 and LMP2.
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1.3.1.3 Post transplant lymphoproliferative disease
Post transplant lymphoproliferative disease (PTLD) is a heterogeneous group of B 
cell lymphoproliferative disorders together with a small number of T and NK 
lymphomas which occur in immunocompromised patients whose defective T cell 
immunity is unable to control EBV-driven B cell proliferation. Commonly these 
lymphomas occur after solid organ and haematopoietic stem cell transplantation
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where immunosuppressive drugs are required to suppress T cell immunity to 
alloantigens and graft rejection or graft versus host disease (GVHD).
The World Health Organisation classifies PTLD into four histological types: ‘early 
lesions’, polymorphic PTLD, monomorphic PTLD and Hodgkin lymphoma and 
Hodgkin lymphoma-like PTLD (Jaffe et al., 2001). ‘Early lesions’ includes reactive 
plasmacytic hyperplasia and IM-like PTLD. As the name suggests this form of PTLD 
occurs after primary EBV infection, early in the course of transplantation and is 
associated with IM-like symptoms. In this form the nodal architecture o f involved 
lymph nodes remains unaltered.
Polymorphic PTLD lesions show destruction o f the LN architecture with areas of 
necrosis and large atypical cells. Immunophenotyping typically shows a mixture o f B 
and T cells. Monomorphic PTLD tumours usually resemble diffuse large B cell non- 
Hodgkin’s lymphomas, however lesions resembling Burkitt’s or Burkitt’s-like 
lymphoma, plasma cell myeloma, plasmacytoma and T-cell lymphomas are also seen. 
EBV is associated with PTLD in 71% of cases (P.Amlot , personal communication), 
however its precise role in pathogenesis remains undefined. The majority o f lesions 
are monoclonal (Knowles et al., 1995; Chadbum et al., 1998) and although were 
previously thought to express an unrestricted pattern o f EBV latent gene expression 
similar to LCLs (Thomas et al., 1990; Young et al., 1989), research has now shown 
that PTLD lesions express different patterns o f EBV latency (Table 1.2), with 
variable expression o f EBNA 2 and LMP common (Cen et al., 1993; Timms et al.,
2003). Ig variable (IgV) gene analysis has shown that EBV-positive PTLD lesions can 
arise from naive cells, memory cells and atypical germinal centre B cells that have 
destructive Ig mutations that are normally inconsistent with cell survival (Timms et
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al., 2003; Capello et al., 2005; Brauninger et al., 2003). This demonstrates that EBV- 
positive PTLD can arise from many points along the B cell development pathway 
both within the germinal centres and post-germinal centre compartments (Figure 1.8) 
and illustrates similarities with EBV-positive HD (Timms et al., 2003), suggesting a 
common initiation event may be performed by EBV. One hypothesis is that EBV 
creates a pool of non-malignant atypical B cells either by rescuing cells from within 
the germinal centre or activating SHM in post-germinal B cells. Malignant 
transformation may then occur as a result o f additional genetic mutations. In support 
o f this are the findings that EBV-positive PTLD is commonly associated with BCL-6 
(Cesarman et al., 1998) mutations as well as mismatch repair deficiency (Duval et al.,
2004). Mutations of other oncogenes such as c-myc, N-ras and p53 occur sporadically 
however, and show no consistent association.
Others have suggested that a cytokine imbalance from persistently activated CD4+ T 
cells may provide the cofactor required for the malignant transformation o f EBV- 
infected B cells. Activated CD4+ T cells stimulated by alloantigens in the context of 
transplantation produce a spectrum of cytokines which may promote atypical B cell 
survival and proliferation. This suggestion is supported by the infiltration o f CD4+ T 
cells in the majority o f PTLD lesions (Perera et a l ,  1998) as well as experiments on 
severe combined immunodeficient (SCID) mice showing that the development of 
EBV-positive B-cell lymphoproliferative disease-like lesions after injection with 
mononuclear cells from EBV sero-positive healthy individuals is dependent on the 
presence o f donor CD4+ T cells (Johannessen et al., 2000).
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Figure 1.8: Pathogenesis of EBV-positive PTLD
PTLD lesions are heterogeneous in terms of cellular origin. Lesions may arise from memory B cells 
(A), naive B cells (B) or atypical B cells that are rescued from apoptosis within the germinal centre 
(C).
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EBV-negative PTLD accounts for 29% of all PTLD lesions (P.Amlot, personal 
communication). These tumours usually occur late after transplantation and are often 
more aggressive resulting in a poor prognosis compared to EBV-positive PTLD 
(Leblond et al., 1998). The pathogenesis for EBV-negative PTLDs has yet to be fully 
elucidated. Some studies have suggested that they represent sporadic lymphomas that 
have occurred in immunosuppressed patients and should not be considered under the 
PTLD classification umbrella (Dotti et a l,  2000; Sivaraman and Lye, 2001). Other 
studies however, have suggested that EBV was initially involved in the oncogenesis
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of EBV-negative PTLD tumours but loss of the EBV antigen subsequently occurred 
through a series o f mutations resulting in viral-independent cell proliferation. Whether 
this event was driven by selection pressure to avoid the vigorous cellular immune 
response to EBV is unclear. Support for this proposed ‘hit and run’ oncogenesis 
theory (Ambinder, 2000) includes evidence that some clones o f the EBV-associated 
Burkitt’s lymphoma-derived cell line, Akata (Shimizu et a l., 1994) and the 
nasopharyngeal carcinoma cell line, NPC-C666, (Chen et al., 1999) are capable of 
losing their viral episomes when grown in culture. In addition, a recent series o f non­
endemic Burkitt’s lymphomas showed that in some cases where EBV could not be 
detected by standard molecular techniques, partial fragments o f EBV genome were 
evident (Razzouk et al., 1996).
1.3.1.4 T-cell and NK-cell lymphomas
EBV preferentially infects and transforms B cells in vitro and therefore the 
association o f the virus with specific forms o f T-cell and NK-cell lymphomas was a 
surprise finding (Harabuchi et al., 1990; Jones et al., 1988). Peripheral T cell 
lymphomas are rare and are most common in South-East Asia. The lymphomas show 
CD4+ or CD8+ T cell phenotypes and typically express latency type I or II 
programmes. This type of T cell lymphoma can either arise after acute primary EBV 
infection when it manifests as a haemophagocytic disorder or as a sequelae o f chronic 
active EBV (Kimura et al., 2003; Kanegane et al., 2002), a rare life threatening 
disorder characterised by recurrent or persistent-IM like symptoms (fever, fatigue 
lymphadenopathy and hepatosplenomegaly) in combination with an elevated EBV 
viral load and an abnormal EBV antibody profile. Mortality from chronic active EBV
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is high (40%) with the majority of patients dying from hepatic failure, 
haemophagocytic disorders or lymphomas (Kimura et al., 2001).
EBV is also associated with an extra-nodal lymphoma which presents as a lethal mid­
line granuloma in the nasal cavity (Kanavaros et al., 1993). This lymphoma is most 
common in south-east Asia and can arise from both T and NK-cells. Latent EBV 
antigen expression typically follows the type II programme.
The role of EBV in the pathogenesis o f these lymphomas has yet to be fully 
determined, however EBV infected T cells in vitro express the same CD21 receptor 
required for EBV entry into B cells (Fingeroth et al., 1988) suggesting that T cell 
lymphomas may arise from a pre-malignant pool of T cells in vivo.
1.3.2 EBV associated epithelial malignancies
1.3.2.1 EBV infection o f epithelial cells
EBV is associated with epithelial malignancies (NPC and gastric carcinoma) 
however, the mechanism by which EBV infects epithelial cells remains poorly 
understood. Squamous epithelial cells lack the CD21 receptor used by EBV to access 
B cells and are resistant to EBV infection in vitro (Sixbey et al., 1984; Imai et al., 
1998). This finding led to the suggestion that EBV must undergo a preliminary round 
o f replication in the B cells o f the oropharynx before the virus can access the 
epithelial cells. However, recent evidence has shown not all the EBV viral particles 
are internalised on binding to the surface o f B cells and that EBV infection can be 
transferred directly to the epithelial cells by B cells through gp350/CD21 complexes 
(Shannon-Lowe et al., 2006).
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1.3.2.2 Nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) arises from the squamous epithelium of the post­
nasal space and is classified according to the degree of differentiation o f the 
malignant cells. 70% are undifferentiated which are invariably associated with EBV 
(Vasef et al., 1997). Undifferentiated NPC is rare in most regions o f the world but 
with a particularly high incidence in certain areas o f China and south-east Asia, 
reaching a level o f 20-30 cases per 100,000 (Yu and Yuan, 2002). In addition to a 
preponderance for geographical regions, the aetiology o f NPC has also been 
associated with dietary factors such as salted fish (Armstrong et al., 1998; Ning et al., 
1990). Early stage NPC is curable in the majority of patients with a combination of 
radiotherapy and chemotherapy, however the prognosis o f patients with locally 
advanced or metastatic disease remains poor (Chan et al., 2002). Recent clinical 
studies however have shown some therapeutic benefits with adoptive CTL therapy in 
patients with advanced disease (Straathof et al., 2005; Comoli et al., 2005).
The point in time at which EBV infects epithelial cells in vivo remains controversial. 
The epithelial cells o f undifferentiated NPC carry monoclonal viral genomes which 
suggests that EBV infection occurs before the outgrowth o f the malignant clone 
(Raab-Traub and Flynn, 1986). However, although EBV has been identified in high 
grade pre-invasive lesions such as carcinoma in situ and severe dysplasia, it is not 
present in normal epithelial cells from patients at risk o f developing NPC or in low- 
grade pre-invasive lesions (Pathmanathan et al., 1995). This finding argues against the 
premise that EBV-positive NPC develops from a pre-existing normal reservoir of 
EBV infected epithelial cells. Interestingly genetic defects (deletions of the short arms 
o f chromosomes 3 and 9) have been found in normal epithelial cells o f patients at
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high risk o f developing NPC as well as frankly malignant epithelial cells (Lo and 
Huang, 2002). These findings have raised the possibility that this loss of 
heterozygosity on chromosomes 3p and 9p may result from environmental cofactors 
such as continued dietary exposure to salted fish and that this leads to the 
development o f low-grade pre-invasive lesions. Following a series of additional 
genetic and epigenetic events these lesions are then predisposed to EBV infection. 
Subsequent latent EBV gene expression could then promote cell survival and 
proliferation resulting in the development of NPC. This possible sequence o f events is 
supported by in vitro data which shows that the stable maintenance o f EBV in 
epithelial cells requires an altered undifferentiated cellular environment (Knox et al., 
1996).
Undifferentiated NPC expresses a restricted pattern o f viral latent genes according to 
latency programme type II. Despite normal antigen processing and efficient 
recognition by EBV-specific CTLs, these cells are not destroyed in vivo. Possible 
explanations for this immune evasion include an increase in EBV-encoded IL-10 
leading to an increased production of IL -la  and IL-(3 by both epithelial cells and 
surrounding CD4+ T cells (Bejarano and Masucci, 1998; Huang et al., 1999): two 
cytokines that have been linked with increased cell survival. Bcl-2 over-expression is 
also seen in NPC and may contribute to oncogenesis by allowing the cell to bypass 
apoptosis (Lu et al., 1993).
1.3.2.3 Gastric carcinoma
EBV is associated with approximately 10% o f the common gastric adenocarcinomas 
and over 90% o f the rarer lymphoepithelioma-like gastric carcinomas (Tokunaga et
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al., 1993; Shibata and Weiss, 1992; Takada, 1999). The latent viral expression of 
EBV-positive gastric adenocarcinomas is similar to NPC, however, LMP-1 is usually 
absent while expression o f BARF 1, a homologue o f human colony-stimulating factor 
1 is common (Imai et al., 1994). The precise role of EBV in the pathogenesis of 
gastric carcinoma is unknown however as with NPC, EBV has not been detected in 
the normal gastric mucosa of high-risk patients or pre-malignant lesions (zur Hausen 
et al., 2004), suggesting that EBV infection occurs late in the oncogenesis o f this 
disease and is reliant on pre-existing genetic alterations within the gastric epithelial 
cells.
1.4 Clinical Management of PTLD
PTLD is a life-threatening complication of both solid organ transplantation (SOT) and 
haematopoietic stem cell transplantation (HSCT) and is caused by an ineffective 
cellular immune response to EBV resulting in uncontrolled B cell proliferation. In 
SOT patients ineffective anti-EBV immunity is caused by immunosuppressive drugs 
administered after transplantation to control graft rejection. In HSCT patients 
however, anti-EBV immunity is suppressed by a combination o f high-dose 
chemotherapy and/or bone marrow irradiation given as part of the conditioning 
regime, T cell depletion from the graft and immunosuppressive drugs: therapies used 
to reduce the incidence o f GVHD. Due to the nature o f the graft PTLD arising in SOT 
patients is typically o f recipient origin whereas PTLD in HSCT patients is of donor 
origin.
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1.4.1 Incidence and risk factors
The incidence o f PTLD in both SOT and HSCT patients is highest in the first year 
after transplantation due to the intensive immunosuppression required during this time 
to control alloreactivity (Curtis et al., 1999; Bhatia et al., 1996; Ho et al., 1988; Sokal 
et al., 1997). In SOT patients the incidence increases if the recipient is sero-negative 
at the time o f transplantation and receives a sero-positive graft; a scenario common in 
paediatric patients, or if prolonged intensive immunosuppression is required (Cox et 
al., 1995; Shapiro et al., 1999). The incidence also varies according to the type of 
graft received (Table 1.3). In adult recipients the incidence is highest amongst small 
bowel transplants (up to 20%) followed by lung transplants (4.2-10%) and heart-lung 
transplants (2.4-5.8 % (Taylor et al., 2005). The incidence o f PTLD in renal 
transplants ranges from 1-2.3% (Libertiny et al., 2001; Shapiro et al., 1999). Reasons 
for these differences in incidence are unclear, however the intensity o f the 
immunosuppressant regimes used as well as the amount o f lymphoid tissue in the 
different graft types may be important factors.
In HSCT patients the incidence after allogeneic transplant is approximately 1% 
(Bhatia et al., 1996; Curtis et al., 1999). The risk factors are listed in Table 1.3 and 
include pure T-cell depletion as opposed to combined T- and B-cell depletion with 
agents such as the monoclonal anti-CD52 antibody (CAMPATH) (Cavazzana et al., 
1998; Hale et al., 1998).
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Solid organ transplant Haematopoietic stem cell transplant
EBV sero-negative recipient receiving a 
graft from an EBV sero-positive donor
Small bowel or heart-lung transplant
Intensive immunosuppressive drugs
T-cell depletion
HLA-mismatched transplant
Anti-thymocyte globulin for prophylaxis 
o f GVHD
Underlying immunodeficiency
Table 1.3: Risk factors for developing PTLD 
1.4.2 Clinical features
PTLD presents with a diverse spectrum of clinical symptoms and signs and the index 
o f suspicion for diagnosing this disorder should be high in all transplant patients. 
Commonly patients present with the non-specific symptoms such as fever, malaise, 
tonsillitis and weight loss, however, rarely PTLD presents as a fulminant 
disseminated disease resembling septic shock. The symptoms o f PTLD in children, 
who are commonly EBV sero-negative at the time o f transplant, are often similar to 
those o f primary EBV infection (infectious mononucleosis) which usually occurs in 
the first weeks following transplantation, with fever, tonsilar and adenoid 
hypertrophy, cervical lymphadenopathy and hepatomegaly typically with raised 
hepatic enzymes. Biopsy and histological examination is therefore necessary to 
distinguish between the two disorders.
PTLD can present as solitary or multiple tumours, affecting both nodal and extra- 
nodal sites. Common extra-nodal sites include the kidneys, liver, lungs, bowel, 
mediastinum, skin, bone marrow and spleen. The central nervous system (CNS) can
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also be involved. A recent series o f 910 adult and paediatric PTLD patients showed 
that CNS involvement occurred in 15% of cases and with half o f these cases 
presenting as an isolated tumour (Buell et al., 2005). This contrasts to non-Hodgkin’s 
lymphoma (NHL) in the immunocompetent population where the incidence o f disease 
confined to the CNS is 0.28 per 100,000 (Cote et al., 1996).
1.4.3 Diagnosis
The diagnosis o f PTLD is made on histological examination o f the tumour. In-situ 
hybridisation for EBERs is used to determine the presence o f EBV in the cells (Howe 
and Steitz, 1986) together with immunostaining for LMPs. Characterising the cellular 
infiltrate o f the tumour for B-cell markers such as CD 19, CD20, CD21 or CD22 also 
helps distinguish PTLD from acute rejection, which often appear similar using 
conventional histological staining. Clonality o f the tumour is also assessed by 
immunophenotyping and the expression of kappa or lambda chains on the surface of 
the immunoglobulin molecules on the B cells.
Following diagnosis patients are subjected to a CT o f the thorax and abdomen and a 
bone marrow aspiration to ascertain other sites of disease. Once all sites o f disease 
have been localised, the PTLD is staged according to the Ann Arbor classification 
system (Carbone et al., 1971), and used to evaluate prognosis. Other radiological 
imaging is used as clinically indicated e.g. magnetic resonance imaging (MRI) o f the 
brain and/or spinal cord or bowel.
Due to the non-specific clinical presentation o f PTLD and the assumption that early 
diagnosis and treatment improves overall survival, many studies have used EBV load 
to monitor patients at high risk o f developing PTLD. However many variables exist in
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the published methods used to measure EBV load, confounding the data. These 
include: (a) the amplification techniques e.g. semi-quantitative (SC-), quantitative- 
competitive (QC-), real time quantitative (RTQ-) and light cycler quantitative (LCQ-) 
forms o f PCR; (b) the peripheral blood component used as test samples e.g. whole 
blood, PBMC, serum or plasma; (c) the means of expressing EBV copy number e.g. 
per ml whole blood, |ig DNA, numbers o f lymphocytes and (d) no international 
standard for EBV has yet been established so laboratories tend to use their own. In 
addition, an important conceptual problem with measuring the EBV load in blood 
samples is that the virus is exclusively present in the resting memory B cell 
population or shed from the lytic cycle o f these cells into plasma or serum and does 
not reflect EBV in the PTLD tumour (Babcock et al., 1999). Therefore measurement 
o f the viral load in the blood will represent the degree o f immune deficiency allowing 
viral expansion secondary to immunosuppression and not events leading to 
transformation to PTLD in the tissues.
The clinical studies addressing the use o f viral load in the diagnosis o f PTLD are 
difficult to interpret because they mostly involve small numbers of patients and, 
starting with the assumption that a high EBV load will predict development of PTLD, 
most o f the studies incorporated pre-emptive therapeutic intervention when EBV 
levels reached certain levels (Savoldo et al., 2005; Holmes et al., 2002; Lee et al., 
2005; McDiarmid et al., 1998). There is a preponderance o f paediatric studies because 
o f the increased risk o f PTLD in EBV sero-negative individuals undergoing 
transplantation.
The most consistent findings are seen in HSCT patients where the risk o f  PTLD is 
largely restricted to the first 6  months posttransplant, during which the immune
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repertoire is being generated. A combination o f EBV PCR and measurement o f KBV 
specific T cells by means o f tetramers has helped to define patients at risk o f PTLD 
and those at risk were then treated pre-emptively with rituximab to eliminate EBV 
infected B cells during the time required to regain the immune repertoire (Clave et al., 
2004). Most studies in HSCT patients agreed on a cut-off value o f 5x l0 3 -  105/(ig 
DNA as carrying a high risk o f PTLD and there is a consensus that a rapid, 
progressive rise in EBV load is the most important indicator o f PTLD (Clave et al., 
2004; Gartner et a l., 2002; Orentas et al., 2003). Indeed, one group noted that in 
patients developing PTLD, the EBV load a week earlier was below the cut-off value 
indicating the need for frequent estimation of EBV load (Gartner et al., 2002). 
Successful treatment with rituximab led to a prompt fall in EBV load. Encouraging 
though these studies are, they do not equate to solid organ grafts because the presence 
o f tetramer positive EBV specific cytotoxic T cells does not imply that they are 
functional when immunosuppressive drugs are used. In HSCT immunosuppression is 
light and often not required; hence the presence o f tetramer positive cells is 
synonymous with functional CD8 + T cells.
Studies measuring EBV load in solid organ transplantation are more controversial and 
discordant than for HSCT. Cut-off levels for the risk o f PTLD ranged between 200 
and 500/105 PBMC (Green et al., 1998; Gridelli et al., 2000), 600 and 2 .5xl04/|ag 
DNA (Leung et al., 2004; Savoldo et al., 2005) or 104/ml (Benden et al., 2005). Some 
groups even set separate cut-off values for EBV sero-negative (>40/105 PBMC) and 
sero-positive (>200/105 PBMC) recipients (Green et al., 1998; Holmes et al., 2002). 
A meta-analysis o f studies using a cut-off value to predict PTLD showed that 24/135 
(18%) o f patients with high EBV levels actually developed PTLD (Gridelli et al.,
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2000; Kullberg-Lindh et a l., 2006; Schccnstra et a l., 2004; Vajro et a l., 2000; Bcnden 
et a l., 2005; Mcrlino c7 ^/., 2003; Green et al., 2000). In studies where intervention 
was not used the general conclusion was that EBV load could not accurately predict 
the development o f PTLD (Scheenstra et al., 2004; Vajro et al., 2000) and some 
concluded that the EBV load was more value as a negative predictor o f PTLD for 
patients whose EBV was low or negative (Allen et al., 2001; Green et al., 2000). 
However, in the studies that did include therapeutic intervention, some benefit was 
observed against historical controls as a result o f reducing immunosuppression or 
other therapeutic manoeuvres (Lee et al., 2005; McDiarmid et al., 1998). Other 
studies improved the predictive power of EBV load by including an assessment o f the 
immune response to EBV (Smets et al., 2002; Carpentier et al., 2003; Baudouin et al., 
2004).
Therefore, until randomised studies are performed, the predictive value o f EBV load 
for anticipating development o f PTLD following SOT remains uncertain.
1.4.4 Prognosis
Reported rates o f disease-free and overall survival in PTLD are variable due to the 
heterogeneity o f the disease. Estimated survival rates range from 25% -60%  (Leblond 
et al., 2001). A recent study o f  107 cases proposed a multivariate prognostic model in 
which poor performance status, monomorphic disease, and grafted organ involvement 
predicted poor outcome (Ghobrial et al., 2005). Other negative risk factors that have 
been implicated include patients who are EBV sero-negative at the time o f transplant, 
late onset o f disease, disease involving multiple sites, advanced stage, elevated lactate
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dehydrogenase (LDH), severe organ dysfunction, and CNS disease (Tsai et a l., 2001; 
Choquet et al., 2002; Benkerrou et al., 1998; Trofe et al., 2005).
1.4.5 Treatment
The treatment o f PTLD is controversial with no international consensus. To date no 
randomised multi-centre trials have been performed and published studies typically 
reflect the retrospective experience o f single institutions. The basic principle o f 
treatment however, is to stop uncontrolled EBV-driven B cell proliferation; either by 
restoring effective EBV-specific T cell immunity or by targeting the malignant B cells 
with anti-B cell antibodies (rituximab) or cytotoxic chemotherapy. Differences exist 
in the treatment of PTLD following SOT or HSCT and will be considered separately.
1.4.5.1 Treatment o f  established PTLD following SOT
Reduction o f immunosuppressive therapy: Since this strategy was first described in 
1984 to treat PTLD (Starzl et al., 1984) it has been the first line treatment o f PTLD 
occurring after SOT and is used in over 90% o f cases (Amlot et al., 2007). Following 
SOT patients require a combination o f major immunosuppressive drugs to control 
against alloreactivity and graft rejection. Immunosuppression however, has the 
adverse effect o f reducing the number o f functional circulating EBV-specific T cells 
leading to uncontrolled EBV B-cell proliferation. The rationale for reducing 
immunosuppression is therefore to restore EBV immunity allowing the EBV-specific 
cytotoxic T cells to kill the malignant B cells. Studies have shown that this approach 
is effective in approximately 30-50% o f all cases (Starzl et al., 1984; Amlot et al., 
2007). At present there is no standard algorithm for reduction in immunosuppression
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(RIS), however, it is important that the patient is monitored closely throughout for 
deterioration in graft function (indicative o f rejection) or in clinical status.
A novel approach offered as a clinical service in our centre, is to reduce the major 
immunosuppressive drugs (e.g. cyclosporine, tacrolimus) in a step-wise fashion 
tailored to the patient’s clinical performance status according to the Kamofsky scale 
(Appendix 1.2), the size o f the target PTLD tumour used to assess clinical response 
and the re-emergence o f an anti-viral response by immunophenotyping the patients T 
cells for activation markers such as surface MHC Class II expression (Amlot et al., 
1996; Amlot et al., 2007). This approach is illustrated in Table 1.4 and has the 
advantage o f identifying those patients with life threatening PTLD who require urgent 
treatment and rapid RIS. Conversely, it also identifies patients with stable disease who 
can have their immunosuppression tapered more cautiously. At each step o f RIS, 
patients are assessed for an increase in T cell activation indicative o f an anti-viral 
response. Immunosuppression continues to be reduced at a rate determined by the 
patient’s clinical status (Table 1.4) until there is a three fold rise in the number o f 
MHC class II expressing CD 8 + T cells to achieve at least 0.3 x 109/L (Amlot et al., 
2007). RIS is also stopped if  the target PTLD tumour decreases in size by 30% 
according to the RECIST criteria (Appendix 1.3), indicating a partial clinical 
response, or if  graft rejection occurs.
By using this tailored individual approach, PTLD patients are less likely to have graft 
rejection, a scenario which is clinically devastating especially for heart, lung and liver 
transplant patients, where replacement allografts are rare and no effective support 
therapy (such as haemodialysis for failed renal allografts) exists.
66
Introduction
% o f  the starting im m unosuppressive dose at PTLD  diagnosisr ~
W eek Stable Progressive Life th rea ten ing
PT L D 2 PTLD 3 PTLD 4
0 90 90 60
1 90 75
2 75 60 30
3 75 45
4 60 30 0
5 60 12
6 45 0
7 45
8 30
9 30
10 15
11 15
12 0
Table 1.4: Protocol for RIS
Depending on the clinical status it is possible for a patient to move categories, e.g. if a patient had 
progressive disease that became stable at week 3, then subsequent reduction carries on from the dose 
achieved (45%) at fortnightly intervals in the stable disease column.
' Immunosuppressive regimes usually include a combination of azathioprine (AZA) or mycophenylate 
mofetil (MMF) plus Cyclosporine (CSA) or tacrolimus (TAC) with or without steroids. At PTLD 
diagnosis AZA and MMF are stopped and the sliding scale of RIS usually refers to CSA or TAC. The 
exception is where the immunosuppressive regime at diagnosis is AZA or MMF or rapamycin in 
combination with steroids. In this case the drug being reduced according to the sliding scale is either 
AZA or MMF or rapamycin. The dose of steroids remains unchanged.
2 Stable PTLD: No change in the size of measurable PTLD lesions and where the patient’s clinical 
status according to the Kamofsky scale (Appendix 1.2).is unchanged.
3 Progressive PTLD: 20% increase in the size of measurable PTLD lesions or a deterioration in the 
patient’s clinical status according to the Kamofsky scale as a direct result of the PTLD. Patient remains 
in Kamofsky grade > 20%.
4 Life threatening PTLD: PTLD is affecting the vital organs (heart, lungs circulatory system, graft) and 
the patient is moribund (Kamofsky grade 10%).
67
Introduction
Chemotherapy: Combination chemotherapy regimes that are typically used for NHL 
(e.g. cyclophosphamide, doxorubicin, vincristine and prednisolone, CHOP) are often 
used in the treatment o f PTLD when RIS fails to control the disease (Garrett et al., 
1993; Muti et al., 2002). Although combination chemotherapy is effective, treatment- 
related mortality rates secondary to neutropenic sepsis are high. Recent studies 
however, have shown that this may be reduced by using low-dose chemotherapy 
regimes such as cyclophosphamide and prednisolone (Gross et a l., 2005; Gross et a l., 
1998).
Surgery and Radiation: Localised PTLD may be treated with a combination o f RIS 
and surgery (Beynet et al., 2004) or radiotherapy (Koffman et al., 2000). These 
modalities are particularly important where disease is causing compression o f vital 
organs and urgent relief is required.
Anti-viral agents: B cell proliferation in PTLD is associated with the latent cycle of 
EBV infection and is independent of lytic replication. Therefore anti-viral drugs such 
as acyclovir or ganciclovir which prevent lytic viral replication have no clinical value 
in the treatment o f  established PTLD. Some transplant centres use prophylactic anti­
viral therapy in EBV sero-negative patients who receive a sero-positive graft in an 
attempt to limit viral transmission from the donor to the recipient; however the 
evidence to support such management is lacking. Babcock et al showed that in 
asymptomatic EBV sero-positive organ transplant recipients with elevated viral loads, 
the EBV load was maintained in the resting memory B cell population (Babcock et 
al., 1999) and therefore speculated that anti-viral therapy would have limited, if any, 
effect on the prevention o f PTLD. This is supported by a randomised trial which 
showed no reduction in the incidence o f PTLD with prolonged acyclovir therapy
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(Green et al., 1997). Other retrospective clinical studies have shown some benefit 
with anti-viral prophylaxis, however they are limited by the lack o f  contemporaneous 
controls and patient numbers (Punch et al., 2005; Darenkov et al., 1997; Davis et al., 
1995).
Cytokine and anti-cytokine therapy: IFN-a has been used in the treatment o f PTLD 
with some clinical success (Davis et al., 1998), however an increased incidence o f 
graft rejection was also reported and therefore this therapy should be used with 
caution. Antibodies against IL-6 , the cytokine involved in the proliferation and 
maturation o f B cells, have also been trialled as a novel treatment o f PTLD which is 
unresponsive to RIS. In a multi-centre phase I/II trial o f 12 SOT PTLD patients, 
treatment with a murine anti-IL - 6  monoclonal antibody produced clinical remissions 
in 5 patients and partial responses in a further 3 patients. No relapse was observed in a 
15-27 month follow-up period (Haddad et al., 2001). Importantly, these studies used 
abrupt cessation o f immunosuppression as the initial RIS schedule, and if  no response 
had occurred after 8  days patients were assumed unresponsive and eligible for the 
study. Patients in this study m ay therefore not fully represent the poor prognostic 
group o f PTLD patients that are unresponsive to RIS and are more likely respond to 
further immune manipulation. Further trials are required to confirm this beneficial 
effect.
Anti-B cell antibodies: Rituximab, a chimeric monoclonal antibody that targets 
CD20 on the surface o f B cells has been used in several small retrospective studies as 
a treatment for PTLD following SOT (Milpied et al., 2000; Cook et al., 1999; Caillard 
et al., 2000; Zompi et al., 2000; Yang et al., 2000b). Typically Rituximab is used as a 
second-line therapy after RIS has failed (defined as patients who remain unresponsive
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to RIS after a 7-14 day period), either alone or in conjunction with chemotherapy. 
Response rates from the above studies varied (20-100%), emphasising the difficulties 
in assessing rituximab from small and heterogeneous patient populations. Recently, 
however a prospective multi-centre phase II trial o f 46 SOT patients who had failed to 
respond to withdrawal o f immunosuppressive therapy showed an overall response rate 
o f 46% and an overall 1 year survival rate o f 67% (Choquet et al., 2006). W hether 
this response rate could be improved by using rituximab in conjunction with 
combination chemotherapy (e.g. CHOP regime), a strategy which has been used 
effectively in immuno-competent NHL patients (Coiffier et al., 2002), has yet to be 
evaluated in clinical trials. Although rituximab is a promising therapy in patients who 
fail to respond to RIS, it has several potential disadvantages. Firstly as rituximab is 
specific for CD20, it is possible that its use on PTLD tumours that have 
heterogeneous CD20 expression may cause the outgrowth o f  a CD20-negative 
population o f proliferating B cells. This phenomenon has been previously reported in 
a few NHL patients (Kennedy et al., 2002; Davis et al., 1999) but as yet has not been 
seen in PTLD. Secondly, it is unclear what effect the profound B cell depletion caused 
by rituximab (B cells are depleted for 6 - 8  months post treatment) has on patients who 
are already immunosuppressed following transplantation (Suzan et al., 2001).
Cellular Immunotherapy: A novel means o f restoring EBV-specific cellular 
immunity in patients with PTLD is to infuse EBV-specific CTLs that are generated ex 
vivo. PTLD following SOT is invariably o f host origin and therefore CTLs must either 
be expanded from autologous or closely HLA-matched donor PBMCs. Autologous 
EBV-specific CTLs have been piloted as a prophylactic treatment for PTLD in two 
small studies with some clinical response (Comoli et al., 2002; Savoldo et al., 2006).
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This approach however, is limited by the failure o f standard techniques to generate 
CTLs from HBV sero-negative patients; a group who have an increased risk o f 
developing PTLD following transplantation o f a sero-positive organ, and the 
prohibitive time that is required to generate the CTLs (2-3 months). One means o f 
addressing these problems is to develop a bank o f cryopreserved allogeneic EBV- 
specific CTLs from the blood o f healthy EBV sero-positive donors. CTLs can then be 
selected from a panel o f lines according to the HLA type o f the patient and used 
immediately (W ilkie et al., 2004; Haque et al., 2002; Haque et al., 2001). A recent 
phase I/II clinical trial used allogeneic EBV-specific CTLs matched on HLA-A, -B 
and where possible -DR to treat eight patients with EBV-positive PTLD that had 
failed to respond to treatment with RIS +/- rituximab (Haque et al., 2002). Prior to 
infusion the high specificity for EBV antigens and low specificity for alloantigens was 
confirmed by testing the CTLs in in vitro cytotoxicity assays against the autologous 
EBV-immortalised LCL used to generate the CTL line, the patients 
phytohaemagglutinin-blasts or the patients LCL (where available), a HLA- 
mismatched LCL and a NK cell line. Clinical responses were observed in 4 out o f  8  
patients, however two died from causes unrelated to CTL toxicity before assessment 
o f  clinical response was possible. Although these responses are encouraging, this 
approach is limited by the short-term persistence o f the CTLs (EBV-specific 
precursors were only detected by limiting dilution analysis (LDA) for a maximum of 
44 days) and may be best suited to patients with low volume disease. Another 
criticism o f this study is that the time interval from RIS +/- rituximab to infusion o f 
EBV-specific T cells was short, suggesting that the patients had not necessarily failed 
to respond to first-line therapy.
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Vaccination: As EBV sero-negative patients are at high risk o f developing PTLD 
after receiving a sero-positive graft, one approach to reduce the incidence o f PTLD is 
to vaccinate all patients prior to transplantation and induce EBV sero-conversion. A 
vaccine containing the gp350 viral envelope antigen previously demonstrated a good 
immunological response in healthy EBV sero-negative healthy volunteers (Gu et al., 
1995) and is currently being piloted in EBV sero-negative children awaiting 
transplant. The primary endpoint o f this feasibility study however, is to assess the 
safety and optimal dose o f the vaccine and is not powered to show whether the 
vaccine prevents PTLD.
1.4.5.2 Treatment o f  established PTLD following HSCT
The differences in treatment between PTLD following SOT and HSCT relate to the 
means by which these patients become immunosuppressed. Following SOT, patients 
are treated with a combination o f major immunosuppressive drugs to control against 
graft alloreactivity. Immunosuppression is profound and indicated for life. In HSCT 
patients however, the immunodeficiency is caused by the ablation o f  the patient’s 
immune system with a combination o f high dose chemotherapy and/or radiation prior 
to donor stem cell infusion and recovers with immune reconstitution o f the donor 
graft. Immunosuppressive drugs are not usually required following HSCT and RIS is 
therefore rarely used as a therapeutic strategy. Instead, treatment is directed at 
reduction o f  the B cell mass with anti-B cell antibodies or restoring EBV T cell 
immunity with adoptive transfer o f donor EBV-specific T cells. Cytotoxic 
chemotherapy in these patients has the potential to induce graft failure or prolonged 
pancytopenia and is therefore avoided.
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Anti-B cell antibodies: Unlike SOT patients, the efficacy o f Rituximab has not been 
assessed in a multi-centre phase II trial. However, several small case studies have 
reported complete response rates ranging from 6 6  to 100% (McGuirk et a l., 1999; 
Milpied et a l., 2000; Kuehnle et a l., 2000; Faye et a l., 2001; van Esser et a l., 2001). 
Rituximab was used in conjunction with irradiated donor T cells or donor-derived 
EBV-specific CTLs in two o f these studies (McGuirk et a l., 1999; van Esser et a l., 
2 0 0 1 ), thus confounding the data.
The drawbacks o f rituximab as indicated for SOT also apply to its use in HSCT 
patients.
Cellular Immunotherapy: Donor-derived EBV-specific T cells have been used with 
clinical success in several studies as both prophylaxis and treatment for established 
PTLD in HSCT recipients (Gustafsson et al., 2000; Rooney et al., 1995; Rooney et 
al., 1998b; W einstock et al., 2006). PTLD tumours following HSCT are typically of 
donor origin and therefore EBV-specific CTLs are generated from donor blood using 
donor-derived EBV-transformed LCLs as APCs. Donor lymphocytes are readily 
available following HSCT and as donors are adults the majority will be EBV sero­
positive. EBV-specific CTLs still require 2-3 months to prepare and validate however, 
and therefore would need to be prepared prior to transplant from each donor. 
Allogeneic EBV-specific T cells represent an alternative however this has only been 
trialled in one HSCT patient (Haque et al., 2002).
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1.5 Clinical management of EBV-positive HD
HBV-positive HD represents 40-50% o f all HD cases although this figure increases in 
developing countries and in patients with coexistent HIV infection. EBV-positive and 
EBV-negative tumours are currently managed according to the same treatment 
algorithms. However, as further information regarding the role o f EBV in the 
pathogenesis o f HD becomes available, novel treatment strategies for EBV-positive 
HD may be developed. Current interest is directed at the use o f the EBV antigens as 
targets for cellular immunotherapy and this will be discussed in detail below.
1.5.1 Incidence
Many studies have suggested a causative association between EBV and HD 
(Gutensohn and Cole, 1980; Chatila et a l., 1989; Weiss et a l., 1987; Wu et al., 1990) 
however, the precise mechanisms involved remain unclear. The main premise for an 
infectious origin for HD is the distinct pattern o f incidence within age-groups. The 
incidence o f HD is traditionally described as bimodal, with a peak incidence in 
childhood (developing countries) or early adulthood (developed countries) followed 
by a second peak in middle age. The early peak mirrors the age at which primary 
EBV infection occurs suggesting that HD might develop from an atypical response to 
EBV. Against this however, is that the majority o f  HD tumours occurring in young 
adults (who have the highest incidence o f IM) are not associated with EBV. A recent 
population study has proposed that the bimodal incidence model is over simplistic and 
that four distinct types o f HD occur at different ages and geographical areas (Figure 
1.9). The first three represent EBV-positive HD, while the fourth represents EBV- 
negative HD and accounts for the large incidence in young adults from developed
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countries (Jarrett, 2002). It is therefore very possible that the small peaks of EBV- 
positive HD at an early age do represent delayed reactions to primary EBV infection.
Figure 1.9: Incidence of HD by age
The coloured lines represent three distinct forms of EBV-associated HD cases. The first (a) occurs 
below the age of 10 years and accounts for most childhood cases of HD in developing countries. The 
second (b) represents EBV-associated HD among young adults and has a peak incidence between 15- 
34 years. Both forms of HD are thought to represent a delayed atypical reaction to primary EBV 
infection. The third type of EBV-associated HD (c) has a peak incidence in middle age and represents 
over 50% of cases over the age of 55 years. The dotted line (d) represents the cases of HD that are not 
associated with EBV which account for the largest incidence among young adults in developed 
countries.
Figure adapted from (Jarrett, 2002).
1.5.2 Clinical presentation
Patients with HD typically present with painless lymphadenopathy. Other features 
may include the so-called ‘B’ symptoms: unexplained fevers with temperatures over
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38°C, drenching night sweats and unexplained loss o f more than 10% o f body weight 
in the 6  months before diagnosis. Pruritus and fatigue are also commonly described.
1.5.3 Diagnosis
EBV-positive HD is diagnosed from histopathological examination o f an affected 
lymph node. The characteristic R-S cells are identified as large often binucleated cells 
with prominent nucleoli and an unusual CD45-, CD30+, CD 15+/- immunophenotype. 
The presence o f EBV is confirmed by nuclear staining for EBERs using in situ 
hybridization and LMP cell surface expression detected by immunohistochemical 
staining.
Following diagnosis, the patient’s disease is staged using radiological imaging and 
bone marrow aspiration and classified according to the Ann Arbor staging system 
(Appendix 1.1, (Carbone et al., 1971).
1.5.4 Prognosis
The prognosis o f HD can be accurately determined using a series o f seven prognostic 
factors determined from a large international study (Hasenclever and Diehl, 1998). 
These include: age > 45 years, stage IV disease, male sex, haemoglobin < 10.5 mg/dl, 
lymphocyte count < 0.6 x 109/L, albumin < 4.0 mg/dl and white blood count > 15 x 
109/L. Freedom from progression (FFP) at 5 years directly relates to the number o f 
adverse prognostic factors present in each patient. The 5 year FFP for patients with no 
adverse factors is 84%. Each additional factor lowers the 5 year FFP by 7%, such that 
a patient with 5 or more factors has a 5 year FFP o f only 42%.
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Three recent population-based cohort studies have also shown the presence o f KBV to 
be a poor prognostic factor, but only in patients > 45 years (Keegan et al., 2005a; 
Lnblad et a l., 1999; Jarrett et al., 2005). W hether this observation is a consequence of 
two biologically distinct forms o f HD or the decline in EBV-specific cellular 
immunity with age is unclear.
1.5.5 Treatm ent
The treatment o f  HD has changed significantly over the last decades, rendering this 
entity one o f  the most curable human cancers. Currently, approximately 80% of 
patients achieve long-term disease-free survival. Progress has been made by tailoring 
poly-chemotherapy regimes that not only induce high rates o f remission but have a 
reduced incidence o f fatal secondary malignancies. The prognosis o f patients who fail 
to achieve rem ission with primary treatment (Primary progressive disease) or who 
developed relapsed disease however remains poor, necessitating research into novel 
therapeutic strategies.
1.5.5.1 Early Stage HD
Traditionally stage I or II HD was treated with radiotherapy which extended beyond 
the sites o f  disease (extended-field radiation). However due to the high incidence o f 
relapse and the significant long term morbidity and mortality from cardiac toxicity, 
this approach has been superseded by the use o f 2-4 cycles o f combination 
chemotherapy regimes such as doxorubicin, bleomycin vinblastine and dacarbazine; 
ABVD, in conjunction with radiotherapy to the involved nodes only (involved-field 
radiation). Patients with unfavourable risk factors (Large mediastinal mass, age > 50
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years, high erythrocyte sedimentation rate or extra-nodal disease) are treated with 4-6 
cycles o f ABVD +/- involved-field radiation.
/. 5.5.2 A dvanced disease
Patients with stage III or IV HD are typically treated with 6 - 8  cycles o f ABVD 
combination chemotherapy. This strategy has demonstrated overall survival rates of 
between 65-82% in two multi-centre international phase III trials (Duggan et al., 
2003; Canellos and Niedzwiecki, 2002; Canellos et al., 1992). Recent trials have 
shown that survival figures can be further improved by using dose-intensified 
chemotherapy regimes (Homing et al., 2002; Diehl et al., 2003), however at the 
expense o f increased secondary haematological malignancy rates (Diehl et al., 2003). 
The role o f consolidating radiotherapy after effective chemotherapy in the treatment 
o f advanced disease remains controversial. A large phase III trial and a meta-analysis 
o f several trials showed no clinical benefit o f consolidative involved-field 
radiotherapy after achieving a complete remission with combination chemotherapy 
(Aleman et al., 2003; Loeffler et al., 1998), although some benefit was observed in 
patients achieving a partial remission (Aleman et al., 2003).
1.5.5.3 Primary progressive and relapsed Hodgkin’s disease
Patients with primary progressive disease or who relapse after achieving complete 
remission with chemotherapy may be salvaged with high dose chemotherapy in 
conjunction with autologous HSCT (Linch et al., 1993; Schmitz et al., 2002). 
However, many patients will relapse again after this approach and require further 
treatment (Disease-free survival at 3 yrs 75% (Linch et al., 1993) and 55% (Schmitz 
et al., 2 0 0 2 ) in the transplant arms o f both randomised control trials).
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Allogeneic HSCT with reduced intensity conditioning has been trialled with some 
clinical success by several centres for the treatment o f multiple relapsed or primary 
progressive disease (Alvarez et al., 2006; Anderlini et al., 2005; Peggs et al., 2005), 
indicating that a graft-versus-lymphoma effect may exist. The short follow-up period 
for these patients to date however, limits true assessment o f the impact on 
progression-free and overall survival. In addition, treatment related mortality (TRM) 
is high (4-17% at day 100) with this approach restricting its utility. One mechanism 
by which graft-versus-lymphoma may be mediated in EBV-positive HD patients is by 
the EBV-latent antigens (LMP1, LMP2) acting as tumour-associated antigens for 
EBV-specific CTLs. Donor-derived EBV-specific CTLs are known to be transferred 
via allografts from EBV sero-positive donors and require persistent EBV antigen for 
maintenance before EBV-specific CTLs can be generated in the recipient after 
immune reconstitution (Gandhi et al., 2003). Whether this effect contributes to an 
improved clinical outcome for EBV-positive HD after allogeneic HSCT compared to 
EBV-negative HD has yet to be assessed.
Donor lymphocyte infusions (DLI) have also been used for residual disease or relapse 
after allogeneic HSCT (Peggs et al., 2005; Anderlini et al., 2004; Alvarez et al., 
2006), again with some clinical response. This success however, is balanced by a high 
incidence o f GVHD (33-88%) and TRM (11-33%).
Unlike non-Hodgkin’s lymphoma where humanised monoclonal antibodies are used 
extensively, their use in HD is still undefined and subject to further research. Bi- 
specific antibodies against CD30, an antigen on R-S cells and CD 16, an antigen on 
NK cells have been developed to induce tumour directed cytotoxicity and used in a 
small phase I/II trial o f heavily treated refractory HD patients with a 25% response
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rate (Hartmann et al., 2001). Similar results were also achieved with another bi- 
specific antibody against CD30 and CD64 (Borchmann et al., 2002), however both 
studies were hindered by the development of anti-murine antibodies. Studies are 
currently in progress using a fully humanised antibody to CD30 (Borchmann et al., 
2003; Boll et al., 2005).
A novel approach restricted to the treatment o f  relapsed EBV-positive HD is adoptive 
transfer o f EBV-specific CTLs. Early studies used CTLs that had been generated in 
vitro from repeated stimulation with autologous LCLs which preferentially stimulate 
T cells specific for EBNA antigens rather than the LMP 1 and 2 antigens expressed by 
R-S cells (Rooney et al., 1998a; Roskrow et al., 1998; Bollard et al., 2004). Despite 
this broad specificity, however, some clinical responses were demonstrated and using 
tetramer and functional analyses it was possible to track LMP2-specific CTLs 
entering the tumours (Bollard et al., 2004). More recent studies have used a 
recombinant vaccinia-virus polyepitope construct that encodes for multiple LMP1 and 
2 epitopes to generate LMP-specific CTLs in healthy individuals (Duraiswamy et al., 
2004; Duraiswamy et al., 2003). This strategy has yet to be used in patients with HD 
and has the disadvantage o f being technically demanding and extremely time 
consuming. Treating multiple patients with LMP-specific CTLs is therefore unlikely 
to be a realistic future treatment option. One way to circumvent these disadvantages is 
to use allogeneic EBV-specific CTLs from partially HLA-matched donors; an 
approach described above for the treatment o f  PTLD (Haque et al., 2002). To date 
this has been studied in the context o f case reports only (Bollard et al., 2006; Lucas et 
al., 2004).
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1.6 Aims of the thesis
To describe the development a flow cytometry based assay for the rapid 
enumeration o f functional EBV-specific CD8 T cells in PBMCs using production 
o f interferon-y as a readout.
• The assay was optimised in healthy EBV sero-positive individuals testing a 
variety o f different EBV antigens to stimulate responses and then applied to 
patients with two EBV-driven malignancies: PTLD and HD.
• In patients with PTLD, the assay was used to monitor the emergence o f EBV 
immunity in patients whose immunosuppressive therapy was reduced, and 
recovery o f functional EBV immunity investigated for correlation with clinical 
outcome and compared with current immunophenotyping techniques used to 
guide RIS.
• In patients with EBV-positive HD, the assay was used to investigate the role 
o f  EBV-specific CD 8 + and CD4+ T cell responses in the pathogenesis o f this 
disease.
To describe the development o f a novel approach for detecting and quantifying 
EBV-specific T cell responses using real-time quantitative PCR to measure 
cytokine production. This technique was compared to the flow cytometry-based 
assay using samples from healthy individuals and patients with EBV-driven 
malignancies.
To describe the investigation o f whether the presence o f EBV in pathological 
tissues can be accurately detected using a novel murine antibody, RFD3. Results 
were compared to the current detection methods used in clinical practice.
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2.1 Peptide Biochemistry
2.1.1 Source
The amino acid sequences o f previously identified EBV peptides bound by HLA class 
I molecules and recognised by T cells were retrieved from the SYFPEITHI database 
(http://syfpeithi.de). EBV peptides were produced on an ABI synthesiser using F moc 
chemistry and purified by high performance liquid chromatography by Yorkshire 
Bioscience, Heslington, York, UK (http://york-bio.com). All peptides were produced 
to greater than 95% purity and expected molecular weight was confirmed by mass 
spectrometry. Some HLA-A*0201 binding EBV peptides were also produced at 80% 
purity. Peptides were reconstituted in dimethyl sulfoxide (DMSO, Sigma, Surrey, 
UK) to give stock solutions o f lOOmg/ml, 20mg/ml and lOmg/ml (weight:volume), 
and stored at -70°C.
2.1.2 EBV specific peptides
The EBV peptides used are listed in Tables 2.1 and 2.2. Peptides were chosen to 
cover a broad spectrum of HLA alleles.
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Peptide Sequence Protein H LA  restriction
CLGGLLTM V LMP 2 HLA-A *0201
AVFDRKSDAK EBNA3B HLA-A *0201
LLDFVRFMGV EBNA3C HLA-A *0201
GLCTLVAM L BMLF 1 HLA-A *0201
LLW TLVVLL LMP 2 HLA-A *0201
SVRDRLARL EBNA 3A HLA-A *0201
LM IIPLINV gp85 HLA-A *0201
TLFIGSHVV gp85 HLA-A *0201
SLVIVTTFV gp85 HLA-A *0201
VLQW ASLAV gp350 HLA-A *0201
LLW AARPRL BARFO ORF HLA-A *0201
YLLEM LW RL LMP 1 HLA-A *0201
SLREW LLRI EBNA 3A HLA-A *0203
LLSAW ILTA LMP 2 HLA-A *0203
LTAGFLIFL LMP 2 HLA-A *0206
RLRAEAQVK EBNA 3C HLA-A *03
AVFDRKSDAK EBNA 3B HLA-A *1101
IVTDFSVIK EBNA 3B HLA-A *1101
SSCSSCPLSK LMP 2 HLA-A *1101
ATIGTAM YK Rta HLA-A *1101
PYLFW LAAI LMP 2 HLA-A *23
DYCNVLNKEF Rta HLA-A *24
RYSIFFDY EBNA 3C HLA-A *24
TYGPVFM CL LMP 2 HLA-A *24
AYSSWMYSY EBNA 3C HLA-A *3002
AVFDRKSDAK EBNA 3B HLA-A *6801
Table 2.1: EBV peptide sequences presented by HLA-A
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Peptide Sequence Protein H LA restriction
VPAPAGP1V EBNA 3A HLA-B *07
QPRAPIRPI EBNA 3C HLA-B *0702
RPPIFIRRL EBNA 3A HLA-B *0702
FLRGRAYGL EBNA 3A HLA-B *08
QAKW RLQTL EBNA 3A HLA-B *08
RAKFKQLL BZLF 1 HLA-B *08
AYPLHEQHG EBNA 3A HLA-B *08
YIKSFVSDA EBNA 3A HLA-B *08
QNGALAINTF EBNA 3C HLA-B *1501
LEKARGSTY EBNA 3A HLA-B *1501
GQGGSPTAM EBNA 3B HLA-B *1501
DEVEFLGHY BMLF 1 HLA-B *18
HPVGEADYFEY EBNA 1 HLA-B *3501
AVLLHEESM EBNA 3B HLA-B *3501
YPLHEQHGM EBNA 3A HLA-B *3503
IEDPPFNSL LMP 2 HLA-B *4001
SENDRLRLL BZLF 1 HLA-B *4002
VEITPYKPTW EBNA 3B HLA-B *4402
KEHVIQNAF EBNA 3C HLA-B *4402
EENLLDFVRF EBNA 3C HLA-B *4402
AEGGVGW RHW EBNA 3C HLA-B *4403
VSFIEFVGW EBNA 3B HLA-B *5801
YRSGI1AVV BMLF 1 HLA-Cw *06
Table 2.2: EBV peptide sequences presented by HLA-B and HLA-Cw
2.2 In vitro Cell Culture
2.2.1 Blood sample collection
Blood from patients with PTLD or HD was received from five renal transplant 
centres: The Oxford Kidney Unit, The Churchill Hospital, Oxford; Gloucester Royal 
Hospital, Gloucester; Wessex Renal Transplant Unit, Queen Alexandra Hospital, 
Portsmouth; St Bartholomew’s Hospital, London and The Royal Free Hospital, 
London. Ethical permission was granted locally for each participating centre.
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Approximately 3()mls o f  blood in Lithium heparin tubes was taken at the same time 
routine samples were collected for immunophenotyping o f lymphocyte activation 
subsets, a clinical service provided by the Clinical Immunology Department at the 
Royal Free and University Medical School (RFUCMS), London.
EBV sero-positive healthy volunteers from the Anthony Nolan Research Institute and 
the Immunology Department o f the Royal Free Hospital were recruited and consented 
to participate in this study.
HLA genotyping for Class I and II HLA alleles (HLA-A, B, Cw and DR, DP and DQ) 
for healthy individuals was performed by the histocompatibility laboratories o f the 
Anthony Nolan Trust (ANT). HLA typing for the patient group was performed locally 
at the transplant centres using a combination o f low and high resolution techniques.
2.2.2 Media and Reagents
All media and supplements were obtained from BioWhittaker, Wokingham, UK, 
unless otherwise stated. Plastic ware was obtained from Elkay, Basingstoke, UK, or 
Helena Biosciences, Sunderland, UK.
2.2.3 Cell culture conditions
Cell lines (described below) and peripheral blood mononuclear cells (PBMCs) were 
grown in complete media (CM: RPMI 1640 media supplemented with 2mM L- 
glutamine, lOOU/ml penicillin, lOOpg/ml streptomycin, and 10% heat-inactivated 
foetal calf serum), in a 37°C humidified incubator in 5% CO2. Cells were grown at a 
density o f 0.5-1 x 106/ml in 25cm2 or 50cm2 tissue culture flasks (Falcon™, Becton 
Dickinson (BD), Oxford, UK). CM was replaced every three days or earlier if the
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phenol red in the media had turned yellow indicating acidity. Sterile conditions were 
maintained by working in a category 11 microflow cabinet.
2.2.4 Isolation of peripheral blood mononuclear cells (PBMCs) from whole 
blood
Whole blood was collected into lithium heparin (Starstedt, Germany) tubes to prevent 
clotting. A 4ml aliquot o f whole blood was carefully layered onto 4ml Lymphoprep 
(Nycomed Pharma AS, Oslo, Norway) and centrifuged at 2200 rpm for 20 minutes. 
PBMCs were collected from the interface using a wide bore sterile pastette, washed in 
RPMI 1640 media and centrifuged at 1500 rpm for 7 minutes. The cell pellet was 
washed in CM, centrifuged at 1200 rpm for 5 minutes, resuspended in CM, and 
counted in a Neubauer haemocytometer and adjusted to a concentration o f lx l0 6/mL. 
PBMCs were used immediately or cryopreserved for later experiments.
2.2.5 W hole blood preparation
Whole blood was transferred from the lithium heparin collection tubes into 15ml 
conical tubes and centrifuged at 2200 rpm for 10 minutes. Serum was removed with a 
pastette and replaced with an equivalent volume o f CM. Red cells were lysed using 
sterile Hoffman’s lysis buffer (8.3g NH4CI, l.Og KHCO3, 37mg disodium EDTA 
dissolved in 100ml distilled water, pH 7.6) diluted 1:10 with distilled water, by adding 
lm l o f serum-free whole blood to 14ml o f diluted Hoffman’s lysis buffer and 
incubating at room temperature for 5 minutes. After centrifugation the cells were 
washed immediately and resuspended in CM equivalent to the original volume o f 
whole blood.
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2.2.6 Single cell suspension from lymph node biopsies
Single cell suspensions were prepared from fresh lymph node biopsies that had been 
taken at the Department o f Clinical Immunology, Royal Free Hospital after receiving 
ethical permission. Lymph nodes were placed into a Petri dish with CM and cut up 
into small pieces using a sterile scalpel. The tissue pieces were then placed into a 
50ml conical tube with CM and further disintegrated by gently pipetting. The tissue 
pieces and the CM were gently passed through a sieve into a 50ml conical tube, 
generating a cell suspension. The debris was allowed to settle for 2 minutes and the 
single cell suspension was transferred to a clean tube for counting.
2.2.7 Cell counting and viability
Cells were counted using a 0.1mm depth Neubauer haemocytometer (Weber 
Scientific International, West Sussex, UK). A lOpL aliquot was taken from a known 
volume o f cells resuspended in CM and mixed thoroughly with a lOpL aliquot o f 
0.4% Trypan Blue solution (Sigma). lOpL was then transferred to the counting 
chamber and counted under a phase contrast microscope. Viable cells remain 
translucent by excluding Trypan blue, while dead cells are stained blue. Viability was 
expressed as the proportion o f viable cells to the total number o f cells.
2.2.8 Cell cryopreservation and thawing
Cells were frozen using a freezing mix containing 40% DMSO (Sigma), 40% foetal 
calf serum and 20% RPMI 1640 media. Cells were counted and centrifuged at 1200 
rpm for 5 minutes to form a cell pellet. The cell pellet was then resuspended in 0.5ml 
o f CM and added to 0.5ml o f freezing mix. Cells were transferred into a 1.5ml 
cryovial (Cryotube Vials, Nunc®, Denmark) and placed in a Nalgene™  Cryo 1°C
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freezing container (Fisher Scientific, Loughborough, UK) containing 250ml o f 100% 
isopropyl alcohol (BDH) at -70°C. After 24 hours the cryovials were transferred to 
liquid nitrogen containers for long term storage. Up to lOx 106 cells were frozen in a 
single aliquot. When required, cells were thawed rapidly in a 37°C water bath, diluted 
in 15mls o f CM and washed by centrifugation at 1200 rpm for 5 minutes. The cell 
pellet was then resuspended in 1ml o f CM and counted. Cells were then allowed to 
recover in CM at 37°C for 24 hours prior to setting-up any assay.
2.2.9 Generation o f EBV-transformed B lymphoblastoid cell lines
Previously titrated Epstein-Barr virus from the B95D8 EBV-producing marmoset cell 
line was added to a dry cell pellet at a concentration o f 50|il per lxlO 6 PBMCs and 
incubated for 1 hour at 37°C, flicking the cells at 15 minute intervals to ensure 
adequate mixing. The cells were resuspended in CM and 0.5|ig/ml o f previously 
titrated phytohaemagglutinin (PHA, Sigma) was added. PBMCs were aliquoted into a 
24 well plate at lxlO 6 PBMCs/ml and incubated at 37°C for 3-4 weeks. After this 
period, the resultant cell population o f transformed LCLs was transferred to a culture 
flask and grown indefinitely or cryopreserved.
2.2.10 Characteristics of EBV-transformed B lymphoblastoid cell lines
Where possible, LCLs were generated from all healthy volunteers and patients used in 
this study. LCLs from the 10th International Histocompatability Workshop cell panel 
(Yang et a l., 1989) were also kindly donated by Dr S.G.E Marsh, HLA Informatics 
group, ANT).
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2.2.11 EBV specific T cell stimulation using LCLs or HLA-restricted EBV 
peptides
LBV specific T cells were stimulated with either HLA restricted EBV peptides or 
LBV-transformed LCLs at 37°C for 4, 16 or 40 hours (Figure 2.1).
1 ml aliquots o f red blood cell lysed serum-free whole blood, PBMCs at lx l0 6/ml or 
lymph node cell suspensions at lx l0 6/ml were added into 24-well plates for peptide 
stimulation experiments. HLA specific EBV peptides were selected according to the 
sam ple’s HLA type and added at final concentrations o f 0.1, 1 and lOpg/ml. The final 
concentration o f DM SO did not exceed 1%.
For LCL stimulation experiments, 1ml aliquots o f autologous EBV-transformed LCLs 
and LCLs matched for a single or multiple Class I HLA allele were used (Table 2.3) 
at a concentration o f l x l 0 6/ml.
Negative controls were the responder cell populations incubated alone (unstimulated 
sample), or with EBV peptides not presented by the HLA molecules expressed by the 
cells (HLA-irrelevant peptides), and PBMCs incubated with at least two HLA- 
mismatched LCLs. Stimulation with PHA (Sigma) was included as a positive control 
at a final concentration o f lOpg/ml. Prior to incubation, Brefeldin A (Sigma) 
reconstituted in ethanol was added to each condition at a final concentration o f 
lOpg/ml. Brefeldin A blocks protein transport from the ER to the Golgi apparatus and 
thereby ensures all cytokines produced by EBV-specific stimulation remain within the 
cells and can be detected by intracellular cytokine staining (Section 2.3.2).
Anti-human CD28 antibody (R&D systems) was also added to the culture at the time 
o f  Brefeldin A in one set o f experiments using a range o f different concentrations.
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Responder PBMCs = HLA-A, HLA-B, HLA-<
Peptides
PBMCs
Autologous LCLs
Partially 
HLA-matched LCLs
Incubate at 37°C for 16 hours with 
Brefeldin A
Figure 2.1: Schemata to show method of EBV specific T cell stimulation
PBMCs are stimulated with HLA specific EBV peptides, autologous EBV-transformed LCLs or HLA- 
matched LCLs at 37C in the presence of Brefeldin A.
Key
* Autologous LCL (Total H L A -A ,H LA -B and H L A -C w  match)
^  H L A -A  restricted EBV peptide * H LA -A  allele matched LCL only
^  H L A -B  restricted EBV peptide -m H LA -B allele matched LCL only
^  H L A -C w  restricted EBV  peptide * H LA -C w  allele matched LCL only
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Responder Class I HLA type
A*0101 A *0201 11*4402 li*IH0l Cn 0501 Cw 1202
LCL 1 A*0101 A*2402 B*5701 B*35 Cw*040101 Cw*0602
LCL 2 A*0101 A*2601 B*0801 B*1401 Cw*0701 Cw*0801
LCL 3 A*1101 A*0201 B*5001 B*3501 Cw*040101 Cw*0602
LCL 4 A*0301 A*0201 B*4001 Cw*0304
LCLS A*2902 A*680102 B*4402 B*1401 Cw*0801 Cw*1601
LCL 6 A*0301 A*1101 B*4402 B*4901 Cw*0801 Cw*0701
LCL 7 A*2501 A* 1101 B*35 B*1801 Cw *1203 Cw*0401
LCL 8 A*0301 A*3003 B*0702 B*1801 Cw*0801 Cw*0702
Mismatch LCL 
1
Mismatch LCL 
2
A*2601 A*680101 B*3501 B*440301 Cw*030301 Cw*040101
A*2301 A*3301 B*5801 B*4901 Cw*0701 Cw*0302
Table 2.3: Example of a panel of partially HLA-matched LCLs used for one healthy individual
The HLA type of the healthy volunteer is shown at the top of this table. 4 pairs of LCLs were selected 
that match on a single Class I HLA allele only. At least two LCLs that were mismatched on all Class I 
HLA alleles were selected for negative controls
In some experiments EBV-specific T cell populations were expanded in vitro by 
repeat stimulation. PBMCs were adjusted to 4 x l0 6/ml in RPMI 1640 media 
supplemented with 20% FCS and added to lx l0 5/ml irradiated LCLs (13,000 rads) to 
give a final concentration of 2 x l0 6 PBMCs/ml. 2ml aliquots were plated into a 24- 
well plate and incubated at 37°C. On day 9, and every 7 days thereafter, cells were 
removed from culture, spun into a cell pellet, resuspended and adjusted to lx l0 6/ml 
using a combination of the preserved supernatant (50%) and fresh RPMI 1640 media 
containing 20% FCS (50%). Cells were then re-stimulated with freshly irradiated
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LCLs at a ratio o f 4 lymphocytes: 1 LCL and re-plated in 2ml aliquots into clean 24- 
well plates.
After each re-stimulation, an aliquot o f cells was taken from the culture, incubated for 
16 hours in the presence of Brefeldin A, and stained with immunofluorescent 
antibodies (Section 2.3.2). From day 14 IL-2,(R&D Systems) was added at 20IU/ml 
to the culture every 2-3 days.
2.2.12 Tumour cell lines used for immunohistology
EBV-transformed LCLs were generated in vitro and cultured in CM, as described 
previously. Two human herpes virus 8  (HHV 8 )-positive, EBV-negative cell lines, 
BC-3 and BCP-1 were kindly provided by D. Bourboulia (Cancer Research UK Viral 
Oncology Group, UCL). BC-3 cell line required 20% heat inactivated foetal calf 
serum in the CM. The cytomegalovirus (CMV)-positive, EBV-negative cell line BJ1 
was kindly provided by Dr K. Lawson (Dept o f  Virology, RFUCMS) and generated 
by infecting EBV-negative fibroblasts with the AD 169 strain o f CMV.
2.2.13 Mycoplasma testing and treatment
Cell lines used in this study were tested for contamination by M ycoplasma every 4-6 
weeks using a PCR based kit (VenorGem®, Minerva Biolabs, Berlin, Germany). Cell 
lines were harvested, centrifuged into a cell pellet and the supernatant decanted into a 
15ml conical tube. The PCR sample was prepared by briefly heating the supernatant 
(95°C for 5mins) and centrifuging again to remove cell debris. 2pl o f supernatant was 
used as the PCR sample. The reaction volume o f the PCR was 50 pi, which contained 
10 mM Tris-HCI, pH 8.5, 50 mM KCI, 3.0 mM MgC12, 0.05 mM deoxynucleotide 
triphosphates (dNTPs), 0.2 pM  o f each primer and 1 unit o f  a Thermus aquaticus
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(Taq) DNA polymerase (Invitrogen). The PCR reaction was executed by a Peltier 
thermal Cycler 200, (MJ Research Inc, Massachussetts, US) with an initial cycle of 
94°C for 2 minutes, 55°C for 2 minutes, 72°C for 2 minutes, followed by 34 cycles of 
94°C for 30 seconds, 55°C for 1 minute and 72°C for 1 minute. This was followed by 
a final cycle of 72°C for 4 minutes and 4°C indefinitely. A previously amplified 
DNA-fragment of Mycoplasma orale was used as a positive control, and as a negative 
control the sample was substituted with nuclease-free water. The amplified PCR 
product was separated by DNA electrophoresis in a 1.5% agarose gel (Section 2.4.4).
1 2 3 4 5 6 7
 *-----  267 bp
 *-----  191 bp
<4----------------------------------------------- ►
-ve Test samples +ve 100 bp
control control DNA
ladder
Figure 2.2: Mycoplasma detection
Mycoplasma contamination was detected using a PCR-based kit (VenorGem®, Minerva Biolabs, 
Berlin, Germany). Positive contamination is illustrated by two bands; one at 267bp representing the 
mycoplasma amplicon and a second at 191 bp representing the internal control amplicon. The lane 
numbers represent the following samples. Lane 1 = negative control. Lane 2 = negative LCL sample. 
Lane 3 = previously contaminated sample successfully treated with mycoplasma removal agent. Lanes 
4/5 = contaminated samples. Lane 6  = positive control. Lane 7 = lOObp DNA ladder.
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All samples should possess a band o f 191 base pairs (bp) as an internal control to 
indicate successful DNA amplification. Mycoplasma contamination was indicated by 
an additional band 267 bp (Figure 2.2).
Mycoplasma contamination was treated by adding 0.5pg/ml o f mycoplasma removal 
agent (MRA, MP Biomedicals, London, UK) to the infected cell line in CM and 
incubating for 1 week. Cells were then transferred to CM without additional MRA 
and grown for a further week. Successful removal o f mycoplasma contamination was 
confirmed by the VenorGem® PCR detection kit.
2.3 Cellular assays
2.3.1 Immunofluorescent antibody staining for cell surface antigens
Cells were either stained directly using specific antibodies that were conjugated with a 
fluorochrome, or indirectly with a two-stage technique, using unconjugated primary 
antibodies (mouse IgG or mouse IgM), followed by secondary fluorochrome-labelled 
anti-mouse isotype antibodies.
Approximately lxlO 5 cells were resuspended in lOOpl o f phosphate-buffered saline 
(PBS, Oxoid, Basingstoke, UK) with 0.2% sodium azide and 0.2% bovine serum 
albumin (BSA) in a 96-well U bottomed plate. Saturating concentrations o f antibodies 
were added to the cells and incubated at 20°C for 15-30 minutes. The staining plate 
was then centrifuged at 1200 rpm for 5 minutes, flicked to remove the supernatant and 
washed in 150pl PBS with 0.2% sodium azide and 0.2% BSA. Where an indirect 
staining method was used to characterise cell surface activation markers, this washing 
step was repeated four times to remove excess primary antibody prior to adding the
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secondary antibody. 10pl o f Fluorescin isothiocyanate (F1TC) conjugated (Fab2) goat 
anti mouse IgG and Phycoerythrin (PH) conjugated goat anti mouse IgM was added to 
the cells and incubated at 20°C for 15-30 minutes. The cells were then washed and 
fixed by resuspending in 50pl 1% paraformaldehyde diluted in PBS to prevent 
dissociation o f antibody from their ligands. Fixed cells were kept in the dark at 4°C 
and analysed by flow cytometry (Section 2.3.4) within 7 days.
2.3.2 Immunofluorescent antibody staining for intracellular antigens
Following EBV-specific T cell stimulation using EBV peptides or LCLs in the 
presence o f Brefeldin A, cells were removed from the 24-well plate, transferred to 
15ml conical tubes (BD), washed in PBS with 0.2% sodium azide and 0.2% BSA and 
centrifuged into a cell pellet. The supernatant was discarded and the cell pellets were 
resuspended in 150pl o f PBS with 0.2% sodium azide and 0.2% BSA, and transferred 
to a 96-well plate. Cells were centrifuged and washed as before and resuspended in 
lOOpl o f the fixation medium, Reagent A (Caltag Laboratories). The cells were 
incubated at room temperature for 12 minutes in the dark. After incubation, the cells 
were centrifuged and washed as before in 150|il o f PBS with 0.2% sodium azide and 
0.2% BSA and resuspended in lOOpl o f permeabilization medium, Reagent B 
(Caltag). Cells were then incubated in the dark at room temperature for an additional 
12 minutes. Cells were again washed as above and stained with saturating 
concentrations o f previously titrated anti-CD3 Cy5 (Caltag), anti-CD 8  FITC and anti- 
IFNy PE (Pharmingen, BD) (Section 2.3.2),
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2.3.3 Immunofluorescent antibodies
All antibodies used in this study are listed in Tables 2.4 and 2.5. Directly conjugated 
antibodies were purchased from BD Pharmingen, San Diego, USA or Caltag, 
Buckingham, UK and titrated prior to use. Unlabelled antibodies used in the indirect 
method o f staining were generated from in-house hybridomas or purchased from 
suppliers as indicated in Tables 2.4 and 2.5.
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N a m e F lu o ro ch ro m e S o u rc e Target a n d  effec ts
CD 3 Cy5 C altag T cell receptor
C D 8 F1TC BD
Pharm ingcn
T cell co-receptor
C D 8 6 F1TC BD
Pharm ingcn
B7.2 ligand. B inds to CD 28 during cell 
activation
CD83 PE BD
Pharm ingcn
C ostim ulatory ligand
HLA -D R PE/F1TC BD
Pharm ingcn
M HC class II cell surface m olecule
IFN-y PE BD
Pharm ingcn
Produced by T -helper cells, C D 8 + cells 
NK cells.
A ctivates m acrophages, increases M HC- 
class I and II m olecules, increases 
antigen presentation
T N F -a PE BD
Pharm ingen
Produced by C D 8 + cells
1L - 2 PE BD
Pharm ingen
Produced by T cells. Prom otes T -cell, B- 
cell and N K -cell proliferation
IL-4 PE BD
Pharm ingen
Produced by m ast cells and T H2 cells. 
Prom otes T H2 differentiation.
1L-10 PE B D
Pharm ingen
Produced by  T h2 cells. Prom otes T H2 
differentiation.
Table 2.4: Directly conjugated fluorochrome- labelled antibodies used in this study
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N am e/C D  N o C lone S o u rce R eactiv ity
A PC 5 SBA
CD 19 RFB9 Dept. Im m unology , 
RFU CM S
Farly B cell lineage, Follicular 
dendritic cells
CD3 OKT3 A m erican Type Cell 
C ollection (A TC C )
Thym ocytes, T cells, N K 1-T  cells
TCRy5 Tissue culture 
services
T cell receptor y5 heterodim cr
CD25 RFT5y Dept. Im m unology , 
RFUCM S
a  subunit o f  IL - 2  cy tokine receptor
CD 26 Pharm ingen C o-stim ulatory m olecule in T cell 
activation
C D 69 AIM Biogenesis Early activation m arker for 
activated leukocytes
RFD R2 Dept. Im m unology , 
RFUCM S
M HC class II
C D38 R FT10 Dept. Im m unology , 
RFU CM S
A ctivated T and B cells, p lasm a 
cells, germ inal centre B cells
C D 45R a SN 130 Dept. Im m unology , 
RFU CM S
N aive T cells
C D 45R o UCLH1 UCL, P. Beverley Effector T cells
C D 4 RFT4 Dept. Im m unology , 
R FU C M S
M H C class II-restricted  cells, som e 
thym ocytes, m onocytes, 
m acrophages, granulocytes
CD 28 9.3 IgG M . G lennie, 
Southam pton
T cells, p lasm a cells.
CD7 RFT2 D ept. Im m unology , 
R FU C M S
T cells, T hym ocytes, N K  cells
C D w l 50 SLAM A .Im m unochem ical T hym ocytes, Subset o f  T and B 
cells. Involved in B cell co­
stim ulation
Table 2.5: Antibodies used in the indirect method of staining for the characterisation of cell 
surface activation markers
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2.3.4 Multi-parameter flow cytometry
Detection o f immunofluorescent antibody labelled cells was performed using a 
Calibur (BD) Fluorescent Activated Cells sorter (FACs) flow cytometry system. This 
instrument is able to analyse size, granularity and fluorescence o f single intact cells in 
suspension using dual lasers and four different detectors. When a cell passes the laser 
beam, light is deflected from the detector, and this interruption o f signal from the laser 
is recorded. Cells with a fluorescently tagged antibody attached to their cell surface 
antigens are excited by the laser and emit light that is recorded by a second detector 
system at right angles to the laser beam. The argon-ion laser o f the FACsCalibur has 
an emission peak o f 488nm and is able to detect size (Forward Scatter, FSC), 
granularity (Side Scatter SSC) and the fluorochromes F1TC, PE, Cyanine 5 (Cy5) and 
Peridinin chlorophyll protein (PerP). The second red-diode laser has an emission peak 
o f 635nm and is able to detect the fluorochrome Allophycocyanin (APC). Acquisition 
o f fluorochome labelled cells was performed using the Cellquest™ software version
3.3 (BD) and subsequently analysed using the FlowJo software (Treestar). W herever 
possible, data was collected from 2 0 0 ,0 0 0  live cells in the lymphocyte gate for each 
sample.
2.3.5 Statistical analyses
Prism® 4 Software (Graphpad, San Diego, USA) was used in this thesis to calculate 
the mean totals and the standard deviation (sd). Data sets were compared using either 
the non-parametric Mann W hitney U test or unpaired t tests. Statistical correlation 
between data was also performed using Pearson's rank correlation coefficient.
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2.4 Molecular Biology
2.4.1 RNA extraction
Total RNA was extracted from PBMCs that had been stimulated by EBV peptides or 
LCLs in culture, using the RNeasy Mini Kit™ (Qiagen, UK) according to the 
manufacturer’s instructions. Throughout the procedure, RNA degradation was 
avoided by using RNase-free plastic ware, washing all pipettes and surfaces with 
RNaseZap* and molecular grade water (Sigma, Aldrich, St Louis, USA), and 
changing gloves regularly.
Cells were harvested, washed in ice-cold PBS and centrifuged for 5 minutes at 13,000 
rpm. The supernatant was completely removed from the cell pellet and cells were 
lysed by adding 350pl o f RLT Buffer (Lysis buffer, Qiagen) with 1% (3- 
Mercaptoethanol (P-ME). Genomic DNA within the cell lysates was sheared by 
passing the sample at least 5 times through a 20-gauge needle fitted to an RNase-free 
syringe. RNA extraction was either performed immediately or the cell lysates were 
frozen at -80°C and then thawed at 37°C for 20 minutes prior to use.
350pl o f  70% molecular grade ethanol was added to the cell lysate and transferred to 
an RNeasy mini column placed inside a collection tube. The ethanol ensured 
appropriate conditions for the total RNA to bind to the silica-gel membrane. The 
columns were centrifuged for 15 seconds at 1 0 ,0 0 0  rpm and the flow-through 
discarded. The samples were then washed in 350pl o f RW1 buffer and treated with an 
on-column DNase digestion kit (Qiagen) to remove residual genomic DNA. lOpl of 
DNase I stock solution was diluted in 70pl o f RDD buffer mixed gently, pipetted 
directly onto the silica-gel membrane and incubated at room temperature for 15
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minutes. After incubation the DNase was removed with 350pl o f RW1 buffer, 
followed by two further washes with ethanol-containing RPH buffer. After each wash 
the columns were centrifuged for 15 seconds at 10,000 rpm and the flow-through 
discarded. To avoid any carryover o f RPH Buffer, the column was transferred to a 
new collection tube and centrifuged at 10,000 rpm for 2 minutes. RNA was eluted 
from the membrane and collected into a sterile RNase-free collection tube by adding 
50pl o f RNase-free water to the column and centrifuging the column at 10,000 rpm 
for 1 minute. When the expected RNA yield was low (<30pg), a second elution was 
performed by pipetting the first eluate back onto the silica-gel membrane and 
repeating the centrifugation. RNA was used immediately as a template for 
complementary DNA (cDNA) synthesis or stored at -80°C until required.
2.4.2 Generation of complementary DNA
cDNA was generated by reverse transcribing total RNA using Murine Moloney 
Leukaemia Virus reverse transcriptase (M-MLV RT, Promega, Southampton). 
Approximately lp l o f RNA was mixed with 0.5pg random primers (Promega, 
500pg/ml) and lp l o f lOmM dNTPs in an RNase-free microcentrifugation tube. In 
order to remove secondary structures, the RNA, random primers and dNTPs were 
heated to 70°C for 5 minutes in a hot-block (Block Thermostat, Grant Instruments 
Ltd, Cambridge UK) and then cooled immediately on ice for a further five minutes to 
prevent secondary structures reforming. Each sample was centrifuged for 15 seconds 
at 10,000 rpm and then added to 8 pl o f master mix (detailed in T able 2.6) and mixed 
well. To check that all genomic DNA had been degraded by the on-column DNase 
digestion step included in the RNA extraction procedure, a duplicate tube was made
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up for each RNA sample as a negative control. These tubes contained all the reagents 
except for the M-MLV RT which was replaced with nuclease-free water (-RT 
sample). Tubes were then incubated in a hot-block at 37°C for 60 minutes followed 
by 70°C for 10 minutes to inactivate the M-MLV RT enzyme. cDNA samples were 
either kept on ice and used immediately in PCR reactions (Section 2.4.3 and 2.4.4) or 
stored at -20°C until required.
Reagent Volume 
( x l  reaction)
5x M-MLV buffer (Promega) 4pl
Dithiothreitol (DTT) 0 .1M (Promega) 2 pl
RNase inhibitor 40U/pl (RNaseln, Promega) lp l
M-MLV RT 200U/pl (Promega) (+RT samples) OR 
nuclease-free water (-RT samples)
lpl
Total volume 8pl
Table 2.6: Reagents used in the synthesis of cDNA from RNA
This table lists the reagents used in the master mix for generating cDNA from total RNA in the reverse 
transcriptase reaction. The test samples contain M-MLV RT and are labelled +RT samples. To check 
genomic DNA is not present in the samples, a duplicate tube is made up for each RNA sample where 
the M-MLV RT is replaced with nuclease-free water (-RT sample).
2.4.3 Gene amplification by Polymerase chain reaction
Production o f cDNA and absence o f genomic DNA in the RNA preparation was 
verified by amplification o f the Glyseraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene by conventional PCR.
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GAPDH was amplified from the DNA template using 5’ and 3’ primers (Appendix 
1.4), dNTPs, the heat stable DNA polymerase, Taq and buffer containing magnesium. 
A reaction master mix was prepared according to Table 2.7, and added to 2pl o f +RT 
and RT samples. A sample in which cDNA was replaced with nuclease-free water 
and a sample containing a previously amplified GAPDH PCR product diluted 1:1000- 
1:5000, were used as negative and positive controls respectively.
PCR reactions were run on a Peltier Thermal Cycler-200 (MJ Research, Inc, 
Massachusetts, US) according to the protocol in Table 2.7.
R ea g en t V olum e
(fil)
Tem pera ture
(°C)
T im e
(m ins)
P urpose
lOx Taq buffer w ith M g++ 
(Prom ega)
5 95 5 D enaturation
5 ’ prim er lOOpM (S igm a) 0 . 2 - 9 4 1 D enaturation
3 ’ prim er lOOpM (S igm a) 0 . 2 36 cycles ^ 55 1 A nnealing
dN T Ps lOmM (B iogene) 1 . 0 72 1 Extension
Taq 5U /pl (P rom ega) 0.5 72 1 0 Extension
N uclease-free w ater 
cD N A  tem plate
41.1
2
4 forever storage
T o ta l vo lum e 50
Table 2.7: Reagents and the PCR thermal cycler program used to amplify GAPDH by 
conventional PCR
2.4.4 DNA electrophoresis
Successful amplification o f  the target gene was confirmed by electrophorectic 
separation o f  the PCR product on an agarose gel. A 2% agarose gel was prepared by
104
Chapter 2
dissolving 4g o f electrophoresis grade agarose (Invitrogen) in 20()ml o f Tris-boric 
acid-EDTA buffer (TBE: 0 .1M Tris, 0.09M boric acid, ImM EDTA, Biowhittaker). 
Ethidium bromide (Ipg/m l final concentration, Sigma) was added to the gel to 
visualise DNA. The gel was poured into a sealed gel tray (Biorad, Hercules, 
California, US) with combs to create loading wells, and left to solidify. Once set, the 
combs were removed and the gel was covered with TBE buffer. 20pl o f PCR product 
was added to lp l o f Orange G loading buffer (0.1 mg final concentration, Pel Freez, 
Merseyside, UK) and pipetted into the loading chambers. A DNA ladder (DNA 
Hyperladder IV, Bioline, London) was added to the first and last lanes o f each gel. 
Electrophoresis was performed by running the gel for 30-60 minutes at 130 volts. 
Once adequate separation o f the DNA bands was achieved, the gel was removed and 
photographed under UV light using molecular analyst® software (Biorad, Hercules, 
California, US)
An example o f a DNA electrophoresis agarose gel showing amplification o f GAPDH 
is shown in Figure 2.3.
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Lane No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Lane No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
B
319 bp
Figure 2.3: A representative example of GAPDH amplification by conventional PCR
Successful production of cDNA and amplification of GAPDH was verified using conventional PCR. 
Positive amplification of GAPDH is represented by a band at 319 bp. Lanes 1+22 = DNA bp ladder. 
Lanes 2-18 = test samples. Lane 19 = negative control. Lane 21 = positive control. Panel A represents 
samples that had no reverse transcriptase added and show no GAPDH amplification and Panel B 
represents samples that had reverse transcriptase and show successful GAPDH amplification in all test 
samples.
2.4.5 Q uantitative real-tim e PCR (RT-PCR)
Quantitative real-time RT-PCR was performed throughout this work using an ABI 
Prism® 7500 (Applied Biosystems, Foster City, California, US). This technique uses 
fluorescence emitted during the exponential phase o f  the PCR reaction as an indicator 
o f  amplicon production during each PCR cycle, and thereby allows accurate
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quantitation o f RNA. Gene expression was determined by using pre-optimised 
TaqMan* gene expression kits (Applied Biosystems).
Each kit includes a forward and a reverse primer to amplify the gene o f interest, and a 
fluorescent labelled internal probe specific for the amplified gene. A schematic 
representation o f the amplification and detection of fluorescence is shown in Figure 
2.4. RT-PCR reactions were performed for the gene o f interest and an endogenous 
house keeping gene.
For each experiment, a reaction plate was designed using the ABI Prism® 7500 
software (Applied Biosystems). Each cDNA sample was run in triplicate wells for 
both the gene o f interest and the housekeeping gene. The mastermix was prepared 
according to Table 2.8 and dispensed into the reaction plate, lp l o f cDNA, diluted 
1 : 1 0  with nuclease-free water was added to each well and run according to the 
thermal cycler conditions listed in Table 2.8.
R ea g en t V olum e
(m0
T em perature
(°C)
T im e
(m ins)
P urpose
2x TaqM an®  
universal M aster M ix 
(A pplied B iosystem s)
12.5
T aqM an®  gene 
expression assay 
(A pplied B iosystem s)
1.25 95 1 0 D enaturation
N uclease-free w ater 10.25 40 cycles f  95 
|^60
15 secs 
I
D enaturation
A nnealing and 
extension
Total volume 24
Table 2.8: Protocol for quantitative RT-PCR using the TaqMan® gene expression kit
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Polymerisation
Forward Primer
3’
5’
5’
3’
Reverse Primer
Probe displacement
Forward Primer
3’
Reverse Primer
Probe cleavage
Forward Primer
C 3
5’
3’
Reverse Primer
5’
3’
D
Q
Forward Primer
3’
5’
Reverse Primer
Figure 2.4: The TaqM an® gene expression assay.
After denaturation, two template-specific primers anneal to the cDNA copy of the mRNA defining the 
ends of the amplicon. A third oligonucleotide probe (■) then hybridizes to the amplicon (A). This 
hydolysis probe is conjugated with a non-fluorescent quencher (Q) dye at the 3’ end which absorbs the 
fluorescence of the reporter (R) FAM dye at the 5’ end, as long as the probe remains intact. 
Polymerization proceeds at the same temperature as the annealing step causing displacement and 
hydrolysis of the labeled probe (B). The reporter dye is cleaved by the 5’-nuclease activity of Taq (C) 
and released from the close proximity of the quencher dye. Fluorescence is detected and 
polymerization is completed (D). During each consecutive PCR cycle the fluorescence increases due to 
the progressive and exponential accumulation of free reporter fluorochromes.
fluoresce
5’
Completion of 
polymerisation and 
detection of
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2.4.6 The comparative Ct method (AACt) for relative quantification of gene 
expression
Data from each experiment was quantified using the comparative threshold cycle (Ct) 
method (AACt) (Livak and Schmittgen, 2001) and analysed using the ABI Prism K 
7500 software (Applied Biosystems). The threshold cycle or the Ct value is calculated 
from the amplification plot and is shown in Figure 2.5. The threshold line is the point 
at which the PCR reaction reaches fluorescence intensity above background and is set 
during the exponential phase when the reaction is at its most efficient. The cycle at 
which the sample first reaches this threshold is called the threshold cycle or Ct value. 
The comparative Ct method eliminates the need for standard curves by comparing the 
fold change in expression o f the target gene sequence relative to the house keeping 
gene in a test sample, to that o f a calibrator sample such as an unstimulated control. 
For this method to be valid, the efficiency o f both the target gene amplification and 
the house keeping gene amplification should be approximately equal, and test samples 
and the calibrator sample for both the target gene and the housekeeping gene should 
always be run on the same plate. TaqMan gene expression assays have been 
validated by the manufacturer.
The calculations used to quantitate the data from a sample spreadsheet using the 
comparative Ct method are shown in Figure 2.5.
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AACt
ACt Mean (ACt test
House­ Target (Target gene ACt for sample-
keeping gene Ct - House­ calibrator Mean ACt
gene Ct keeping gene sample calibrator
Well Details Ct value value Ct) sample) 2*AACt
H 26.718 36.569 9.851 9.819
a*
1 Calibrator 
sample
26.444 36.12
9.676
*
a3 26.553 36.484 9.931
“ 1
1
26.632 32.337 5.705 -4.114 17.704
b2 L je s t Sample 26.616 32.483 5.867 -3.952 15.824
„3 | 26.761 32.613 5.852 -3.967 16
Figure 2.5: A representative spreadsheet of data showing calculations used in the comparative 
threshold Ct method
The samples were analysed using quantitative RT-PCR and Ct values were obtained. The mean fold 
change in expression of target gene was normalised using the AACt method, where ACt = Ct (target 
gene) - Ct (house-keeping gene), and AACt = ACt (test sample) -  ACt (calibrator). Gene expression 
was then converted into arbitrary normalized units using the equation 2 _AACl.
2.5 Immunohistology
2.5.1 P reparation of Cytospins
150pl of lx 106 cells/ml resuspended in PBS was spun onto slides coated with poly- 
L-lysine (PLL) or 3-aminopropyltriethoxysilane (APES) using cytocentifuge carriers. 
The slides were removed immediately after cytocentifugation and dried overnight at 
room temperature. The following day the slides were fixed with fresh acetone and 
frozen at -40°C wrapped in aluminium foil.
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2.5.2 Preparation of fresh tissue sections
A piece o f tissue 3-5mm2 was cut using a scalpel and mounted onto a cork base with 
tissue mounting gel (Tissue-Tek® O.C.T. Compound). The block was then frozen in 
iso-pentane which had been cooled in liquid nitrogen. Once frozen the blocks were 
removed and stored at -70°C. Six micron sections were cut from the block using a 
Frigocut Cryostat and placed onto PLL slides. The sections were left to dry overnight 
and then fixed in acetone (BDH, AnalaR quality) for 10 minutes followed by absolute 
alcohol (Hayman Ltd, Waitham, UK, AnalaR quality) for a further 10 minutes. Once 
dry, the tissue sections were stored at -40°C, until required for staining.
2.5.3 Preparation of formalin-fixed tissue sections
Paraffin-embedded sections that had been prepared according to standard histological 
techniques were cut onto sialin-coated slides and paraffin removed by one o f two 
methods. Sections were either placed in xylene and 100% ethanol and microwaved in 
lOmmol/L citrate buffer, pH 6.0, at 600W for 5, 10, 15 and 20 minutes, (Shi et al., 
1991) or incubated at 37°C with Tris buffed saline, pH 7.8, containing 0.05% trypsin, 
0.05% chymotrypsin and 0.1% calcium chloride for various times.
2.5.4 Antibodies used to detect EBV antigen
The antibodies used in the detection o f EBV by immunohistochemistry are listed in 
Table 2.9. The murine LN53 antibody was kindly provided by Professor C Boschoff, 
Centre for Virology, RFUCMS (Dupin et a l., 1999). Normal mouse serum (Harlan 
Sera-lab) was used as a negative control at a dilution o f 1/2000 during 
immunoperoxidase staining.
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The RFD3 antibody was recloned from the hybridoma RFD3 line produced by the 
Clinical Immunology department, RFUCMS, prior to staining to ensure specificity.
N a m e C lone C lass/Subclass Source R eactiv ity
M urine anti-LM P 1 CS 1-4 lgG | kappa Dako LM P 1, EBV
M urine anti-LM P 2 CS 1-4 IgG i kappa Dako LM P 2, EBV
M urine anti-EB N A  2 PE2 IgGi kappa Dako EBNA 2, EBV
M urine LN53 LN53 Centre for LNA 1, H H V 8
Virology,
RFUCM S
M urine RFD3 RFD3 IgG 2 Clinical EBV
Im m unology,
RFUCM S
Table 2.9: Antibodies used to detect EBV by immunoperoxidase staining 
2.5.5 Detection o f EBV by immunoperoxidase staining
Slides prepared from cytospins or fresh tissue sections were removed from -40°C and 
allowed to reach room temperature. 50pl o f PBS containing 10% normal human 
serum (used to block non-specific binding o f the antibody via the Fc receptor) and 
1 0 % aprotinin (used to block proteolytic enzymes) was added to each section. 
Previously titrated primary antibodies were then added to the sections and incubated 
for 1 hour at room temperature. This was followed by incubation with a second layer 
o f Peroxidase-conjugated rabbit anti-mouse Ig (Code no P0260, Dako, Ely, Cambs) 
for a further hour at room temperature. After each incubation, sections were then 
washed in freshly prepared PBS for 5 minutes, fixed in formalin buffered saline, pH
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7.6 for 10 minutes, and washed again in PBS. Results from the staining were 
visualised by incubating the sections in DAB Peroxidase Substrate Solution (0.05% 
DAB, (Sigma) 0.05% Nickel Ammonium Sulfate and 0.015% H2O2 in PBS, pH7.2) 
for 5 minutes. The slides were then washed in PBS, stained in cobalt chloride solution 
for 5 minutes, rinsed in distilled water for 5-10 seconds and counterstained for 2 
minutes with Nuclear Fast Red solution (Sigma). Finally, sections were washed in 
running tap water for 5 minutes and dehydrated by progressive immersions in 70%, 
90% and 100% alcohol, followed by 50% alcohol/50% citroclear (HD supplies, 
Aylesbury, Bucks) and 100% citroclear.
2.5.6 Detection of EBV by complement indirect immunofluorescent technique
Sections prepared from cytospins or fresh tissue sections were initially rinsed in 
freshly prepared complement fixation buffer (CFB, Oxoid) and incubated with heat 
inactivated human immune serum and human complement, diluted in CFB for 1 hour 
at 37°C. Human immune serum was taken from a healthy EBV sero-positive donor as 
a source o f anti-EBNA antibodies. Human immune serum from a healthy EBV sero­
negative donor was used as a negative control. Human complement was obtained 
fresh from EBV sero-negative donors and stored at -70°C. After incubation, the 
sections were washed twice in CFB and incubated for 45 minutes at room temperature 
with FITC-conjugated rabbit anti-human complement (Dako). Sections were further 
washed in CFB and mounted in AF1 citifluor (Citifluor Ltd, London).
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2.5.7 Detection of Latent EBV infection by in situ hybridisation
Epstein-Barr virus encoded RNA (EBER) was detected by a peptide nucleic acid 
(PNA) in situ hybridization (ISH) Detection Kit (Dako), using a fluroescein- 
conjugated EBER PNA probe and according to the manufacturer’s instructions. 
Formalin-fixed, paraffin-embedded tissue sections were de-paraffinised by immersion 
in xylene and rehydrated by progressive immersions in 99% and 96% ethanol, 
followed by distilled water. Sections were then pre-treated with 150|il proteins K, 
diluted 1:10 in Tris-Buffered Saline (TBS), pH 7.5 and incubated for 20-30 minutes. 
Sections were washed in distilled water and dehydrated in 96% ethanol. Hybridisation 
was performed by adding 2-3 drops of the fluroescein-conjugated EBER PNA probe 
and incubating in a humidity chamber at 55°C for VA hours. After incubation, the 
sections were washed in a Stringent Wash solution (PNA ISH Detection Kit, Dako) 
that had been warmed to 55°C for 25 minutes. 2-3 drops o f alkaline phosphatase- 
conjugated rabbit F(ab) anti-FITC were then added to each section, incubated at room 
temperature for 30 minutes and washed off in TBS followed by distilled water. Use o f 
the antibody F(ab) fragment ensured that non-specific binding was kept to a 
minimum. Enzyme substrate, 5-bromo-4-chloro-3-indolylphospate (BCIP) nitroblue 
tetrazolium (NBT), combined with an inhibitor o f endogenous alkaline phosphatase, 
levamisole was added to each section and incubated for 30-60 minutes at room 
temperature. Finally the sections were washed in tap water, counterstained in Nuclear 
Fast Red solution and mounted.
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Chapter 3
Development of a rapid immuno-assay to enumerate 
EBV-specific T cell responses: Healthy Individuals.
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3.1 INTRODUCTION
An effective immune response to EBV is o f crucial importance in controlling EBV 
driven B cell proliferation, as evidenced by the increased frequency and severity of 
EBV driven malignancies in immunocompromised individuals.
The immune response to EBV has been well characterised. The humoral response to 
the virus has been quantified in both primary and persistent EBV infection. However, 
its main effect is in removing circulating virus from the blood with IgG antibodies 
directed at both lytic and latent EBV antigens and plays no role in controlling EBV- 
driven B cell proliferation. In contrast, EBV is known to stimulate a vigorous cell- 
mediated immune response and evidence suggests that this is the main immune 
mechanism protecting individuals against the development o f EBV driven 
malignancies (Hislop et al., 2001; Rickinson and Moss, 1997; Callan et al., 1998b). 
From these and other studies, numerous techniques have been developed to measure 
the EBV-specific T cell response (Table 3.1). Although these techniques were 
originally designed in the context o f research, many have potential for use as a 
clinical assay. Measuring EBV-specific T cell responses is particularly important in 
patients with EBV-driven malignancies where manipulation o f the immune response 
may be used to treat the disease. An assay that rapidly and reliably enumerated 
functional EBV-specific T cells would therefore have widespread clinical application. 
An example o f a clinical situation where measurement o f functional EBV-specific T 
cell responses would be useful is in patients with PTLD. Withdrawal of 
immunosuppressive therapy has been shown to lead to regression o f PTLD by 
allowing recovery o f anti-EBV immunity so that an increase in the numbers of
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functional EBV-specific T cells controls the EBV-driven proliferation (Starzl et al., 
1984). However, without an effective assay to measure the recovery o f a functional 
EBV-specific T cell response, reduction in immunosuppression is arbitrary and reliant 
on the judgment o f the clinician responsible for the patient. This therefore increases 
the risk of graft rejection significantly. An effective assay that enumerates the EBV- 
specific cellular immune response would therefore enable the clinician to tailor step­
wise reductions in immunosuppression to the recovery o f EBV-specific immunity. 
EBV-driven B cell proliferation has the potential for exponential growth, therefore the 
assay must provide a rapid report to clinicians in order to be clinically effective. 
Current techniques used to monitor EBV immunity during reduction of 
immunosuppression include immunophenotyping for an increase in T cell surface 
activation markers, particularly MHC class II expression on CD8* T cells (Amlot et 
al., 1996), indicative o f emergence o f immune reactivity. Increased frequencies of 
CD8+MHC class II+ T cells were originally observed in primary EBV infection 
(Crawford et al., 1981) and subsequently reported in a patient with PTLD (Leaver et 
al., 2004; Rees et al., 1998). MHC class II expression has also been shown to 
correlate with the frequency o f viral-specific T cells identified by HLA class I 
tetramers (Webster et al., 2000), but importantly not with alloreactive T cells in renal 
transplantation. This non-specific method o f monitoring the recovery o f cellular 
immunity as immunosuppression is reduced has been successfully employed in PTLD 
patients, resulting in a marked reduction in the frequency o f graft rejection (Amlot, 
2001; Amlot et al., 2007). This method does not require in vitro culture and is very 
rapid. Results can therefore be reported back to the clinician within 2-4 hours of 
receiving a blood sample. The disadvantage, however, is that it does not provide any
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information about the antigen-specificity o f the functional T cells and therefore an 
increase in CDS 'MHC class II' T cells could be a response to a co-existing viral 
infection.
Screening for a decrease in EBV viral load is also used to monitor recovery o f EBV- 
specific immunity in patients with PTLD. However, this is often misleading with 
increased EBV load post transplant not always progressing into PTLD and falls in 
viral load post diagnosis not always correlating with clinical response. One example 
o f this, as discussed in the Introductory chapter, is use o f the anti-CD20 monoclonal 
antibody, rituximab, which can cause rapid disappearance of detectable EBV genome 
copy numbers without necessarily leading to effective treatment o f the PTLD. A new 
approach is therefore needed that provides information on EBV antigen specificity as 
well as the size and functionality of the response.
A variety o f assays are used to evaluate EBV-specific immune responses. Each has 
their own advantages and limitations for use in the context o f monitoring treatment 
for PTLD (Table 3.1). Traditionally LDA is the ‘gold standard’ assay and has been 
used to measure the frequencies o f functional EBV-specific T cells in both EBV sero­
positive individuals (Tan et a l., 1999; Kuzushima et al., 1999) and PTLD patients 
receiving allogeneic CTL infusions (Haque et a l., 2001). However, although this 
assay quantifies the number and function o f the cells, the method is laborious 
requiring several weeks o f in vitro expansion rendering it unsuitable for clinical use. 
The 5lCr-release assay (Brunner et al., 1968) is also used to detect functional cytolytic 
EBV-specific CD8+ T cells (Hislop et al., 2001; Kuzushima et al., 1999; Crotzer et 
al., 2000). However, regulatory requirements associated with use o f hazardous
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radioactive materials limits utility o f this assay to laboratories with the necessary 
accreditation.
More recently fluorochrome-labelled HLA-peptide tetramers have been used to detect 
and quantify antigen-specific T cells. Originally described in 1996 (Altman et al., 
1996), HLA tetramers comprise o f 4 biotinylated molecules o f a defined HLA:peptide 
combination bound to fluorescently labelled streptavidin. Multivalency enables 
sufficient binding affinity to the low affinity T cell receptors specific for the 
HLA:peptide complex in order that tetramer-bound T cells can be detected by 
conventional flow cytometry. HLA class I tetramers, have been extensively used to 
quantify the CDS’ T cell response to viral infections such as HIV (Wilson et al.,
2000), Hepatitis virus C (HCV (Lechner et al., 2000), CMV (Lacey et al., 2002; 
Gillespie et al., 2000) and EBV (Tan et al., 1999; Callan et al., 1998b), as well as 
tumours such as melanoma (Lee et al., 1999; Anichini et al., 1999) and chronic 
myeloid leukaemia (CML) (Molldrem et al., 2000). HLA tetramer staining alone, 
however, provides no information as to the functionality o f the antigen-specific T 
cells. This is particularly important in the context o f PTLD arising in solid organ 
transplant patients where EBV-specific CD8+ T cells may be present, but not 
functional, due to immunosuppression. Validity o f this concern is supported by 
studies with EBV seropositive healthy individuals which demonstrated that the 
frequencies o f EBV-specific CD8+ T cells obtained by HLA-peptide tetramer staining 
were significantly higher than those obtained by limiting dilution analysis and 
ELIspot; a method that assesses functionality (Tan et al., 1999). Tetramers can be 
combined with intracellular cytokine staining to assess functionality after antigen 
stimulation, but this adds to the complexity and cost o f the assay. A disadvantage with
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HLA tetramers is that prior knowledge o f the precise antigenic peptide epitope is 
required. As EBV epitopes have only been identified for common HLA class I alleles, 
many patients with rare HLA alleles would not be able to be tested using this method. 
In addition, as tetramers only measure the frequency o f T cells specific for one 
peptide several different tetramers would need to be tested per patient requiring 
availability o f a large spectrum of HLA tetramers to perform a comprehensive 
assessment o f EBV T cell immunity. Another limitation o f tetramers is that class II: 
peptide reagents are not routinely available for detection o f CD4^ T cells.
A technique that is often used to quantify functional EBV-specific T cells is ELIspot 
(Bollard et al., 2004; Comoli et a l., 2005; Straathof et al., 2005; Tan et al., 1999). 
This method uses antibodies specific for mediators o f T cell function (anti-cytokine, 
anti-granzyme, or anti-perforin antibodies) that are bound to the surface o f a tissue 
culture plate and capture secreted functional mediators from antigen stimulated T 
cells. Individual functional T cells are revealed as spots, thereby allowing 
quantification o f antigen-specific T cells. Although this technique is very sensitive, 
with a threshold detection rate o f 20 spots per million PBMCs (0.0026%) (Lalvani et 
al., 1997), it is known to produce erratic results especially when whole cells are used 
as stimulators (Pass et al., 1998). This has negative implications for selecting an assay 
where accurate sequential monitoring o f EBV-specific immunity is crucial because 
treatment will be guided by changes in EBV immunity.
Intracellular cytokine staining (ICS) is another technique that can be used to quantify 
functional EBV-specific T cells (Kuzushima et al., 1999; Lucas et al., 2004). T cells 
are cultured briefly in vitro with EBV antigen in the presence o f Brefeldin A that 
disables the release o f newly synthesized cytokines from the endoplasmic reticulum.
120
Chapter 3
Following cell permealization, the accumulation o f intracellular cytokines can be 
labelled by fluorochrome-labelled antibodies and detected by flow cytometry.
ICS has several advantages over ELIspot for detection o f EBV-specific T cells. The 
reliability o f ICS over ELIspot has been proven in several studies. Kuzushima et al 
showed that on average EBV-specific T cell responses stimulated by autologous 
LCLs and detected by ICS were four times higher than those seen with ELIspot 
(Kuzushima et a l., 1999). This apparent increase in sensitivity with ICS over ELIspot 
was also seen in data determining the frequency o f CMV-specific C D 41 T cells in 
healthy individuals and HIV patients (Waldrop et al., 1997) and in determining the 
CDS' T cell response to restimulation with tetanus toxoid (Tassignon et al., 2005). 
Another advantage o f ICS is that it uses flow cytometry as a platform for analysis. 
This means it is highly amenable to standardization (Landay, 2004) and can be readily 
combined with cell surface activation antigen marker phenotyping to enable multi­
parameter evaluation o f  EBV-specific T cells. In addition, flow cytometry is an 
established technique in many specialist clinical immunology departments and 
therefore very cost effective in terms o f reagents, specialist equipment and staff 
training. ELIspot, however, cannot be combined with other techniques, requires 
dedicated instrumentation for enumerating spot-forming cells and is not used 
routinely in clinical laboratories.
Due to these advantages, ICS was selected as the method o f choice for the 
development o f a rapid and functional EBV-specific immuno-assay.
The aims o f the work described in this chapter were to develop a rapid and reliable 
assay that could be used in the clinical setting to enumerate EBV-specific T cell 
responses in patients with EBV-driven malignancies. The assay was optimized using
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EBV sero-positive healthy individuals and investigated several different forms of 
EBV antigen as stimulators o f an EBV-specific T cell response. Autologous EBV- 
transformed LCLs were initially used as they are easily generated in healthy 
individuals and express the full complement o f EBV latent antigens. However, in 
patients with EBV-driven malignancies, autologous LCLs take longer to generate in 
vitro and are not always successful. Such a delay is impractical in patients with 
PTLD, and therefore partially HLA-matched LCLs were investigated as alternatives 
to autologous LCLs. HLA-restricted EBV peptides were also investigated as 
stimulators o f an EBV-specific T cell response. Peptides can be stored at -80°C and 
made available for immediate use as required. LCLs, however, require at least 24 
hours o f in vitro culture prior to use as a T cell stimulator.
Each o f these sources o f EBV antigen was compared to ascertain which was the most 
effective and reliable at stimulating an EBV-specific T cell response.
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Table 3.1: Available assays for enumerating EBV-specific T cells (Adapted from (Kern et al., 2005)
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3.2 RESULTS
3.2.1 Q uantification o f  EBV -specific T cell responses using EBV -transform ed  
LCLs as stim ulators presenting EBV antigens
EBV -transform ed LCLs represent ideal stim ulators o f  an EBV -specific T cell 
response as they express all o f  the EBV latent antigens as well as high surface levels 
o f  M HC Class I and C lass II, m aking them  potent EBV APCs. It was therefore 
appropriate initially to optim ize an EBV -specific assay in healthy sero-positive 
individuals using autologous LCLs and then investigate the use o f  H LA -m atched 
LCLs.
3.2.1.1 Autologous LCLs as stimulators o f  an EBV-specific T cell response 
IFN-y production by both  C D 8+ T cells (Callan et al., 2000; H islop et al., 2001; 
H oshino et al., 1999) and CD 4+ T cells (Am yes et al., 2003) has been used to 
successfully m onitor EB V -specific T cell effector function. H ow ever, other cytokines 
can also contribute to antigen specific T cell-m ediated im m une responses, including 
production o f  T N F-a by CD8+T cells and IL-2 or T N F-a by ThI CD 4+T cells.
In order to investigate w hich was the m ost effective cytokine to m onitor for detection 
o f  a functional EB V -specific T cell response, PBM Cs from  sero-positive healthy 
individuals were stim ulated with autologous LCLs, and intracellular staining w as 
perform ed using a spectrum  o f  anti-cytokine m-Abs. C om pilation o f  the results for 
six EBV sero-positive healthy individuals (Figure 3.1) reveals that IFN-y production 
by C D 8+ T cells w as significantly the m ost reliable indicator o f  an EBV -specific 
im m une response com pared to the background response (p=0.0022) w ith a positive
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response detected in all individuals. IFN-y production from CD4+ T cells was also 
reasonably reliable (p=0.04) with a positive response detected in five of the six 
individuals. Production of all other cytokines by CD8+ and CD4+ T cells was not 
consistently positive. Therefore, IFN-y production from CD8+ and CD4+ T cells was 
chosen to demonstrate an EBV-specific T cell response in all subsequent experiments.
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Figure 3.1: Comparison of cytokine production by EBV-specific T cells
PBMCs from 6 different healthy individuals were stimulated by autologous LCLs for 16 hours in the 
presence of Brefeldin A. EBV-specific T cells were enumerated by measuring cytokine production by 
CD8+ and CD4+ T cells using intracellular cytokine staining, and expressed as percentages of 
CD3+CD8+ T cells (Panel A) or CD3+CD4+ (Panel B). Horizontal lines represent the mean values. 
Statistical analysis to compare the cytokine production from CD8+ and CD4+ T cells was performed 
using a Mann-Whitney U test. NB: Different scales are used for each graph.
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In order to dem onstrate the specificity o f  the assay, PBM Cs from an EBV sero­
positive and sero-negative healthy individual were stim ulated w ith autologous LCLs. 
Figure 3.2 shows that a positive response was elicited from the sero-positive 
individual (Panel C) and no response w as seen with the sero-negative individual 
(Panel D), despite a large response on stim ulation with PHA. This data confirm s the 
EBV specificity o f  the T cell response. The results also dem onstrate that EBV 
specific T cell recognition is se lf  HLA restricted because PBM Cs from  the 
seropositive donor only respond to the HLA m atched autologous LCLs and not to the 
HLA m ism atched LCL. Also illustrated in Figure 3.2 Panels A and B is the gating 
strategy used to identify cytokine production by CD 3+C D 8+ T cells. G ates were 
applied to the unstim ulated PBM C CD8/IFN-y dot plot and then transferred to all test 
conditions w ithout change.
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Figure 3.2: A representative example of EBV-specific T cell responses after stimulation with 
autologous LCLs
PBMCs from an EBV sero-positive healthy individual (Panels A-C) and an EBV sero-negative 
healthy individual (Panel D) were stimulated with autologous LCLs and HLA-mismatched LCLs, and 
compared to unstimulated PBMCs (negative control) and PBMCs stimulated with PHA (positive 
control).
Lymphocytes were gated from the cell debris on the forward scatter/side scatter plot (Panel A). 
CD3+CD8+ T cells (Panel B) within the lymphocyte population were gated on a second dot plot using 
the CD3/CD8 plot. IFN-y production by CD8+ T cells was evaluated in a third dot plot (Panel C/D). 
The numbers in each panel represent the percentage of CD3+CD8+ T cells producing IFN-y.
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-C D 8
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£ D 8
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The EBV-specific im mune response was substantially amplified when EBV-specific 
T cells that had been expanded in vitro by antigen specific stimulation were used as 
responder cells (33% at Day 16, Figure 3.3). Although the delay in obtaining results 
incurred by in vitro expansion makes this option clinically im practical, the results 
obtained are characteristic of antigen-specific memory responses (Hislop et al.,
2001), consistent with EBV specificity. Further experiments to confirm  EBV 
specificity would include stimulating the EBV-specific T cells that had been 
expanded in vitro by autologous LCLs with a HLA mismatched LCL.
Unstimulated 
Auto LCL
1 9  16 22  29
Days of stimulation
Figure 3.3: Amplification of the EBV-specific T cell response using previously in vitro expanded 
antigen-specific CD8+ T cells
EBV-specific T  cells were expanded in vitro from EBV sero-positive PBMCs by stimulation with 
irradiated autologous LCLs. PBMCs were initially stimulated on Day 0 with freshly irradiated LCLs as 
described in Section 2.2.12. Every 7 days thereafter cells were restimulated at a ratio of 4 responder 
cells: 1 LCL. IL-2 was added to the culture (20iU/mL final concentration) from Day 14 every 2-3 days. 
After each restimulation, an aliquot of cells were removed from culture, incubated for 16 hours in the 
presence of Brefeldin A and analysed using intracellular cytokine staining for IFN-y producing CD8+ T 
cells. The bars and error bars represent the mean and the sd respectively.
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One of the requirements of an assay to enumerate EBV-specific T cell responses in 
patients with PTLD is that results are available rapidly so that clinicians can tailor 
reductions in immunosuppression accordingly. In addition, the total duration of the 
assay should ideally fit into the normal working hours o f a clinical laboratory. Figure 
3.4 com pares EBV-specific T cell responses detected in PBM Cs from a representative 
healthy individual after different periods of antigen stimulation. W hen PBM Cs were 
stimulated with autologous LCLs, 40 hours incubation produced the maximal EBV- 
specific T cell response (6.3%), however, 16 hours (overnight) incubation also gave a 
clear positive result (4.8%) above the backgrounds of 0.1% with unstimulated cells 
and 0.2% with mism atched negative controls.
EI3!4hr
■ E l 16hr 
UH2 40hrs
Unstimulated Autologous LCL Mismatch LCL 
Figure 3.4: Experiments to determine the optimal assay duration
PBMCs from a healthy individual were stimulated for 4, 16 and 40 hours respectively with autologous 
LCLs or an HLA-mismatched LCL, in the presence of Brefeldin A. After the incubation periods, 
PBMCs were removed and analysed using intracellular cytokine staining for IFN-y producing CD8+ T 
cells. The bars and error bars represent the mean and the sd respectively.
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experim ents were perform ed to determ ine the optimal ratio o f  responder cells and 
stim ulator LCLs to use, and to evaluate feasibility o f  using w hole blood as responder 
cells. PBM Cs are traditionally  used as responders in the enum eration o f  EBV -specific 
T cell responses. H ow ever, using w hole blood w ould significantly reduce setting up 
tim e for the assay by circum venting the need to isolate PBM Cs.
Serum -free w hole blood w as prepared and red cells were lysed according to the 
m ethod described in chapter 2, adjusted to lx lO 6 cells/m l and stim ulated with 
different ratios o f  autologous LCLs for 16 hours. EBV -specific T cell responses w ere 
com pared to unstim ulated controls. Figure 3.5 shows that equivalent EBV -specific T 
cell responses w ere detected using PBM Cs or red cell lysed serum -free w hole blood. 
In addition, the responses w ere com parable for both PBM Cs and w hole blood from a 
2:1 to 1:2 responder to stim ulator ratio. These results dem onstrate that w hole blood 
could be used in the clinical setting. However, all subsequent experim ents were 
perform ed using PBM Cs for convenience and because frozen aliquots can be stored 
enabling the perform ance o f  m ultiple experim ents on a consistent batch o f  cells. In 
addition, sam ples prepared from  w hole blood m ust be analysed by flow  cytom etry 
w ithin 48 hours because o f  rapid deterioration.
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Figure 3.5: Comparison of EBV-specific T cell responses detected using PBMCs (A) and red cell 
lysed whole blood (B) and different ratios of LCLs as stimulators
PBMCs (A) or serum-free whole blood (B) from a healthy individual, were adjusted to lx l0 6/mL and 
stimulated with different ratios of autologous LCLs for 16 hours in the presence of Brefeldin A. 
Unstimulated serum-free whole blood or PBMCs were used as a negative control. EBV-specific T cells 
were enumerated by measuring the IFN-y production from CD8+ T cells using intracellular cytokine 
staining, and expressed as percentages of CD3+CD8+T cells.
A crucial consideration in evaluating and optimising the assay was determining its 
consistency over time. EBV sero-positive healthy individuals are able to control EBV 
driven proliferation due to continuous presence of effective EBV specific immunity. 
To evaluate whether IFN-y production after stimulation with autologous LCLs 
consistently detected EBV immunity, EBV-specific T cell responses from four EBV 
sero-positive healthy individuals were serially monitored over a 1.5 to 2 year period. 
Figure 3.6 Panel A demonstrates that EBV-specific responses were detected at all 
the time points tested in each of the four individuals. This data therefore confirms that
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detection o f  EBV -specific CD8 T cells by the assay is consistent with continuous 
im m une surveillance by EBV sero-positive individuals.
A lthough IFN-y production was above the background seen with unstim ulated cells 
(F ig u re  3.6) and m ism atched LCLs (data not shown) at all the tim e points tested, the 
percentage o f  IFN-y producing C D 8+ T cells fluctuated around a m ean frequency o f  
the EBV -specific C D 8+ T cells, characteristic for each individual. M ean frequencies 
w ere relatively high in individuals A (3.19 %) and B (2.08 %) both o f  w hom  had 
experienced prim ary EBV infection relatively recently (5 years prior to assay). In 
contrast individuals C and D had a relatively low m eans (1.06 %  and 1.20 %, 
respectively) and had experienced prim ary EBV infection 30-40 years prior to the 
assay.
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Figure 3.6: Serial monitoring of EBV sero-positive healthy individuals to determining the consistency 
with which the assay detects EBV-specific T cell responses
PBMCs from four healthy EBV sero-positive individuals (Panels A-D) were stimulated for 16 hours 
with autologous LCLs (A ) and compared to an unstimulated control (■) and a mismatched LCL 
control (data not shown). The frequency of EBV-specific T cells was analysed by intracellular 
cytokine staining and flow cytometry after stimulation. EBV-specific T cells were expressed as a 
percentage of CD3+CD8+ T cells. The dotted lines show the mean EBV-specific T cell responses from 
stimulation with autologous LCLs and the unstimulated control.
3.2.1.2 H  LA -m atched LCLs as stimulators o f  an EBV-specific T  cell response 
Generating EBV-transformed LCLs from PBMCs takes approximately 3-4 weeks of 
in vitro culture, and is usually successful in 100% of healthy individuals. However, in 
patients with PTLD who are often severely immunosuppressed, generating 
autologous LCLs takes longer and has a lower success rate. Therefore, unless
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autologous LCLs w ere generated prior to transplant the use o f  autologous LCLs as 
stim ulators o f  an EBV -specific T cell response could be im practical. H LA -m atched 
LCLs w ere therefore investigated as alternative stim ulators, with the main em phasis 
on assessing their reliability com pared to stim ulation with autologous LCLs.
PBM Cs from five healthy EBV sero-positive individuals w ere stim ulated for 16 hours 
w ith a panel o f  LCLs m atched on single HLA class I alleles (as described in Table 
2.3, C hapter 2) and results com pared to those obtained using autologous and 
m ism atched LCLs. EB V -specific T cells w ere enum erated by m easuring the IFN-y 
production from C D 8+ T cells using in tracellu lar cytokine staining, and expressed as 
percentages o f  C D 3+C D 8+ T cells. Figure 3.7 shows the EBV -specific T cell 
responses detected from  each individual. In four o f  the five individuals, the largest 
EBV -specific T cell response was seen w ith the autologous LCLs. Individual 3 did 
not respond to stim ulation w ith the autologous LCL in this experim ent, despite 
having a positive response to the same LCL on several other occasions. A possible 
explanation for this negative result is M ycoplasm a  contam ination o f  the LCL. In 
individual 1, large EB V -specific T cell responses w ere seen on stim ulation w ith LCLs 
m atched on HLA-A*0201 (Panel la )  and HLA-B*1801 (Panel lb )  alleles alone 
com pared to w eaker responses seen on stim ulation w ith HLA-A*0101 (Panel la )  and 
B*4402 (Panel lb )  m atched LCLs. Sim ilar results w ere also observed in individual 5, 
w here the largest C D 8+ T  cell responses w ere restricted through H LA-A*0201 (Panel 
5a) and H LA -B*0702 alleles (Panel 5b).
These results suggest H LA -restricted im m unodom inance, a phenom enon w hich has 
been described in the context o f  cytom egalovirus (CM V ) (Lacey et a l., 2003), EBV
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(Hollsberg, 2002) and HIV-1 (K iepiela et al., 2004). The patterns o f 
im m unodom inance w ere not consistent am ongst the individuals tested. Individuals 1 
and 5 showed im m unodom inant responses restricted through H LA -A*0201, but 
individuals 2, 3 and 4 showed no patterns o f  H LA -restricted im m unodom inance, 
despite all possessing the HLA-A*0201 allele. All the responses in individuals 2 and 
4 w ere w eak and individual 3 had responses o f  sim ilar strength restricted through 
both HLA-A and HLA-B alleles.
Therefore, in order for a panel o f  LCLs m atched on single HLA alleles to enum erate 
an EBV -specific T cell response successfully, it is essential that all single HLA-A and 
HLA-B allele are screened in each individual to avoid m issing a positive response 
(e.g. selecting LCLs m atched on HLA-A*0101 alone in individual 1 w ould have 
failed to detect im m unity to EBV).
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Figure 3.7: EBV-specific T ceil responses after stimulation with single HLA class 1 allele matched 
LCLs in live healthy individuals
PBMCs from five healthy individuals (1-5) were stimulated with a panel of LCLs, matched at HLA-A 
alleles (a), HLA-B alleles (b) and HLA-mismatched LCLs (c). Stimulation with autologous LCLs, 
PHA and unstimulated samples were used as controls. EBV-specific T cells were enumerated by 
measuring the IFN-y production from CD8* T cells using intracellular cytokine staining, and expressed 
as percentages of CD3 CD8* T cells. The error bars represent the sd between duplicate samples. 
Individual I: HLA A*0201, A*0101, B*4402, B*1801. Individual 2: HLA A*0201, A*0101, 
B*4402, B*5701. Individual 3: HLA A*0201, A*3201, B* 1801, B*2703. Individual 4: HLA 
A*020I, A*1101, B*3501, B*5001. Individual 5: HLA A*0201, A*2402, B*0702, B*5101.
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Figure 3.7 reveals variations in the magnitude of EBV-specific T cell responses 
detected from different LCLs expressing the same single shared HLA class I allele. 
This is illustrated by individual 1 who had a positive response to stimulation with only 
three out of four different LCLs matched on HLA-A*0201, despite demonstrating an 
immunodominant EBV-specific response restricted through HLA-A*0201. These 
false negative results were particularly frequent in individuals where EBV-specific T 
cell responses were weak and no patterns of immunodominance were seen. For 
example individual 4 had a positive response to 2 out o f 3 different LCLs matched on 
HLA-A*0201 and HLA-A* 1101 and only 1 out of 3 different LCLs matched on 
HLA-B*3501. A summary o f the total number o f positive responses o f each HLA 
allele for each individual is shown in Table 3.1. Possible explanations for this 
variation are loss of HLA molecule expression and therefore EBV epitope 
presentation on the surface o f some LCLs, an observation which had been seen in 
Burkitt lymphoma cell lines (Torsteinsdottir et al., 1988; Masucci et al., 1987), or that 
some LCLs have insufficient surface concentrations of HLArpeptide complexes 
necessary to trigger T cell activation (Hill et al., 1995).
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Individual Individual Individual Individual Individual
I 2 3 4 5
Autologous LCL Y Y N Y Y
A*0201 LCL a Y Y Y Y Y
A*0201 LCL b Y Y Y N Y
A*0201 LCL c N N nd Y nd
A*0201 LCL d Y nd nd nd nd
A*0101 LCL a N N
A*0101 LCL b N N
A*3201 LCL Y
A*2401 LCL a Y
A*2401 LCL b Y
A* 1101 LCL a Y
A* 1101 LCL b Y
A* 1101 LCL c N
A* 1101 LCL d N
B*4402 LCL a Y Y
B*4402 LCL b N Y
B*4402 LCL c nd N
B* 1801 LCL a Y Y
B* 1801 LCL b Y Y
B* 1801 LCL c Y Y
B*2702 LCL a Y
B*2702 LCL b N
B*3501 LCL a Y
B*3501 LCL b N
B*3501 LCL c Y
B*5001 LCL a N
B*5001 LCL b N
B*5101 LCL a N
B*5101 LCL b N
B*5101 LCL c N
B*0702 LCL a Y
B*0702 LCL b Y
Total number of 7/11 4/8 7/8 m i 6/9
positive responses
Table 3.2: Summary of results obtained for five healthy EBV sero-positive individuals using 
single HLA class I allele matched LCLs as stimulators
The mean EBV-specific T cell responses after stimulation with a panel of HLA-matched LCLs were 
compared to mismatched LCLs, in 5 healthy individuals. A positive result was identified when the 
mean value exceeded the highest mean value obtained from at least 2 different mismatched LCLs.
Y = positive result. N= negative result, nd = not done.
Individual 1: HLA A*0201, A*0101, B*4402, B*1801. Individual 2: HLA A*0201, A*0101, 
B*4402, B*5701. Individual 3: HLA A*0201, A*3201, B*1801, B*2703. Individual 4: HLA 
A*0201, A *1101, B*5001, B*3501. Individual 5: HLA A*0201, A*2402, B*5101, B*0702.
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The implications for using a panel o f single HLA class I allele matched LCLs as 
stimulators of an EBV-specific T cell response in a clinical assay are twofold. Firstly, 
several different LCLs sharing the same allele need to be tested to ensure a positive 
response is detected. Secondly, the LCLs need to represent all the HLA-A and HLA- 
B alleles expressed by the responder in order to accommodate biases in HLA- 
restriction due to immunodominance. Many different LCLs are therefore required, 
necessitating large numbers o f PBMCs. This is illustrated by individual 2 in which a 
positive EBV-specific T cell response was detected from only four o f the eight LCLs 
used in the panel. This panel with the appropriate positive and negative controls 
required l l x l  06 PBMCs to detect a positive response. This approach would be 
impractical for patient samples where the PBMC numbers are often limited.
In contrast, autologous LCLs almost always gave much higher responses than the 
LCLs matched on single HLA class I alleles. In individuals where autologous LCLs 
fail to detect a positive EBV-specific T cell response (individual 3) or where they are 
not available, LCLs matched on multiple HLA class I alleles may provide an 
alternative. This was evaluated with patient PBMC samples and results are presented 
in Chapter 4.
3.2.1.3 HLA class I  restricted EBV peptides as stimulators o f  an EBV-specific T 
cell response
Previous studies have identified a large number o f EBV peptide epitopes restricted 
through a wide range o f HLA class I alleles (Tables 2.1 and 2.2) and a hierarchy o f T 
cell responses to both latent cycle proteins (reviewed by (Rickinson and Moss, 1997)
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and lytic cycle proteins (Pudney et a l., 2005) has been detected in healthy individuals. 
Studies to enumerate EBV-specific T cells include detection o f IFN-y release from 
epitope-specific CDS' T cells following peptide stimulation (Lalvani et al., 1997; Tan 
et al., 1999; Yang et al., 2000a) and use o f fluorochrome-labelled HLA class I- 
peptide tetramers to detect EBV specific T cells in healthy individuals (Altman et al., 
1996; Tan et al., 1999) paediatric transplant patients (Falco et al., 2002) and patients 
with Hodgkin’s lymphoma receiving adoptive T cell therapy (Bollard et al., 2004). In 
all o f these studies, only CD8+ T cell responses to single immunodominant EBV 
epitopes restricted through common HLA class I alleles have been examined. To be of 
utility for routine clinical assays it would be necessary to use pools o f EBV peptide 
epitopes to enumerate EBV-specific T cell responses restricted by a wide spectrum of 
HLA class I alleles.
Initial experiments to optimize peptide stimulation conditions were performed using 
HLA-A*02 EBV sero-positive individuals as a large number o f HLA-A*02 restricted 
peptide epitopes have been characterised. lOpg/mL final concentration o f each EBV 
peptide within the HLA-A*02 restricted peptide pools stimulated detectable EBV- 
specific T cell responses (Figure 3.8, Panel A). Higher final concentrations were not 
tested as the DMSO concentration in each peptide pool would exceed the threshold 
known to cause cell death (1% final concentration). Synthetic peptides purified to 
80% or 95% were tested to assess whether costs could be reduced by using 
preparations o f lower purity. Although peptides o f 80% purity were able to induce 
responses, peptides o f 95% purity produced higher responses (Figure 3.8, Panel B). 
Optimal assay duration was shown to be 16 hours (Figure 3.8, Panel C) and therefore
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consistent with the data using autologous LCLs (Figure 3.4). These set of conditions 
were subsequently used for all further experiments.
Figure 3.8: Optimisation of the ICS assay to enumerate EBV-specific T cell responses in PBMCs 
stimulated with synthetic peptides
Panel A: PBMCs were stimulated with peptide pools containing 15 EBV HLA-A*02 restricted 
peptides each at 0.1, 1 and 10pg/l final concentration, or an autologous LCL for 16 hours. PBMCs 
stimulated with a combination of an EBV peptide restricted by an irrelevant HLA class I allele (final 
concentration lOpg/1) and DMSO were used as a negative control. Panel B: PBMCs were stimulated 
with 80% (CLG-80) and 95% (CLG-95) pure CLGGLLTMV, a latent epitope restricted through 
HLA-A*02, and 80% (GLC-80) and 95% (GLC-95) pure GLCTLVAML, a lytic epitope restricted 
through HLA-A*02, for 16 hours. Panel C: PBMCs were stimulated with HLA-A*02 restricted EBV- 
peptide pools (15 peptides all at lOpg/ml final concentration) for 4 (■) and 16 (■) hours respectively. 
EBV-peptide pools restricted through irrelevant HLA alleles (Irrelevant peptide) and mismatched LCLs 
were used as negative controls. EBV-specific T cells were enumerated by measuring the IFN-y 
production from CD8+ T cells using intracellular cytokine staining, and expressed as percentages of 
CD3+CD8+ T cells. The bars and error bars represent the mean and the sd respectively, from at least 3 
healthy HLA-A*02 EBV sero-positive individuals.
3 A ^ 02-j B
Irrel 0.1 1.0 10.0 Auto LCL
Peptide concentration (pg/ml)
DMSO CLG-80 GLC-80 CLG-95 GLC-95
EBV Peptides 
(final concentration 10pg/mL)
C 10.0-.
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Figure 3.9: Example of EBV-specific T cell responses seen on stimulation with individual and 
pools of HLA-A*02 restricted EBV peptides
PBMCs from a healthy individual were stimulated with 4 individual HLA-A*02 EBV peptides and a 
pool of 15 HLA-A*02 restricted EBV peptides at lOpg/ml final concentration. An autologous LCL and 
PBMCs stimulated with PHA were used as positive controls. A mismatched LCL, unstimulated 
PBMCs and PBMCs stimulated with an EBV-peptide restricted through an irrelevant HLA allele (Irrel. 
Peptide) were used as negative controls. The names of the EBV peptides refer to the first three letters 
of the epitope. Lymphocytes were gated from the cell debris on the forward scatter/side scatter plot 
(panel A). CD3+CD8+ T cells (panel B) were gated on a second dot plot using the CD3/CD8 plot. The 
plots were then gated for IFN-y in a third dot plot (panel C). The numbers in each panel represent the 
percentage of CD3+CD8+ T cells producing IFN-y.
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Figure 3.10: Spectrum  of EBV-specific T cell responses to HLA-A*02 restricted EBV peptides in 
four HLA-A*02 healthy individuals
PBMCs from four HLA-A*02 healthy individuals (A-D) were stimulated with 15 individual A*02 
EBV peptides (final concentration, lOpg/mL) and a pool of 15 HLA-A*02 restricted peptides (Pep. 
Pool). EBV-peptides restricted through irrelevant HLA alleles (Irrel. Peptide/DMSO) and autologous 
LCLs were used as negative and positive controls respectively. EBV-specific T cells were enumerated 
by measuring the IFN-y production by CD8+ T cells using intracellular cytokine staining, and 
expressed as percentages of CD3+CD8+ T cells. The names of the EBV peptides refer to the first three 
letters of the epitope. The bars and error bars represent the mean and the sd respectively.
Individual HLA-A *02-restricted EBV peptides were then used to stimulate EBV- 
specific T cell responses with PBMCs from four healthy HLA-A*02 individuals 
(F igures 3.9 and 3.10).
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The results show no consistent patterns in responses from the four individuals. 
Responses to latent EBV epitopes are known to be skewed towards the EBNA 3A, 3B 
and 3C subsets of antigens (Gavioli et al., 1992; Khanna et al., 1992; Murray et a l.,
1992), which explains why responses to LLDFVRFMGV peptide (EBNA 3C 
antigen), SVRDRLARL peptide (EBNA 3A antigen), SLREWLLRI peptide (EBNA 
3C antigen) and AVFDRKSDAK peptide (EBNA 3B antigen) are seen in the majority 
o f individuals (Figure 3.10, Panels A-D). Interestingly, in accordance with 
previously published work (Tamaki et al., 1995; Gavioli et a l., 1992; Khanna et al., 
1992; Murray et al., 1992; Tamaki et al., 1995), responses were also seen to the 
subdominant EBV antigen LMP-2 (epitopes CLGGLLTMV, LLWTLVVLL, 
LLSAWILTA, LTAGFLIFL) in the majority o f  individuals, but not LMP-1 (epitope 
YLLEMLWRL).
Previous work has shown that in healthy individuals, most EBV-specific CD8* T cell 
responses are directed against intermediate or early lytic proteins: BZLF1, BRLF1 
and BMLF1 (Khanna et al., 1992; Callan et al., 1998b; Landais et al., 2005; Murray 
et al., 1992; Saulquin et al., 2000; Tamaki et al., 1995). Therefore, although only one 
lytic epitope, GLCTLVAM L (BMLF-1 antigen), was available for testing, 
surprisingly small responses were seen and only in two individuals. Weak responses 
to structural proteins gp85 (epitopes: LMIIPLINV, TLFIGSHVV and SLVIVTTFV) 
and gp350 (epitope VLQW ASLAV) were also seen in three o f individuals (Khanna et 
al., 1999).
This data demonstrates the limitations o f using single EBV-peptides to enumerate 
EBV-specific T cells in a clinical assay. Firstly, responses to many o f the known 
immunodominant peptides could not be detected and secondly, no consistent patterns
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o f response were seen for the same HLA-A*02 epitopes amongst the four HLA-A*02 
individuals tested. A possible explanation for these results is that the individuals with 
lower responses to immunodominant EBV peptides (F igure 3.10, Panels B and C) 
both acquired primary EBV 30-40 years prior to the assay. Precursor frequencies o f 
EBV-specific T cells in these individuals would be expected to be low and therefore 
may be below the level required for detection by ICS. In order to determine a positive 
EBV-specific T cell response, all peptides for each HLA class I allele would need to 
be tested for each person. Testing each peptide individually requires lxlO 6 PBMCs 
per peptide and thus enumerating an EBV-specific T cell response from individuals 
with common HLA alleles with this approach could require up to 25x106 PBMCs. 
This is clearly impractical in a clinical setting and therefore the use o f pools o f 
peptides to stimulate PBMCs was investigated. A cocktail o f the 15 HLA-A*02 
binding epitopes stimulated a detectable T cell response in all four healthy HLA-A*02 
individuals tested (F igure 3.10). Interestingly, the responses to HLA-A*02 peptide 
pools did not equate to the sum o f the responses to individual peptides in any o f the 
individuals - this may be due to competition between peptides for binding to HLA- 
A*02. Peptides with higher affinity are likely to competitively inhibit binding o f 
peptides with lower affinity thus diminishing the magnitude o f the T cell response 
stimulated by the weaker HLA-A*02 binding peptides.
It was hypothesised that a combination o f peptide pools tailored to an individual’s 
HLA type might generate EBV-specific responses comparable to those achieved with 
an autologous LCL. In each peptide pool, DMSO toxicity was avoided by ensuring 
that the final DMSO concentration did not exceed 1% o f the culture media. F igure 
3.11 shows EBV-specific T cell responses produced by stimulation with peptide pools
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and LCLs in a representative healthy individual, and details the gating strategy used 
for the flow cytometry analysis. The negative control is PBMCs stimulation with an 
irrelevant peptide/DMSO (Panel D). The HLA-A*02 peptide pool produced the 
largest response (Panel G), while weaker responses were produced by the HLA- 
B*4402 (Panel H) and HLA-B* 1801 pools (Panel I). The EBV-specific response 
was further increased by combining the three pools (Panel J ,0.85 %) but did not 
equate to the sum of the three individual pools restricted through single HLA alleles 
(0.65 % + 0.3 % + 0.39 % = 1.34 %). The EBV-specific T cell response from a 
combination o f peptide pools restricted to 3 HLA class I alleles was significantly less 
(0.85 %) than the response with the autologous LCL (5.0 %).
Six healthy EBV sero-positive individuals were screened with tailored peptide pools 
for each HLA class I allele and a pool containing both HLA-A and HLA-B restricted 
peptides. Results are summarized in Figure 3.12. In 5 out o f the 6 individuals tested, 
use o f a cocktail o f peptides comprising epitopes restricted by several HLA-A and 
HLA-B alleles stimulated detectable EBV-specific T cell responses (Figure 3.12 
Panels A, C, D ,E , F). All positive responses were, however, consistently weaker 
than those observed after stimulation with autologous LCLs. In addition, the response 
for the combined peptide pools restricted through different HLA alleles consistently 
gave a lower response than expected from the sum o f the single HLA class I allele 
restricted pools in all individuals tested - this may be due to competition between 
peptides for binding to HLA class I molecules.
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Figure 3.11: Example of EBV-specific T cell responses seen on stimulation with pools EBV 
peptides
PBMCs from a healthy individual (HLA A*0201, A*0101, B*4402, B*1801) were stimulated with 
HLA-restricted EBV peptide pools (panels G-J). The final concentration of each peptide used was 
lOpg/ml. Responses were compared to an unstimulated sample (panel C), PBMCs stimulated with a 
peptide restricted to an irrelevant HLA allele (Irrel. Peptide) (panel D, DMSO concentration was 
equivalent to the highest concentration in the peptide pools), an autologous LCL (panel E) and a 
mismatched LCL (panel F). Lymphocytes were gated from cell debris on the forward scatter/side 
scatter plot (panel A). CD3+ve were gated on a second dot plot using the CD3/CD8 plot (panel B). 
IFN-y+ cells were then gated and plots show results for the total CD3+ T cells (panel C-J). The 
numbers in each panel represent the percentage of CD3+CD8+ T cells producing IFN-y.
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Figure 3.12: Comparison of LBV-specific T cell responses detected using HLA class I restricted 
peptide pools in PBMCs from six healthy individuals
PBMCs from six healthy individuals were stimulated with HLA-restricted peptide pools (final 
concentration of individual peptides lOpg/ml) and compared to HLA-irrelevant peptide/DMSO and 
unstimulated samples.
Panel A: HLA A *0201, A*0101, B*4402, B* 1801, Panel B: HLA A*0201, A* 1101, B*3501, 
B*5001, Panel C: HLA A*0201, A *2402, B*0702, Panel D: HLA A*0201, A*0101, B*4402, 
B*5701, Panel E: HLA A*0201, A*32()l, B*1801, B*2703, Panel F: HLA A* 1101, A*2402, B* 1501, 
B*5601. The bars and error bars represent the mean and the sd respectively. The responses after 
stimulation with autologous LCLs, HLA-mismatched LCL, combined peptide pools and an EBV 
peptide restricted through an irrelevant HLA class I allele plus DMSO were collated from each 
individual and the mean response from each compared using the Mann-Whitney U test. The mean 
response after stimulation with autologous LCLs was significantly higher than HLA-mismatched LCLs 
(p-0.0022). Responses with the HLA-restricted combined HLA class I restricted peptide pools were 
significantly higher than the irrelevant peptide control (p=0.026).
150
Chapter 3
The individual who failed to show a positive response (Panel B) in this set of 
experiments had a positive response to the HLA-A*02 peptide pool in previous 
experiments (Figure 3.10, Panel B), and therefore these results can probably be 
attributed to an abnormally high background response from the negative control 
peptide.
A concern with use of peptides to stimulate responses is that the assay relies on 
peptide presentation by APCs within the population of PBMCs. APC numbers may 
vary between individuals and there may also be variation in co-stimulatory potential. 
Waldrop et al (Waldrop et al., 1998) originally showed that exogenous costimulation 
with CD28 mAbs increased the observed frequencies of cytokine-producing CD4+ T 
cells in response to a CMV antigen by 50-100% but had no stimulatory effect alone. 
More, recently anti-CD28 mAb has been used as an exogenous costimulatory 
molecule in flow-cytometry based intracellular cytokine assays to quantify HIV- 
specific CD84 T cell responses to novel HIV (Betts et al., 2001) and CMV (Sylwester 
et al., 2005) epitopes. Preliminary experiments were therefore performed to 
investigate the impact o f providing additional co-stimulation with anti-CD28 mAb in 
healthy individuals, but no augmentation of EBV-specific T cell responses was 
observed (data not shown).
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3.3 DISCUSSION
This chapter discusses the optimisation o f an assay to enumerate EBV-specific T cell 
responses using multiparameter flow cytometry. Optimisation was performed using 
PBMCs from EBV sero-positive healthy individuals and evaluated various forms o f 
EBV antigen as stimulators.
Interferon-y production from CDS' T cells was shown to be the most consistently 
positive cytokine at demonstrating a functional EBV-specific T cell response after 
stimulation with autologous LCLs. This data is consistent with previous work which 
showed that the large expansion o f EBV-specific CD 8+ T cells seen in patients with 
infectious mononucleosis has effective cytolytic function (Callan et al., 2000; Steven 
et a l., 1996) and that a subpopulation release IFN-y in response to EBV antigen 
(Callan et al., 2000; Hoshino et al., 1999). These functions have also been 
demonstrated in the memory EBV-specific CD 8f T cells from healthy EBV sero­
positive individuals (Hislop et al., 2001) suggesting that these cells play a protective 
role in the immune response to EBV. Two further studies have shown that the level of 
expansion o f  activated T cells directly correlates with the severity o f clinical 
symptoms in patients with IM (Silins et al., 2001; Williams et al., 2004) supporting 
the view that flu-like symptoms o f IM, which are indicative o f a beneficial immune 
response, are a direct sequelae o f the expansion o f activated EBV-specific T cells. 
Experiments using autologous LCLs as stimulators o f an EBV-specific T cell 
response showed that maximal responses were detected from PBMCs and whole 
blood after 16 hours. The assay was therefore shown to reliably and rapidly enumerate 
the functional EBV-specific immune response. The assay could be set up at the end of
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a working day, incubated overnight, analysed and results communicated to clinicians 
the next day. In this way, decisions about reducing immunosuppressive therapy in 
patients with PTLD can be tailored by the clinician appropriately within 24 hours o f 
the laboratory receiving a blood sample.
Experiments using autologous LCLs as stimulators o f an EBV-specific T cell 
response also highlighted both variations in the magnitude o f the response between 
healthy individuals, and also within individuals over time. This was particularly 
evident in two healthy individuals who were young (< 40 years) and who had 
acquired primary EBV infection less than 5 years prior to the start o f  monitoring. 
Compared to the two older healthy individuals (41 and 63 years respectively), the 
mean response was higher and wide fluctuations in the response were seen over time. 
This data is consistent with evidence that the number o f functional EBV-specific T 
cells declines with advancing age (Khan et al., 2004), a response that may be 
influenced by coinfection with another persistent herpes virus, CMV, which had been 
strongly implicated in immune senescence (reviewed by (Pawelec et a l ,  2005). 
Several studies have shown virtual disappearance o f initially expanded virus-specific 
CD8+ T cell clones following primary infection with EBV (Callan et al., 1998a; 
Annels et al., 2000; Callan et al., 1998b) and HIV (Pantaleo et al., 1997), with new 
dominant clones emerging as the main components o f the memory EBV T cell 
response (Annels et al., 2000). These studies, however, only used one time point to 
examine the memory response, 1-4 years after primary infection (Annels et al., 2000; 
Callan et a l ,  1998a). Therefore, a dynamic process may be occurring in which new T 
cell clones continuously emerge in response to cumulative episodes o f intermittent 
EBV viral reactivation that occur in the initial period after primary infection, and
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could explain the fluctuations seen over time. Despite variation in the magnitude of 
the EBV-specific immune response, the assay consistently detected a positive EBV 
immune response at all time points and in all individuals regardless o f age and time 
from initial EBV infection.
Production o f LCLs requires 3-4 weeks o f in vitro culture before B cells from a 
PBMC sample are immortalized, and unfortunately are often difficult to generate from 
patient samples. The possibility o f using LCLs matched at single HLA class I alleles 
was investigated as an alternative to autologous LCLs, but these cells often failed to 
stimulate a detectable EBV-specific T cell response. Detection rates were improved 
by summating the responses from a panel o f LCLs matched on single alleles but this 
approach has the disadvantage of requiring many more PBMCs per individual. A 
practical solution to this may be to stimulate the responder PBMCs with a mixture o f 
LCLs matched on single alleles. LCLs would need to be mixed immediately prior to 
the assay as growing a mix o f LCLs in vitro would probably lead to outgrowth o f the 
fastest growing cell line. This approach would require optimisation to determine the 
numbers o f  each different LCL that could be used in the mixture without 
overcrowding the culture, however results from the autologous LCL experiments 
showed that the EBV specific immune responses were relatively consistent using 
responder to stimulator ratios between 2:1 and 1:2. Another option is to use LCLs 
matched on multiple HLA alleles as stimulators. This was investigated using patient 
samples and results are presented in chapter 4.
HLA class I restricted EBV peptides were also investigated as an alternative source o f 
EBV antigens. A practical advantage for using peptides as stimulators o f an EBV- 
specific T cell response is that they can be stored at -80°C and used as required. In
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contrast, HBV-transformed LCLs require at least 24 hours o f in vitro culture prior to 
being used as CD8 T cell stimulators.
Screening healthy individuals for EBV-specific T cells by stimulation with individual 
HLA-A*02 restricted peptides produced variable patterns o f response. This may 
reflect age and time from primary EBV infection as discussed previously. Responses 
to known immunodominant peptides were often negative or failed to show a 
consistent positive response in all the individuals tested. Reasoning that combining 
peptides tailored to the HLA class I type o f the responder cells should produce 
summation o f individual responses, peptide pools were tested. The percentage o f 
responding cells increased using a combination o f peptides tailored to the HLA type 
o f the responder cell and was able to detect a positive response in 5 o f 6 individuals 
tested. Therefore, although the magnitude o f the EBV-specific T cell response was 
less than with autologous LCLs, peptide pools could be used as an alternative source 
o f EBV antigen in individuals with common HLA alleles.
One interesting finding with the peptide pools was that the positive response 
consistently failed to reach the sum o f the individual peptide components. This was 
observed when individual peptides restricted through one HLA class I allele were 
combined in a peptide pool, and also when several peptide pools restricted through 
different alleles were combined. A possible explanation for the absence o f complete 
summation o f  responses to individual peptides is competition for binding to class I 
molecules. Peptides presented by the same HLA class I allele compete for binding. 
This phenomenon is exploited for identifying peptides bound by HLA molecules and 
for quantifying binding affinities. Putative T cell epitopes are combined with a known 
HLA binding peptide and competition for class I binding assessed directly by
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monitoring for reduction in binding o f the labelled known class I binding peptide 
(Sette et a l., 1994; Ruppert et a l., 1993). Results from these studies have shown that 
the affinity o f EBV peptide epitopes for binding to class I molecules range from 2.3- 
360.0nM (The Immune Epitope Database and Resource Analysis (IEDB), 
www.beta.immuneepitope.org). When peptides with differing affinities are bound and 
presented by the same HLA class 1 allele, those with high affinity will be 
preferentially bound and inhibit binding o f the peptides with lower binding affinities. 
The impact on T cell recognition is reduction in responses to the lower affinity 
peptides because the amount o f antigen is less.
Competitive inhibition o f peptide binding may also account for the absence o f 
complete summation o f responses seen when combining multiple peptide pools 
restricted to different HLA allele. Although each class I allele has a distinctive peptide 
binding preference, known as the peptide binding motif, overlap in the repertoires o f 
peptides bound by different allele has been described (Levitsky et al., 2000; 
Livingston et al., 1999; Threlkeld et al., 1997). Class I allele are grouped into ‘super­
types’ based on shared structural features in the peptide binding m otif and thus similar 
peptide binding specificities (Sette and Sidney, 1999). An example pertinent to this 
study is the HLA-B*44 super-type comprising o f a preference for peptides with 
negatively charged residues (D,E) at position 2 and hydrophobic residues at the C- 
terminus (DiBrino et al., 1995; Harris et al., 1993; Thorpe and Travers, 1994). It has 
been suggested that HLA-B*1801 also shares the same specificities as members o f the 
HLA-B*44 super-motif group (Steven et al., 1997). Therefore failure to summate the 
T cell response from the individual HLA-B*4402 and B*1801 peptide pools with a 
combination o f both pools (Figure 3.12) and may reflect competitive inhibition.
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Possible ways o f  reducing the effects o f competitive inhibition include titrating each 
o f the individual peptide components and using the minimum concentration o f peptide 
required to produce a maximal T cell response. In the experiments presented here, all 
peptides were added at the same concentration (lOpg/ml) and therefore the high 
affinity peptides are likely to be present in excess augmenting competitive inhibition 
within the pool.
The weak responses to stimulation with HLA class I restricted peptides may be 
improved by enhancing the function o f APCs. A preliminary assessment o f adding 
additional co-stimulation to cultures was undertaken using anti-CD28 antibodies, 
however no improvement was observed (data not shown). Alternative ways of 
maximizing antigen presentation that could be investigated include stimulating the 
PBMCs with EBV peptide-pulsed autologous PHA blasts (Bollard et al., 2004) or 
dendritic cells (Redchenko and Rickinson, 1999; Santodonato et al., 2003; Subklewe 
et al., 1999; Subklewe et al., 2005). However, the disadvantage with both strategies is 
that additional in vitro culture would be required resulting in a longer assay duration. 
As previously discussed such an approach is impractical in the context o f PTLD, 
where the clinical effectiveness o f the assay rests on how quickly results can be 
generated and communicated back to the clinicians responsible for reducing 
immunosuppression.
In conclusion, results presented in this chapter demonstrate that EBV-specific T cells 
can be rapidly and reliably enumerated from PBMCs and whole blood o f healthy 
sero-positive individuals using autologous LCLs as stimulators. In addition, the assay 
fulfils many important criteria necessary for successful use in the clinical setting. 
Autologous LCLs from healthy individuals are relatively easy to establish in vitro,
157
Chapter 3
and can be cryopreserved in liquid nitrogen until required. As liquid nitrogen storage 
is possible in most clinical laboratories, the additional cost o f setting up an LCL is 
minimal. By definition, autologous LCLs present multiple EBV epitopes restricted by 
all HLA class I alleles recognised by the responder T cell. Therefore a positive EBV- 
specific response using autologous LCLs can be reliably demonstrated from 4 
samples (autologous LCL (test), HLA-mismatched LCL (negative control), PHA 
stimulated PBMCs (positive control) and unstimulated PBMCs (negative control) 
requiring only 4 x l0 6 PBMCs. In contrast, use o f LCLs matched at single HLA class I 
alleles involves testing responses to a panel o f LCLs to accommodate the complete 
HLA-A, B and Cw type o f the responder cells requiring large amounts o f blood which 
is not practical in the clinical setting. A combination o f multiple peptide pools tailored 
to the individual’s HLA class I type was shown to stimulate a positive EBV-specific T 
cell response in the majority o f individuals tested. However an assay based on use o f 
peptide pools for the general population is currently hindered by lack o f knowledge of 
the epitopes presented by less common HLA class I alleles. Using flow cytometry as 
the platform for analysis has the advantage o f using equipment that is already 
available to most clinical immunology departments and a technique familiar to 
laboratory technicians so initial start-up costs would be low. Enumeration o f IFN-y 
producing CD8+ T cells by ICS and flow cytometry therefore represents a reliable 
method for detecting functional EBV specific T cell immunity in a manner which is 
highly amenable to clinical applications.
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Chapter 4
Development of a rapid immunoassay to measure 
EBV-specific T cell responses: Patients with EBV-
driven malignancies
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4.1 INTRODUCTION
In the previous chapter, staining for intracellular IFN-y production in CDS' T cells 
from healthy individuals, stimulated overnight by autologous EBV-transformed LCLs 
or HLA-restricted peptide pools was shown to be a reliable and rapid means of 
enumerating an EBV-specific T cell response. The work described in this chapter 
assesses the clinical value of this assay by investigating its use to measure EBV- 
specific T cell responses in patients with two EBV-driven malignancies - PTLD and 
LBV-positive HD.
Reduction o f immunosuppression (RIS) is widely used as the initial strategy in the 
treatment o f patients with PTLD. This allows the patient to recover effective 
immunity to EBV and the functional EBV-specific T cells control EBV-driven 
cellular proliferation. Transplant patients, however, require immunosuppression to 
control detrimental T cell alloreactivity that causes rejection o f solid organ allografts. 
Depending on the graft and host conditioning o f haematopoietic patients receiving 
stem cell or bone marrow transplants, immunosuppression may also be required to 
prevent GVHD. Any withdrawal o f immunosuppression risks compromising 
suppression o f T cell alloreactivity and an approach that monitors stepwise 
withdrawal o f  immunosuppression so as to detect the recovery o f EBV-specific 
cellular immune responses before damaging allograft reactivity would be o f 
significant clinical benefit.
Current methods used to monitor recovery o f the cellular immune response in patients 
with PTLD include quantifying activated CD8+ effector cells using 
immunophenotyping o f surface activation markers by flow cytometry (Amlot et al.,
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1996; Rees et a l., 1998; Amlot et al., 2007). Patient samples are monitored from the 
diagnosis o f PTLD throughout R1S to detect an increase in cell surface expression o f 
lymphocyte activation markers with MHC Class II being the most informative. An 
absolute three-fold rise in the number o f CDS* T cells expressing MHC class II to 
achieve at least 0.3 x 10;/L is used to demonstrate sufficient recovery o f the cellular 
immune response and adequate reduction in the levels o f immunosuppression 
necessary for the treatment o f PTLD (Amlot et al., 2007). Although it may take 
several weeks after the appearance o f these activated CD8+ T cells before a clinical 
response to the PTLD occurs, further reductions in immunosuppression are not 
required. The main disadvantage with this method is that it does not provide 
information regarding the EBV antigen specificity o f the CD8+ effector cells. Immune 
responses to other co-existing infections may produce misleading results.
Another parameter that can be used to identify patients at high risk o f developing 
PTLD is the EBV load. There are a variety o f methods for measuring EBV load 
(described section 1.4.3) but at present no standardised protocols exist. As might be 
expected, some studies have shown that EBV load can predict the development o f 
PTLD and that viral load falls in patients that respond to immunosuppression 
reduction (Lee et al., 2005; McDiarmid et al., 1998). However results are ambiguous 
as other studies show no value in measuring EBV load (Scheenstra et al., 2004; Vajro 
et al., 2000). Indeed treatment can result in a transient rise o f viral load in blood 
plasma probably due to release o f antigen by immune-mediated lysis o f EBV-infected 
B cells (Savoldo et al., 2006).
Use o f the immunoassay described in Chapter 3 to quantify EBV-specific CD8+ 
effector T cells in EBV-positive PTLD patients as immunosuppression is reduced
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should represent a better measure o f response to treatment because the control o f EBV 
in resting B cells and o f EBV-positive PTLD is directly related to the immune 
response to EBV.
Another malignancy that is associated with EBV is HD. Approximately 40-50% of 
tumours are EBV-positive. The role of EBV in the aetiology o f HD and the efficacy 
o f EBV specific immunity in patients with HD is not well understood. EBV positive 
HD is more prevalent among older adults (>45 years) and young children. Some 
studies indicate that EBV-positive HD has a poorer prognosis (Keegan et a l., 2005b; 
Enblad et a l., 1999; Jarrett et a l., 2005). These observations may reflect compromised 
EBV immunity due to the immune naive status of children and decline o f the immune 
response in older patients.
A paradox in the pathogenesis o f  EBV-positive HD is that despite an effective cellular 
immune response to EBV after primary infection, patients subsequently fail to control 
proliferation o f the EBV-infected malignant R-S cells in HD. Evidence suggests that 
immune avoidance strategies are employed by the virus, leading to persistence in the 
R-S cells. One strategy is down regulated expression o f the EBNA 3A, 3B and 3C 
antigens by the virus so that R-S cells express only EBNA1, LMP1 and LMP2 known 
as latency pattern II. Studies suggest peptide epitopes from these antigens presented 
by HLA molecules stimulate relatively weak EBV specific T cell responses 
(Chapman et al., 2001; Frisan et al., 1995; Roskrow et al., 1998). Cytotoxic T cells 
specific for EBNA-1 have not been detected and studies indicated this is because the 
antigen possesses a Glycine-Alanine repeat sequence that inhibits proteolytic 
degradation and therefore generation o f peptide T cell epitopes by the proteasome 
(Blake et al., 1997; Levitskaya et al., 1995; Levitskaya et al., 1997). However a more
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recent study questions this conclusion because IFN-y producing CD8' T cells specific 
for FBNA-1 have now been detected (Lee et al., 2004). Despite exploitation of 
immune avoidance strategies by EBV in HD, two pilot studies involving adoptive 
transfer o f EBV specific T cells to control HD have had some success, as discussed in 
section 1.5.5.3 o f the Introductory Chapter (Bollard et al., 2004; Lucas et a l., 2004). 
Both studies used EBV-specific CTLs that had been generated from in vitro 
stimulation with LCLs and were therefore specific for all EBV antigens. However, 
tetramer and functional analyses demonstrated that it was the T cells specific for 
LMP2 that expanded in vivo and entered the tumour (Bollard et al., 2004). More 
information on the functional phenotype and antigen specificity o f EBV specific T 
cells in HD patients is evidently required. These details could be deduced using the 
immunoassay described in Chapter 3. In addition, the assay could also be utilized to 
monitor responses to novel immune-based therapies for HD that aim to augment 
protective T cell responses.
Another factor contributing to persistence o f EBV-infected R-S cells in HD patients is 
that any EBV-specific T cells that penetrate the tumour tissue may be rendered 
anergic by the immunosuppressive environment within the malignant lymph nodes. 
R-S cells secrete IL-10 (Herbst et al., 1996; Ohshima et al., 1995), TGF-P (Hsu et al.,
1993) and the Thymus and Activation-Regulated Chemokine (TARC) (Peh et al., 
2001; van den et al., 1999), and recruit regulatory T cells (Marshall et al., 2004; 
Alvaro et al., 2005). In addition, development o f an EBV-specific immune response 
seems to be inhibited through EB B , an EBV-induced cytokine homologous to the p40 
subunit o f IL-12 and highly expressed in R-S cells that antagonizes IL-12 (Niedobitek 
et al., 2002). Studies need to be performed to determine if the CD44 tumour
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infiltrating lymphocytes (TILs) in EBV-positive HD are functional and contribute to 
anti tumour immunity or if  they are counter-productive regulatory T cells that 
suppress other tumour reactive cells. This could be achieved using the assay described 
Chapter 3.
The aims o f the work described in this chapter are twofold. First, measurement of 
IFN-y production by EBV-specific T cells (after stimulation with LCLs and HLA 
class I-restricted pooled EBV peptides) in patients with PTLD was performed serially 
as immunosuppression was withdrawn. Results were correlated to clinical response 
and compared with the conventional immunophenotyping for surface activation 
marker expression by T cells that is currently used by clinical laboratories to monitor 
treatment efficacy.
Second, the assay was used to measure the EBV-specific C D 81 and CD44 T cell 
responses in a different EBV-associated tumour model. By using both TILs and 
PBMCs o f patients with EBV-positive and EBV-negative HD it was possible to 
examine whether defects in anti-EBV immunity existed in the EBV-positive HD 
patients and could be responsible for ineffective tumour control.
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4.2 RESULTS
4.2.1 Measurement of EBV-specific CD8+ T cell responses in patients with 
PTLD
4.2.1.1 Patient Characteristics
The characteristics o f the 12 patients used in this study are listed in Table 4.1. All 
patients developed a PTLD after receiving a renal transplant. The male to female ratio 
was 2:1 and the average age at diagnosis was 57 years. Two patients presented within 
1 year o f transplantation, but most presented several years post transplant. Eight 
patients developed an EBV-positive PTLD (confirmed by the presence o f EBER by in 
situ hybridization) with a mean time from transplant to diagnosis o f 74.2 months. 
Seven o f the eight EBV-positive PTLD patients had a clinical response to treatment 
with RIS (3 had a complete response, 4 had a partial response). All 4 patients who had 
a partial response and the one patient who had no response to RIS did not respond to 
further therapy and died o f  their PTLD or associated complications.
4 patients developed an EBV-negative PTLD with a mean time from transplant to 
diagnosis o f 118.3 months. 3 patients were initially treated with reduction of 
immunosuppressive therapy and 1 patient with cytotoxic chemotherapy. O f the 3 
patients that were treated with RIS, one had a complete clinical response to treatment, 
one had no response and was treated with chemotherapy and rituximab, and one was 
not evaluable as the lesion was removed surgically.
All clinical responses to treatment were measured by standard radiological imaging 
and defined according to the RECIST criteria (Appendix 1.3, (Therasse et a l., 2000).
165
Chapter 4
Patient
Code
Age at Tx
(yrs)/Sex
Pre-TxEBV
serostatus
Time from 
Txto 
PTLD (months)
Site o f Disease Treatment
Regime
Clinical
Outcome
EBV+1 57/M Unknown 129 Skin Surgery/RlS CR
EBV+ 2 68/M Negative 4 Generalised LN, BM 
Pleura
1. RIS
2. Rituximab
NR
t
EBV+3 68/F Unknown 95 Sigmoid colon 1. RIS
2. Rituximab
PR 
MR t
EBV+ 4 65/F Unknown 11 Perirenal mass 1. RIS CR
EBV+ 5 40/M Negative 42 Tonsil 1. RIS/CTL CR
EBV+ 6 68/M Unknown 216 Skin l.RIS/RT PR
t
EBV+ 7 59/M Unknown 39 Pancreas 1. RIS
2. Chemo
PR
NR t
EBV+ 8 63/M Negative 58 Generalised LN 1. RIS
2. Chemo
PR
t
EBV a 34/F Unknown 150 Mesenteric/ para-aortic 
LN, Bowel
1. RIS
2. Chemo + 
Rituximab
NR
CR
EBV b 59/M Positive 80 Neck LN 1. RIS CR
EBV c 65/F Positive 100 Skin 1. RIS
2. Radiotherapy
NE
EBV d 40/M Unknown 143 Tonsil, Neck and 
abdominal LN
1. RIS
2. Chemo
NR
CR
Table 4.1: Characteristics of patients who developed a PTLD following renal transplantation
EBV status of tumour: EBV^ positive; EBV' negative M, male; F, Female; LN, Lymphadenopathy; Chemo, Chemotherapy; RIS, Reduction in immunosuppression; CTL, 
adoptive cytotoxic T cell infusion; RT, Radiotherapy; BM, Bone marrow; CR, complete clinical response; PR, partial clinical response; MR, minor response; NR, no 
response; NE, not evaluable, t  died.
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4.2.1.2 Patient sample collection and EB V antigen stimulation conditions tested
The number o f samples, mean cell number and viability o f thawed cryopreserved 
cells obtained from each patient are shown in Table 4.2.
To measure the EBV-specific T cell responses in patients with PTLD, PBMCs from 
12 patients were collected at diagnosis and at multiple time points during treatment 
and EBV specific T cell mediated immunity assessed using the intracellular cytokine 
assay optimized in Chapter 3. Autologous LCLs consistently stimulated the largest 
CD 8' T cell response in healthy individuals and this was re-assessed in the PTLD 
patient group. W herever the numbers o f PBMCs from patients permitted, pooled 
EBV peptides tailored to the patients HLA class I type and a panel o f partially HLA- 
matched LCLs were evaluated along with autologous LCLs. For five patients 
autologous LCLs could not be generated, possibly due to their immunosuppressed 
status at the time o f diagnosis. For these patients, only LCLs matched on single and 
multiple HLA class I alleles were tested (Table 4.3). At each time point, the EBV- 
specific T cell responses were compared to the percentage o f MHC class II+ CD8+ T 
cells obtained from the lymphocyte activation immunophenotyping data performed 
as a routine clinical monitoring service for all PTLD patients in the Department o f 
Clinical Immunology, Royal Free Hospital.
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Patient Code N um ber o f  samples
Cell Num ber (x 106) Mean  
(sd)
Viability (%) 
M ean (sd)
EBV+ 1 3 17.3 (4.62) 97.3 (2.08)
EBV+2 1 20.0 96.0
EBV+ 3 6 20.5 (10.17) 97.8 (0.75)
EBV+ 4 9 10.9 (5.80) 95.7 (3.28)
EBV+ 5 8 6.3 (2.25) 96.9 (2.10)
EBV+ 6 5 7.6 (1.95) 90.8 (6.38)
EBV+ 7 2 4.5 (0.71) 89.5 (3.54)
EBV+ 8 2 10.5 (2.12) 92.5 (7.78)
E B V 'a 2 7.5 (3.53) 87.5 (10.6)
EBV b 3 2.3 (0.58) 92.6 (3.06)
EBV' c 5 9.0 (1.58) 96.4 (1.82)
E BV 'd 4 2.2 (0.50) 94.5 (2.08)
Total Mean 9.22 94
Table 4.2: Patient samples
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Patient
Code
Patient
IIL A -A , B, C  type
A M alagans 
LCL
H LA-m atched LCL 
(Number)
Peptide Paal 
(N um ber o f  peptides)
EBV* 1 A ’*‘0201, A* 1 101 
B*4402, B*2705 
C'w *01 2, C'w*050l
N Y
A *0201 single 
A* 1 101 single 
B*4402 single 
B*2705 single 
A* 1 101 + B*4402 
A* 1 101+B *2705 
A *0201 +B*2705
(2)
(1)
(2)
(1)
(1)
(2)
(1)
Y (23)
EBV * 2 A *0301
B*1402, B*5 101 
C'w*0102. C'w*0802
N Y
A*0301 single (1) 
8*5101 single (1) 
A*030l+Cw*0802 (1) 
A*0301 + B * 5 101 (1) 
B * 5 101 +Cw*0l02 (1)
Y (1)
EBV + 3 A *0101, A*0301 
B*5701, B * 3 5 0 1/7/8 
C w*04, Cw*0602
N Y
A*0101 single (2)
A *0301 single (2) 
Cw*04 single (2) 
Cw*0602 single (2) 
B*3501+Cw*0401 (2) 
A*0301+B*3501+Cw*0401 
A *0101+
B*5701+Cw*0602
Y (4)
EBV * 4 A *0201, A*2402 
B * 5 101
C’w*0202, Cw*1502
Y N Y (19)
EBV 4 5 A *0101, A*0301 
B*0702, B*0801 
Cw*0701, Cw*0702
Y Y
A*0101 single (1) 
A *0301 single (1) 
B*0702 single (1)
Y (9)
EBV + 6 A *0101, A *0201 
B *080 l ,  B*4001 
Cw*0304, Cw*0701
Y N Y (21)
EBV + 7 A*0101, A*2402 
B*5501, B*3501 
Cw*0303, Cw*0401
Y N Y (6)
E B V + 8 A *0101, A*2402 
B*0702, 8*1801 
Cw*0701, Cw*0702
N Y
A*0101 single ( 
A*2402 single (
)
)
N
EBV a A *0201 , A*0301/3, 
B*1801, B*0702
Y Y
A*0301 single 
A*0201 single 
A*0301+B*l 801
(2)
(2)
(1)
Y (20)
EBV b A*0101
B*0801
Cw*0701
Y N N
EBV c A *0101, A*0201 
B*4402, B*0801 
C w *05 0 1 ,C w * 0 7 0 2
N Y
A*0201 single (1) 
B*4402 single (1) 
A*0101+A*0201+B*4402 
A*0101 +B*0801+Cw*0702
Y (24)
EBV d A*6801, A*6802 
B*4402, B*1402 
Cw*0704, Cw*0802
Y Y
B*4402+B*I402 (1)
N
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Table 4.3: Sources of EBV antigen used to stimulate an EBV-specific CD8+ T cell response in 
each PTLD patient
PBMCs from 12 PTLD patients were stimulated with autologous LCLs, HLA-matched LCLs or 
HLA-restricted peptide pools as indicated (Y or N). Where autologous LCLs could not be generated, 
a panel of single HLA-matched LCLs e.g. A*0201 single = a LCL matched on A*0201 allele alone) 
and LCLs matched on at least two HLA-alleles (e.g. A*2402+B*0702+Cw*0701) were used. The 
number in brackets after each line refers to the number of different LCLs matched for the allele that 
were tested. The number of peptides in each pool is shown in brackets.
4.2.1.3 Measurement o f  EBV-specific CD8+ T cell responses in PTLD patients 
with EB V-positive tumours during RIS 
Figure 4.1 shows the serial data for the IFN-y producing CD 8’ T cell responses and 
the RIS strategy, in conjunction with creatinine measurements in three EBV-positive 
PTLD patients that each had more than 5 serial samples available for study.
Panel a represents data from EBV+ 4 who presented with a peri-renal mass 11 
months after renal transplantation. Histology demonstrated a diffuse, large B cell 
lymphoma which was EBER positive. She was treated with RIS alone and 
monitored for an increase in activated lymphocyte subsets. Figure 4.1 shows that by 
4 months there had been a three-fold increase in the absolute number o f MHC Class 
IIC D 8 + T cells and further RIS was stopped. EBV+ 4 went on to achieve a complete 
clinical remission by standard imaging criteria. RIS in this patient was complicated 
by a steady increase in the baseline creatinine measurements. A biopsy at 6 months 
confirmed graft rejection which was treated with an increase in the dose o f 
immunosuppressive drugs.
Panel b represents data from EBV+ 3 who presented with a mass within the sigmoid 
colon and abdominal lymphadenopathy 7.9 years after renal transplantation. The 
histology o f  the tumour also confirmed a diffuse large B cell lymphoma which was
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EBER positive. HBV' 3 was treated with RIS and monitored by 
immunophenotyping for lymphocyte activation markers. By 3 months the absolute 
number o f  MHC Class IICD 8* T cells had increased by three-fold and further RIS 
was halted. EB V 1 3 had an initial partial response to RIS, however recurrent 
diarrhoea and rectal blood loss, suggestive of tumour recurrence at 12 months after 
diagnosis led to further RIS. Despite withdrawal of all immunosuppression, 
persistent disease in the rectum and colon required second-line treatment with 
rituximab. EBV* 3 had a minor response to rituximab at the abdominal lymph nodes 
but subsequently died from cachexia and intractable diarrhoea.
Panel c represents data from EBV* 5 who was EBV sero-negative at the time o f 
renal transplant and developed a primary EBV illness with encephalitis and a 
tonsilar mass 42 months after renal transplantation. A biopsy from the tonsilar mass 
confirmed an EBV-positive PTLD by EBER staining and the EBV viral copy 
number within the CSF was high. EBV* 5 was treated with RJS and 4 infusions o f 
HLA-matched allogeneic EBV-specific T cells, and was monitored by both 
immunophenotyping and serial EBV viral copy numbers from serum samples. By 3 
months a three-fold increase in the absolute number o f MHC Class II+CD8* T cells 
had occurred and further RJS was stopped. Radiological imaging confirmed a 
complete clinical response to treatment.
Figure 4.1 demonstrates that an increase o f EBV-specific IFN-y-producing CD8* T 
cells accompanied clinical response to treatment. All eight EBV positive PTLD 
patients were treated with RIS. 3 patients (EBV" 1, (Appendix 1.4) EBV" 4 and 
EBV" 5) had a complete response to RIS and demonstrated a rise in EBV-specific 
CD8* T cells as immunosuppression was reduced. 4 patients (EBV" 3, EBV" 6, 
EBV" 7 and EBV* 8 (Appendix 1.4) had a partial response to treatment. Although
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only limited time points were available, the number of EBV-specific CDS' T cells in 
all four patients was high or rising after treatment with RIS. In two patients (E B V 4  
and E B V '5) complete clinical response was associated with a subsequent decline in 
EBV-specific immunity; a response appropriate to the effective removal o f EBV 
antigen. A decline in EBV-specific T cells was also observed in E B V 3. Although 
this patient had a partial response to RIS, she subsequently had a clinical relapse 
requiring further treatment, suggesting that a fall in EBV immunity prior to 
achieving a complete clinical response may predict relapse. EBV* 2 (Appendix 1.4) 
was treated with RIS followed by rituximab and cytotoxic chemotherapy for a 
diffuse large B cell EBV positive PTLD tumour. The patient died on treatment 
secondary to neutropenic sepsis before any clinical response was seen, however 
EBV-specific CD8* T cells were high after immunosuppression had been 
withdrawn, suggesting that functional EBV specific immunity was emerging.
The emergence o f functional EBV-specific T cells was observed in the context of 
several different immunosuppressive regimes and occurred at different levels of 
reduction for each patient. A rise in EBV immunity occurred with an 80% RIS 
compared to pre-treatment levels o f immunosuppression for EBV+4, 60% for EBV+3 
and 10% for EBV+5 in combination with infused allogeneic EBV-specific T cells.
In addition to showing a rise with clinical response, the increase in EBV-specific 
CD 8+ T cells also accompanied the rise in CD8+MHC Class II4 T cells. An 
exception was EB V f 6 where a partial response to RIS was associated with an 
increase in EBV-specific CD84 T cells but no change in the cell surface expression 
o f MHC class II. This patient was also unusual in presenting with late-onset EBV- 
positive PTLD, 18 years after transplantation.
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In two patients (HBV'3, HBV'4) the time course o f the expansion of functional 
HBV-speeific T cells was more restricted than for the increase in MHC class II 
expression, suggesting that the latter encompasses the EBV-specific response as 
well as other activation related processes that may include an increase in T 
regulatory cells. Although data on EBV viral load was available for only one patient 
(EBV’ 5), Figure 4.1 also demonstrates a relationship between the frequency o f 
EBV-specific CD8' T cells and EBV load. Patient EBV* 5 (Panels C and D) had a 
complete response to treatment with RIS and CTL therapy which accompanied a rise 
in the frequency o f EBV-specific CD8* T cells and a fall in the EBV viral copy 
number. The viral copy number at 2 months after diagnosis (0.0 genome/mL) is 
thought to be an erroneous result. EBV* 5 therefore provides an example where 
EBV load corresponds with response to treatment for PTLD (Smets et al., 2002)
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Figure 4.1: Serial measurement of EBV-specific T cell responses in three EBV-positive PTLD 
patients during R1S
PBMCs from EBV* 4, EBV* 3 and EBV* 5 were sampled at regular time points throughout treatment 
with RIS, and stimulated with an autologous LCL or partially HLA class 1 matched LCLs or HLA 
class I restricted peptide pools. Results were compared to mismatched LCLs and an EBV peptide 
restricted through an irrelevant HLA alleles plus DMSO (Irrelevant peptide) as negative controls. The 
EBV-specific T cells were enumerated by measuring the IFN-y production from CD8* T cells using 
intracellular cytokine staining, and expressed as an absolute number. EBV-specific CD8* T cell were 
compared to the number of CD8*MHC class I f  T cells at each time point. The EBV-specific T cell 
response from stimulation with EBV antigens was also compared to the reduction in dose of the 
immunosuppressive drugs used for each patient and serial creatinine measurements. In patient EBV* 
5 the EBV-specific T cell response was compared to EBV load. Note the EBV load measurement of 
0.0 genome/ml at 2 months post diagnosis is thought to be an erroneous result, and the correct fall in 
viral load with RIS is suggested with the dotted line.
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4.2.1.4 Assessment o f  EBV-specific CD8+ T cell responses in PTLD patients with 
EBV-negative tumours during RIS
EBV-negative PTLDs usually occur late after transplantation and are often more 
aggressive resulting in a poor prognosis compared to EBV-positive PTLD (Leblond 
et al., 1998). The pathogenesis for EBV-negative PTLDs remains unclear; some 
studies have suggested that they represent sporadic lymphomas that have occurred in 
immunosuppressed patients and should not be considered under the PTLD 
classification umbrella (Dotti et al., 2000; Sivaraman and Lye, 2001). Other studies, 
however, have suggested that EBV was initially involved in the oncogenesis o f 
EBV-negative PTLD tumours but loss o f the EBV antigen subsequently occurred 
through a series o f mutations resulting in viral-independent cell proliferation. 
W hether this event was driven by selection pressure to avoid the vigorous cellular 
immune response to EBV is unclear. Support for this proposed ‘hit and run’ 
oncogenesis theory (Ambinder, 2000) includes evidence that some clones o f the 
EBV-associated Burkitt’s lymphoma-derived cell line, Akata, (Shimizu et al., 1994) 
and the nasopharyngeal carcinoma cell line, NPC-C666, (Chen et al., 1999) are 
capable o f losing their viral episomes when grown in culture. In addition, a recent 
series o f non-endemic Burkitt’s lymphomas showed that in some cases where EBV 
could not be detected by standard molecular techniques, partial fragments o f  EBV 
genome were evident (Razzouk et al., 1996).
Despite loss o f  EBV antigen, a small percent o f EBV-negative PTLD patients will 
respond to RIS (Nelson et al., 2000). The basis for a clinical response to RIS is 
unknown but thought to involve the emergence of anti-tumour reactivity that is not 
mediated by EBV specific T cells. EBV immunity is unlikely to change during RIS 
and therefore this cohort o f patients was included as a negative control.
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Figure 4.2 shows the serial data from two EBV-negative PTLD patients with more 
than 5 serial samples who were treated with RIS. EBV' b presented with cervical 
lymphadenopathy 6.6 years after renal transplantation. Histology showed an 
anaplastic large cell lymphoma which was negative for EBV by EBER staining. He 
was treated with RIS alone and went on to have a complete clinical response. EBV' 
c presented 8.3 years after renal transplantation with multiple skin lesions involving 
the scalp. Histology showed a diffuse large B cell lymphoma which was negative for 
EBV markers, and she was treated with both RIS and localized radiotherapy to the 
scalp. To date she has achieved a partial clinical response.
In all four EBV-negative PTLD patients, (Figure 4.2 and Appendix 1.4) there was 
no association between the level o f EBV-specific IFN-y producing CD8+ T cells and 
clinical response to treatment. This finding was consistent among the patients treated 
with RIS (EBV' b and EBV' c) and those treated with cytotoxic chemotherapy 
(EBV* a and EBV* d Appendix 1.4), suggesting that EBV immunity is unchanged 
by either therapeutic approach. The frequencies o f MHC class iT  CD8+ T cells also 
did not show consistent change during RIS for all four patients.
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Figure 4.2: Serial measurement of EBV-specific T cell responses in two representative patients 
with EBV-negative PTLDs during RIS
See Legend 4.1
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4.2.1.5 Comparison o f  peak EBV-specific T cell responses in patients with PTLD 
measured after stimulation with LCLs or HLA class 1 restricted peptide 
pools
A comparison o f detection and size of the responses promoted after stimulation with 
autologous LCLs, partially HLA class I matched LCLs or peptide epitope pools was 
performed for 11 patients with PTLD. For each patient, the sample screened at the 
peak o f functional EBV immunity was selected for study and the magnitude o f the 
responses obtained by stimulation with each EBV antigen source compared. EBV+ 2 
was not included as only one sample was available for assessment.
Figure 4.3 compares the magnitude o f the response measured when functional EBV 
immunity was at its peak after stimulation with autologous LCLs, partially matched 
LCLs and HLA-restricted peptide pools in EBV-positive PTLD patients (Panel A) 
and EBV-negative PTLD patients (Panel B). Regardless o f the EBV status o f their 
PTLD tumours, IFN-y producing CD8+ T cells specific for EBV were detectable in 
all patients after stimulation with at least one o f the antigen sources tested. This 
result is expected given their history o f previous EBV infection. Six patients had 
autologous LCLs available and in all cases these cells stimulated a positive EBV- 
specific T cell response. This made autologous LCLs the most reliable source o f 
antigen to use for detection o f EBV immunity and is consistent with results 
presented in Chapter 3 for studies with healthy individuals.
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Figure 4.3: Comparison of peak EBV-specific T cell responses on stimulation with different EBV antigens in patients with PTLD
Results shown are those obtained at the peak of the EBV response for each patient. PBMC samples from EBV-positive (Panel A) and EBV-negative (Panel B) PTLD 
patients were stimulated with autologous LCLs (pink), partially matched LCLs (yellow), mismatched LCLs (magenta), HLA class I-restricted peptide pools tailored to patient 
HLA type (blue) or irrelevant peptide (green). EBV-specific T cells were quantified by measuring production of IFN-y by CD8+ T cells using intracellular cytokine staining 
and expressed as an absolute number using the lymphocyte count. The bars and error bars represent the mean and sd respectively. The graphs shown far right of Panels A and 
B present the magnitude of the EBV-specific T cell responses after stimulation with each antigen source calculated from the test sample-relevant negative control 
(mismatched LCL or irrelevant peptide) to give increase above background. Statistical analysis to compare the magnitude of the positive responses generated after 
stimulation with each antigen source was performed using a Mann-Whitney U test.
182
Chapter 4
Unfortunately, attempts to generate autologous LCLs are not always successful. 
Use o f LCLs matched at a single HLA class I allele as an alternative source of 
stimulator cells was investigated for healthy individuals but found to be unreliable 
(see Chapter 3 section 1.2). Assessment o f single HLA class I allele matched LCLs 
for patient samples also showed they failed to stimulate consistent positive 
responses. LCLs matched on single alleles were tested as alternative source o f EBV 
antigens for 7 PTLD patients (Table 4.3). In some cases, no responses were detected 
when restricted by a single HLA allele. This could be due to the phenomenon of 
immunodominance as discussed in Chapter 3 section 1.2 whereby the immune 
response is biased to one epitope to the exclusion o f others. Variation in stimulating 
capacity o f different LCLs sharing the same HLA class I allele was also noted and 
both problems are illustrated by the representative example shown in Figure 4.4. 
Patient EBV+ 3 was screened with a panel o f 8 different LCLs matched on single 
alleles on two separate occasions at the peak o f the EBV-specific T cell response. 
No responses were detected after stimulation with LCLs matched at HLA-Cw*0602 
(Figure 4.4, Panel C). Only one o f two LCLs matched for Cw*0401 produced a 
positive response (Figure 4.4, Panel C) and only one o f  two LCLs matched at 
B*3501 and Cw*0401 stimulated a response (Figure 4.4, Panel B). Note that due 
to linkage dysequilibrium between HLA-B and HLA-Cw alleles, LCLs matched 
only for the HLA-B alleles o f this patient could not be obtained. Variation in levels 
o f expression o f the EBV peptide epitopes may account for differences in the 
stimulating capacity o f cell lines sharing the same HLA class I allele. The 
phenomenon o f  immunodominance together with unpredictable variation in 
stimulating capacity o f  cell lines matched only at single HLA alleles would 
necessitate screening o f several different LCLs for each patient to ensure all positive
183
Chapter 4
responses are detected. However this would require testing a large number of 
PBMCs which cannot realistically be obtained from patients for routine analysis. It 
may be possible to circumvent these problems by using LCLs matched on multiple 
alleles or pools of peptide epitopes tailored to patient HLA type, so their use as 
alternative stimulators to autologous LCLs was investigated.
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Figure 4.4: Representative example from patient EBV+3 of EBV-specific T cell responses after 
stimulation with a panel of single HLA class I allele matched LCLs
PBMCs from EBV+ 3 (HLA-A*0101, A*0301 B*5701, B*3501 Cw*04, Cw*0602) were stimulated 
with a panel of LCLs matched on HLA-A alleles alone (Panel A), both HLA-B and HLA-Cw alleles 
(Panel B) or HLA-Cw alleles alone (Panel C). Background stimulation was calculated from the 
mean value obtained with 3 different mismatched LCLs (Panel D) and is represented by black 
vertical lines in all panels. Data from this experiment is representative of results from two 
consecutive samples collected at the height of the EBV-specific T cell response (4 and 4.8 months 
post PTLD diagnosis). EBV-specific T cells were quantified by measuring IFN-y production by 
CD8+ T cells using intracellular cytokine staining, and expressed as percentages of CD3+CD8+ T 
cells. The bar and error bar values represent the mean and sd values respectively.
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Figure 4.3 shows positive EBV-specific T cell responses were detected in 6 of the 7 
patients stimulated with LCLs matched on 2 or more HLA class I alleles and 7 out 
o f 8 patients stimulated with HLA class I restricted EBV peptide pools. EBV'a did 
not respond to an LCL matched at two alleles (A*0301 and B*1801) despite a 
positive response to autologous LCLs and E B V '3 did not respond to a peptide pool 
containing 4 epitopes despite a positive response to a partially matched LCL. A 
statistical comparison o f the magnitude of the peak EBV specific T cell responses 
detected with each antigen source was performed for EBV-positive PTLD patients. 
Comparative analysis o f results from EBV-negative PTLD patients was not 
performed because only two were tested with peptide and only two o f three 
responded to partially matched LCLs. No significant difference in the size o f the 
response after stimulation with autologous LCLs, partially HLA-matched LCLs or 
HLA class I restricted peptide pools was detected, confirming that all three represent 
effective stimulators o f an EBV-specific T cell response. O f note, the response of 
EBV+ 5 to a tailored HLA-restricted peptide pool was larger than to autologous 
LCLs (Figure 4.1, Panel C). This indicates peptide pools have the potential to be a 
better source o f antigen than autologous LCLs. All nine peptides in the pool for 
EBV+ 5 were immunodominant EBV antigens including the HLA-B*0801 restricted 
epitope RAKFKQLL from the immediate early lytic EBV antigen BZLF 1 that 
produces strong EBV-specific T cell responses in healthy individuals (Pudney et a l., 
2005). The concentration o f these immunodominant peptides in the pool may exceed 
that found on the surface o f LCLs (Hill et al., 1995) and account for why the 
response to a peptide pool can be greater than that to autologous LCLs.
These results indicate that both partially matched HLA class I LCLs and peptide 
pools could be practical alternatives to autologous LCLs as a source o f EBV antigen.
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However, neither showed the absolute reliability o f autologous LCLs - one false 
negative result was obtained with both antigen sources. LCLs need to be selected 
that are matched for the maximum number o f HLA class I alleles. The negative 
result with peptides ( E B V 3 )  was obtained with the pool comprising the smallest 
number o f peptides (only 4) and therefore reliability is likely to improve as our 
knowledge o f T cell epitopes grows.
4.2.1.6 Comparison o f  the magnitude o f  the EBV immune response at initiation 
o f  RIS with the maximum response detected 
Comparison o f the magnitude o f the EBV response at initiation o f RIS with the 
maximum response point was performed for EBV-positive and EBV-negative PTLD 
patients. Samples close to the start o f RIS were not available for patients E BV2 ,  
EBV+4, EBV 6, EB V 17 and EBV b, precluding their inclusion in this analysis. 
Results for 4 EBV-positive and 3 EBV-negative patients are shown in Figure 4.5. 
There was no statistically significant difference in magnitude o f the EBV response at 
the start o f RIS between EBV-positive and EBV-negative PTLD patients (p=0.4) 
indicating that susceptibility to EBV-positive PTLD does not result from greater 
compromise o f EBV immunity by immunosuppression in those patients. There was 
no statistical difference between the initial and peak mean responses for the EBV- 
negative PTLD patients (p=0.4) reflecting the absence o f change in functional EBV 
immunity during RIS for EBV-negative PTLD patients (Figure 4.2). Comparison 
o f the initial with the maximum magnitude of the EBV immune response identified 
a borderline statistically significant difference for the EBV-positive PTLD patients 
(p=0.057), with 2 patients (EBV+ 3 (175-fold increase) and EBV+5 (25-fold 
increase)) showing a 3-fold or greater increment in the number o f EBV-specific 
CD8+ T cells. Patients EBV+4 and EBV+6 were not included in the analysis because
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samples at early time points were not available. However, the serial measurements 
presented in Figure 4.1a and A ppendix 1.4 respectively shows these patients had 
impressive rises in EBV immunity. An absolute increase o f 0.0023 x 109 IFN-y 
producing CDS' T cells at the first data point collected 4 months after RIS had 
begun, rising to a peak o f 0.017 x 109 IFN-y producing CD8' T cells, representing a 
7 fold increase was noted for EBV'4, and an absolute increase of 0.0003 x 109 IFN-y 
producing CD8' T cells at the first data point collected 6 months after RIS had 
begun rising to a maximum of 0.00199 x 109 IFN-y producing CD8^ T cells, 
representing a 6 fold increase for EBV 6. These patients were therefore likely to 
have had low EBV immune responses at the start o f RIS. If this is assumed, their 
inclusion in the analysis would have driven the p value comparing EBV immunity in 
EBV-positive PTLD patients at commencement o f RIS with the maximum response 
to significance (p=0.0152).
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Figure 4.5: Magnitude of the EBV immune response at initiation of RIS compared to the 
maximum response detected
The magnitudes of the initial (white) and peak (blue) EBV-specific T cell responses for both EBV- 
positive (A) and EBV-negative PTLD (B) patients were calculated by subtracting the test sample 
response achieved by stimulation with autologous LCL, LCLs matched on multiple alleles or HLA 
class I-restricted EBV peptide pools from the response obtained using the HLA-mismatched LCL or 
irrelevant peptide. The mean of the initial and peak responses were compared in a non-parametric 
Mann-Whitney U test. The bars and error bars represent the mean and the sd respectively.
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4.2.2 Assessment of EBV-specific T cell responses in patients with EBV- 
positive Hodgkin’s Disease
4.2.2.1 Patient Characteristics
The characteristics o f the 6 patients with Hodgkin’s disease (HD) are shown in 
Table 4.4. The average age at diagnosis o f HD was 34.6 years and the male: female 
ratio was 1:1. Five patients were staged according to the Ann Arbor classification 
(Appendix 1.1) as Stage IIB or above. Three patients had an EBV-positive tumour 
confirmed by the presence o f LMP antigen by immunohistochemistry (2=mixed 
cellularity, l=nodular sclerosing histological subtypes). Within this group, 2 patients 
were treated with combination chemotherapy and 1 patient with localised 
radiotherapy. 1 patient achieved a complete clinical response to treatment, but 
relapsed 2 years after diagnosis and was successfully treated with an autologous 
stem cell transplant. The other two patients were lost to follow up and therefore 
clinical response to treatment is unknown.
Three patients had an EBV-negative tumour confirmed by LMP staining (l=m ixed 
cellularity, 2=nodular sclerosing histological subtypes). All three patients were 
treated with combination chemotherapy. 1 patient was also treated with mediastinal 
radiotherapy and has remained in remission. 1 patient had disease refractory to 
treatment and despite further combination chemotherapy died o f disease 14 months 
following diagnosis. The third patient was lost to further follow-up.
6 patients who were investigated for lymphadenopathy and found to have 
reactive/inflammatory changes on biopsy (Reactive hyperplasia) were included as 
histological negative controls. The average age at diagnosis was 41 yrs and the male 
to female ratio was 1:1.
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Patient
Code
Age at
diagnosis
(yrs)/Sex
Histology Stage at 
diagnosis
Site o f disease Primary
treatment
Clinical
response
Relapse
treatment
HD/EBV+1 29/M MC Ilia Cervical and inguinal LN ABVD CR Autologous 
Stem cell 
transplant 
(CR)
HD/EBV+ 2 26/F MC la Cervical RT LTF
HD/EBV* 3 33/F NS lib Supraclavicular, mediastinal LN ABVD LTF
HD/EBV' a 39/F MC m b Supraclavicular, mediastinal, 
para-aortic LN
ABVD + 
RT
CR
HD/EBV b 63/M NS Illb Mediastinal, para-aortic LN ChlVPP SD High dose 
chemotherapy 
(PD). DoD
HD/EBV c 19/M NS lib Supraclavicular, mediastinal LN ABVD LTF
Table 4.4: Characteristics of patients who developed HD
M, male; F, female; MC, mixed cellularity histological subtype; NS, Nodular sclerosing histological subtype; LN, lymphadenopathy; RT, radiotherapy; ABVD/ChlVPP. 
combination chemotherapy; CR, complete clinical response; SD, stable disease; PD, progressive disease; LTF, lost to follow-up; DoD, died of disease. Patients were staged 
according to the Ann Arbor classification (Appendix 1.1). Response to treatment was measured with radiological imaging and defined according to the RECIST criteria 
(Appendix 1.3).
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4.2.2,2 Comparison o f  EBV-specific T cell responses in EBV-positive and EBV- 
negative HD
The main objectives of these experiments were to determine whether the assay could 
detect EBV immunity in a second group o f patients with malignancy and also 
whether any differences could be detected to explain the lack of tumour control seen 
in the EBV-positive HD patients.
TILs were used as this gave an opportunity to investigate the function o f the EBV 
cellular immune response recruited to the site of the disease. Responses from TILs 
o f HD patients were therefore compared to T cells found in patients with lymph 
nodes enlarged in response to inflammation (Reactive hyperplasia). For two HD 
patients (HD/EBV+ 3 and HD/EBV' b), TILs were not available and therefore 
PBMCs were studied. These patients were analysed separately.
T cell responses were assessed by stimulating TILS, LN cells or PBMCs with 
autologous or partially HLA matched LCLs or HLA class I restricted EBV peptide 
pools. To focus the analysis to CD8+ T cell responses, LCLs that were class I 
matched but class II mismatched were used as stimulators. To focus the analysis to 
CD4+ T cell responses, LCLs that were matched for HLA class II alleles and 
mismatched at all class I alleles were used as stimulators. Peptides were not used to 
assess the CD4+ T cell response because very few class II restricted EBV epitopes 
have been identified. Negative controls were class I and II mismatched LCLs and an 
EBV peptide restricted through an irrelevant class I HLA allele plus DMSO (CD8+ T 
cell response only). The activation status o f the CD4+ and CD8+ T cells was assessed 
by staining for MHC class II expression in all patients except HD/EBV' b.
The EBV-specific CD8+ T cell responses together with the proportion o f CD8+ T 
cells and CD8+MHC class II+ T cells from patients with EBV-positive HD, EBV-
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negative HD and reactive hyperplasia are illustrated in Figure 4.6. Results show that 
a functional CD8 HBV-specific response could be detected in all 12 patients tested, 
demonstrating that the assay could be used to assess EBV immunity in a second 
patient cohort.
Comparisons in the magnitude o f the EBV response from TILs o f EBV-positive and 
EBV-negative HD patients showed no significant difference using autologous LCLs, 
partially HLA-matched LCLs and HLA-restricted EBV peptide pools as stimulators 
(Figure 4.7). A statistically borderline difference was detected between the 
magnitude o f the response from TILs o f EBV-negative HD patients and 
lymphocytes from reactive LNs (p=0.04), however this was not observed between 
the magnitude o f the response from TILs o f EBV-positive patients compared to 
reactive LNs (p=0.12). Further examination o f the T cell composition in the LNs 
showed that the proportion o f CD8+ T cells in the EBV-positive HD tumours as well 
as the proportion expressing the activation markers CD69, CD38 and MHC class II 
was significantly higher than both the EBV-negative tumours and the reactive LN 
(p=0.016, p=0.0086, p=0.0033, p=0.0116, p=0.0044 for CD8, MHC class II, CD69, 
CD25 and CD38 respectively, Figure 4.7). Note activation data for patient 
H D /EBV b was not available. It is known that TILs from HD patients are more 
activated than those from reactive hyperplasia (Amlot et al., 1996). These data raise 
the possibility that the EBV antigens present in EBV-positive HD tumours promote 
recruitment o f EBV-specific T cells into the lymph nodes but that this may not 
translate into increased anti-EBV activity as the proportion o f IFN-y producing T 
cells was the same as that detected in the reactive LNs and the EBV-negative TILs. 
Reasons for this include the presence o f regulatory CD8f T cells, represented by the 
increased proportion o f CD25+CD8+ T cells in the EBV-positive TILs.
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EBV-specific CD8 T cell responses were much lower in the two patients where 
PBMCs were analyzed compared to those elicited from the four patients in which 
TILs were studied. This may indicate differences in the frequencies o f EBV specific 
T cells at these two locations however definitive assessment would require analysis 
o f both TILs and PBMCs from each patient.
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Figure 4.6: Comparison of CD8+ T cell responses from patients with EBV-positive HD, EBV- 
negative HD and Reactive hyperplasia
TILs, PBMCs or cells from reactive LNs were stimulated with autologous LCLs, partially HLA class 
I matched LCLs or HLA class 1 restricted EBV peptides. EBV-specific T cells were quantified by 
measuring IFN-y production by CD8+ T cells using intracellular cytokine staining, and expressed as 
percentages of CD3+CD8+ T cells. The number of CD8+ T cells present in each sample was expressed 
as a percentage of the CD3+ T cells. CD4+ and CD8+ T cells and CD8+ T cells expressing MHC class 
II, CD25, CD38 or CD69 were represented as a percentage of the CD3+ T cells. The bar and error bar 
values represent the mean and sd values respectively.
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Figure 4.7: Comparison of the magnitude of the EBV-specific CD8+ T cell response and the proportion of CD8+ T cells expressing activation markers within the 
LNs of patients with EBV-positive and EBV-negative HD and Reactive Hyperplasia
Magnitude of the EBV-specific T cell response was calculated by subtracting the response from the test sample from its relevant negative control. Responses using 
autologous LCLs, partially HLA class I matched LCLs or HLA class I restricted EBV peptide pools were included. Comparisons between groups were calculated using an 
un-paired t-test and expressed as a p value. Note different y axis ranges are used.
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The CD4 T cell responses (assessed by measuring IFN-y production from 
C D 3 C D 8 '  T cells) from patients with EBV-positive HD, EBV-negative HD and 
reactive hyperplasia are illustrated in Figures 4.7 and 4.8.
Results show the assay was able to detect CD4' T cell responses to EBV in addition 
to CD 8+ EBV specific T cells. The magnitude of the EBV response from CD 4f TILs 
in EBV-positive HD patients was significantly higher than the response in patients 
with EBV-negative HD or reactive hyperplasia (Figure 4.9 p=0.014), despite 
significantly increased proportions o f CD4* T cells in the reactive LN group 
(p=0.016). The expression o f activation antigens on CD44 T cells was not 
significantly different between EBV-positive and EBV-negative HD patients or 
patients with reactive hyperplasia. Flow cytometry data representing this result is 
shown in Figure 4.10. The increased CD4* T cell response in TILs from EBV- 
positive HD patients was not reflected in the PBMC samples from a patient with 
EBV positive HD (Figure 4.8) compared to PBMCs from an EBV-negative HD 
patient (Figure 4.8). Responses were equivalent and relatively low in both PBMC 
samples. This again suggests differences in the frequencies o f EBV specific T cells 
in PBMC and TIL samples with preferential homing to EBV-positive TILs, but 
formal demonstration requires measurement o f EBV immunity at both locations in 
each patient.
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Figure 4.8: Comparison of CD4+ T cell responses in patients with EBV-positive HD, EBV- 
negative HD and Reactive hyperplasia
TILs, LNs or PBMCs were stimulated with autologous LCLs, or partially HLA-class II matched 
LCLs. EBV-specific CD4+ T cells were quantified by measuring IFN-y production by CD8 T cells 
using intracellular cytokine staining, and expressed as percentages of CD3+CD8 T cells. CD4+ and 
CD8+ T cells and CD4+ T cells expressing MHC class II, CD25, CD38 or CD69 were represented as a 
percentage of the CD3+ T cells. The bar and error bar values represent the mean and sd values 
respectively.
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Figure 4.9: Comparison of the magnitude of the EBV-specific CD4+ T cell response and the proportion of CD4+ T cells expressing activation markers within the 
LNs of patients with EBV-positive and EBV-negative HD and Reactive Hyperplasia
Magnitude of the EBV-specific T cell response was calculated by subtracting the response from the test sample from its relevant negative control. Responses using 
autologous LCLs or partially HLA class II matched LCLs were included. Comparisons between groups were calculated using an un-paired t-test and expressed as a p value. 
Note different y axis ranges are used.
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Figure 4.10: EBV-specific T cell responses to Autologous LCLs in patients with EBV-positive and 
EBV-negative HD
PBMCs from patients HD/EBV+2 (Panel C) and HD/EBV'a (Panel D) were stimulated with 
autologous LCLs. LCLs mis-matched for all HLA class I and II alleles were used as negative controls. 
Lymphocytes were gated from the cell debris on the forward scatter/side scatter plot (panel A). CD3+ T 
cells (panel B) were gated on a second dot plot using the CD3/CD8 plot. T cells were then assessed 
for IFN-y production in a third dot plot (panels C/D). The numbers in the upper left quadrant of each 
panel represent the percentage of CD3+CD8 T cells producing IFN-y and in the upper right quadrant 
the percentage of CD3+CD8+ T cells producing IFN-y.
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Despite the small numbers o f patient samples available for analysis, these results 
suggest that the presence of EBV antigens on the surface o f EBV positive R-S cells 
does promote recruitment o f both CD84 and CD4* with functional capacity to 
malignant lymph nodes in HD. This raises the question why the disease is not 
controlled; possibilities include the immunosuppressive environment created by the 
R-S cells inhibiting the function o f the effector cells. In addition, the significantly 
higher numbers o f CD25 expressing CD8' T cells found in the HD lymph nodes 
(Amlot et al., 1996) or even the IFN-y secreting CD44 T cells may be 
regulatory/suppressor cells that inhibit EBV specific T cells. Evidence for the latter 
suggestion comes from reports that IFN-y is secreted transiently from a subset of 
regulatory T cells in response to antigen (reviewed by (Wood and Sawitzki, 2006). In 
addition, there is evidence that some HLA class II restricted epitopes from the EBNA- 
1 antigen, which is expressed by all EBV-driven malignancies, preferentially activate 
regulatory T cells (Voo et al., 2002). Further experiments are therefore required to 
characterise the CD25+ T cells and IFN-y producing CD44 TILs stimulated by EBV 
antigens in this assay.
Comparison o f the different EBV antigens used in the assay for patients with HD and 
reactive hyperplasia showed that autologous LCLs were able to stimulate a positive 
EBV-specific CD8+ T cell response in all 11 patients tested. 2/3 partially HLA allele 
matched LCLs were also able to stimulate a positive response in all patients with HD, 
and 5 out o f 6 patients with reactive hyperplasia. Screening with LCLs matched on 
single alleles however produced variable results, stimulating a positive response in 
only 5 out o f 9 patients tested despite all responding to autologous LCLs. HLA- 
restricted EBV peptide pools were only tested in 6 patients due to limited cell
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numbers but in all cases stimulated a positive CD8 T cell response. These results are 
consistent with those obtained from healthy individuals and PTLD patients and 
confirm that autologous LCLs are the most reliable source o f EBV antigen. In the 
absence o f these cells, LCLs matched on at least 2 alleles or HLA-restricted peptide 
pools tailored to patient HLA type represent alternative sources o f antigens. 
Autologous LCLs and LCLs matched on at least 2 class II alleles were also able to 
stimulate CD4’f T cell responses in patients with EBV-positive and EBV-negative HD 
as well as reactive hyperplasia showing that this assay is an effective approach for 
measuring CD4* as well as CD 8f EBV specific T cell immunity.
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4.3 DISCUSSION
Results from work in this chapter established that the clinical assay developed in 
Chapter 3 to measure IFN-y producing EBV-specific T cells in healthy individuals 
could be applied to measure EBV immunity in EBV related disease states.
In patients with PTLD, the main objective was to determine whether the assay could 
be used to measure any increase in the functional cellular immune response to EBV 
during treatment with RIS. Monitoring changes in cell surface expression of 
activation markers such as MHC class II on CD8* T cells has been used successfully 
for this purpose in PTLD patients (Amlot et al., 1996; Rees et al., 1998; Amlot et al., 
2007; Baudouin et al., 2004), however the main disadvantage o f this approach is that 
it is unable to provide information regarding the antigen specificity o f the cellular 
immune response. Work presented in Chapter 3 showed that functional EBV-specific 
T cells could be measured in healthy individuals after a short in vitro stimulation with 
autologous LCLs or HLA-restricted peptide pools. Developing this assay for use in 
the context o f PTLD would therefore address the limitations o f the cell phenotyping 
assay.
Initial experiments looked at 12 PTLD patients with EBV-positive and EBV-negative 
tumours and examined the EBV-specific T cell response from serial PBMC samples 
stimulated in vitro with autologous LCLs, partially HLA matched LCLs or EBV 
HLA-restricted peptide pools.
Results from EBV-positive PTLD patients showed that the assay was able to detect 
emergence o f IFN-y producing EBV-specific CD8+ T cells in response to reduction in 
immunosuppression and that this was associated with clinical response in all 8
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patients tested. This finding confirms that these cells play a critical role in the 
elimination o f malignant B cells transformed by EBV. The importance o f IFN-y 
producing T cells in EBV immunity is beginning to be appreciated with the finding 
that previously undetected EBNA-1 specific CDS’ T cells (Levitskaya et a l., 1995) do 
exist and produce IFN-y rather than lytic activity (Lee et al., 2004). IFN-y production 
may therefore be a more reliable indicator o f target cell recognition by EBV-specific 
T cells rather than lytic activity determined by conventional cytotoxicity assays. 
EBV-specific T cell responses also mirrored the changes in MHC class II expression 
on the surface o f the effector cells but typically lagged behind the initial increase in 
activation marker expression and declined more rapidly. A similarly short duration for 
expansion o f an EBV specific T cell response has previously been seen in IM (Callan 
et al., 1996). The marked difference in duration indicates that the increase in MHC 
Class II expression on activated CD8+ T cells not only encompasses the EBV specific 
T cell response but must also include a wider spectrum of T cell activation as 
immunosuppression is reduced that may include regulatory T cells. A rise in MHC 
class II expression is currently used to guide step-wise reduction o f 
immunosuppression in patients with PTLD (Amlot et al., 2007), however replacement 
o f this non-specific measurement by an EBV specific methodology is likely to 
increase the accuracy. The advantage of an assay which measures IFN-y producing T 
cells in response to EBV antigen stimulation is that it provides a specific measure o f 
EBV immunity. Further studies using a larger cohort o f PTLD patients may also 
determine a threshold number o f IFN-y producing EBV-specific CD8+ T cells in the 
peripheral blood that are required to control PTLD.
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Although the majority o f EBV-positive PTLD patients respond to treatment RIS, a 
small percent will be unresponsive or relapse early. Reasons for this are not known 
but suggest that PTLD tumours are capable of evading the EBV-specific T cell 
response perhaps by down-regulating some or all of the surface antigens. A possible 
example o f this is seen in patient EBV 3 who initially achieved a partial response 
during RIS but relapsed soon after and was then treated with chemotherapy. 
Immunosuppression in this patient was withdrawn over a protracted time scale and 
not according to standard protocol (Amlot et al., 2007). This may have inadvertently 
provided a window in which the tumour had time to adapt by either down-regulating 
the EBV antigens targeted by the slowly emerging EBV immune response or 
outgrowth o f cells within the tumour which had a restricted pattern of EBV antigen 
expression. The fall in the EBV-specific immune response observed in this patient on 
relapse could either represent the decline o f the effector CD8+ T cells specific for the 
immunodominant antigens, or result from immunosuppression induced by cytotoxic 
chemotherapy.
Evidence that PTLD tumours are able to down regulate EBV antigens from their 
surface is supported by studies that have shown development o f PTLD lesions from 
EBV transformed atypical post-germinal B cells (Timms et al., 2003). This finding is 
analogous to the pathogenesis o f EBV-positive HD, a tumour that has evolved 
secondary to genetic mutations and down-regulated EBV antigen expression to LMP- 
1, LMP-2 and EBNA-1 (Re et al., 2005). Such a connection between EBV-positive 
PTLD and HD therefore suggests that EBV-positive PTLD can also employ similar 
immune evasion strategies and down regulate immunodominant EBV antigens from 
its surface. Indeed, the common misunderstanding that PTLD expression o f EBV
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antigens is comparable to LCL and latency type III has been refuted by studies 
showing a position somewhere between latency type II and III with loss o f some of 
the more immunogenic EBV antigens (Timms et al., 2003; Cen et al., 1993). Both of 
the aforementioned studies found variable loss of EBNA 2, 3 or LMP1. Currently, 
PTLD lesions are simply classified on EBV status according to the presence o f EBER 
or EBNA-1 on immunohistochemical staining. It is known that staining for LMP1/2 is 
highly unreliable for determining EBV status and if present is usually only on a 
minority of PTLD cells. False-negative results are therefore possible. Quantifying 
EBV gene expression by molecular techniques such as qRT-PCR on individual 
tumours as well as identifying those PTLD tumours that are derived from atypical 
post-germinal B cells and are more likely to change EBV expression, could therefore 
provide valuable prognostic information.
EBV-negative PTLD tumours as well as EBV-positive Hodgkin’s like PTLD typically 
develop much later than EBV-positive tumours o f large B cell type. These tumours 
may represent a continuation o f the immune evasion strategy described above, but 
with a longer lead time enabling complete down regulation o f all EBV antigens. It 
was anticipated therefore that restoring the EBV-specific cellular immune response by 
withdrawing immunosuppression in these patients would have no effect on controlling 
tumour proliferation or clinical response. The results from all four patients with EBV- 
negative PTLD confirmed this proposal, demonstrating that although EBV-specific T 
cells could be detected in EBV-negative PTLD patients, their frequency remained 
unchanged after RIS. Likewise CD8+MHC class II+ expression was also unaltered. 
Treatment with RIS can be effective however, in a small minority o f EBV-negative 
PTLD patients and is often associated with a transient rise in the activation marker
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CD69 (P. Amlot, personal communication). Expression of other activation T cell 
antigens such as CD25 and MHC class II remains unchanged. This suggests that RIS 
may allow restoration o f an anti-tumour T cell response leading to tumour control.
The main objective in patients with HD was to demonstrate whether the assay could 
be used to evaluate EBV immunity in patients with HD and whether this could 
provide any explanation for ineffective tumour control in EBV-positive disease. 
Analysis o f CD8 T cells from EBV-positive and EBV-negative tumours showed that 
the proportion o f CDS* T cells expressing activation antigens was significantly 
increased in the EBV-positive tumours. In addition, EBV-specific CD8+ T cell 
responses were also detected but there was no difference in the magnitude of the 
responses detected from EBV-positive or reactive lymph nodes. This suggests that 
functional EBV-specific CD8 T cells are recruited to the EBV-positive tumours. 
Possible reasons for why this response is ineffective in controlling the disease may be 
the immunosuppressive environment created by the R-S cells or the presence o f 
regulatory T cells within the LN. Another explanation may be that the TILs do not 
contain or have insufficient numbers o f functional T cells specific for the limited set 
o f EBV antigens expressed by the malignant R-S cells. The in vitro assay for EBV 
immunity uses stimulator cells that express the complete set o f EBV antigens. The 
response measured is therefore likely to comprise a polyclonal memory response 
directed to the immunodominant EBNA 3A-C antigens (Hislop et al., 2001; 
Rickinson and Moss, 1997) with a smaller response to the LMP1, 2 and EBNA-1 
EBV antigens expressed by R-S cells in HD. If  the functional EBV reactive T cells 
detected in TILs are specific for EBNA 3A-C, they will not be able to recognise and 
eliminate R-S cells. However, a problem with this proposal is how to explain
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recruitment of EBNA 3A-C specific T cells to malignant LNs if the antigens are not 
expressed. HLA-restricted peptide pools containing class I and 11 epitopes from 
LMP1, LMP2 and EBNA1 antigens would be helpful in determining the precise EBV 
antigen specificity of TILs but relatively few of these peptides have been described. 
The results also showed an accumulation o f CD 4’ T cells in tumours expressing EBV 
antigens and presence o f EBV specific CD4 T cells among these TILs. This may 
represent an increased EBV specific ThI response or an increased antigen-induced T 
regulatory response or a combination of both. Further experiments to address the 
balance between ThI CD 4f T cells and antigen-induced regulatory cells include 
analysing the full spectrum of cytokines produced from the EBV-specific CD4 T 
cells, as well as other markers associated with antigen-induced regulatory T cells such 
as FoxP3. Definitive evidence for an increased antigen-induced regulatory T cell 
response in EBV-positive tumours however, would be from suppression of CD8+ 
EBV-specific T cell response in functional proliferation assays.
Comparisons between the EBV-specific T cell responses generated from stimulation 
with different EBV antigens in the context o f PTLD and HD revealed that autologous 
LCLs were the most reliable at detecting a positive response. Autologous LCLs 
however, could not always be successfully generated despite repeated attempts. In this 
situation, a positive EBV-specific response was detected in the majority o f patients by 
stimulation with LCLs matched for at least 2 HLA alleles or using HLA class I- 
restricted EBV peptides pools. Importantly, these results were achieved using a cohort 
o f PTLD patients that expressed a diverse spectrum of HLA alleles (6 different HLA- 
A, 11 different HLA-B and 11 different HLA-Cw alleles).
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In order for this assay to be successful clinically as a method of monitoring 
emergence of EBV immunity in PTLD patients, autologous LCLs should either be 
generated pre-emptively in all patients undergoing solid organ transplantation 
anticipating they will be needed if PTLD occurs or PBMC should be stored frozen 
prior to transplantation so that EBV transformation of B cells can be attempted if 
PTLD occurs. These approaches make use o f PBMCs collected before transplant so 
the cells are not altered by immunosuppressive drugs thus maximising the chance of 
successful transformation. These pre-emptive measures also ensure that an autologous 
LCL is readily available immediately on, or shortly after, diagnosis of PTLD. In 
patients where autologous LCLs cannot be generated, possible options include testing 
PBMCs with several LCLs matched on multiple HLA alleles and identifying the one 
capable o f eliciting the maximal EBV-specific T cell response. This LCL could then 
be cryopreserved and readily retrieved in the event of a PTLD diagnosis. 
Alternatively, HLA class I-restricted peptide pools could be used, but due to limited 
knowledge o f the epitopes presented by less common HLA alleles and alleles present 
in non-Caucasoid populations, this approach could not be used for all individuals.
In conclusion, work described in this chapter demonstrates that EBV-specific T cell 
responses can be rapidly and reliably measured in patient samples. In the context of 
PTLD, EBV-specific T cell responses were shown to increase as immunosuppression 
was withdrawn and correlate with current methods of measuring recovery o f EBV 
immunity, thereby demonstrating the clinical utility of the assay. Recovery o f EBV 
immunity was also shown to correlate with control o f the PTLD providing evidence 
that IFN-y producing CD8+ T cells are directly involved in mediating effective tumour 
control.
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Experiments with EBV-positive HD showed no evidence for absence o f EBV-specific 
immunity in the affected LNs, thus failure o f the immune system to control disease is 
not due to absence o f protective T cells. This finding supports accumulating evidence 
that localized suppression o f the immune system may occur mediated either by factors 
produced by the malignant R-S cells or presence o f regulatory T cells that suppress 
the anti tumour response. Limited patient samples prevented a more detailed 
examination o f these possibilities.
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Chapter 5
Assessment of quantitative real-time polymerase 
chain reaction (qRT-PCR) to measure IFN-y 
production by EBV-specific T cells using small cell
numbers.
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5.1 INTRODUCTION
Experiments presented in Chapters 3 and 4 established that detection of functional 
EBV-specific T cells could be achieved by stimulation with autologous LCLs in both 
healthy individuals and patients with EBV-driven malignancies using a flow- 
cytometry based ICS assay. This method was chosen for a clinical assay due to its 
superiority over other methods in terms o f reproducibility, greater signal-to-noise 
ratio, speed of generating results, cost effectiveness and ease o f standardisation.
The main limitation with ICS is the relatively large number o f PBMCs required to 
detect a positive EBV-specific T cell response. Detection o f a positive response 
requires 4 samples (autologous LCL or multiple HLA-allele matched LCL (test)), 
HLA-mismatched LCL (negative control), PHA stimulated PBMCs (positive control) 
and unstimulated PBMCs (negative control) and thus a total o f 4x l0 6 PBMCs. 
However, PBMCs obtained from patients with PTLD are often limited in numbers 
and viability (Table 4.2: mean number and [range] = 9.22xl06 [2.2xl06-  20.5xl06] 
and viability = 94% [87-98%]). Therefore, a method that could reliably detect EBV- 
specific T cell responses using fewer PBMCs would be desirable.
Another limitation with ICS is that the number of parameters that can be examined for 
each sample is restricted by the number of fluorescent detectors available on the flow 
cytometer. Although the latest flow cytometers are capable o f detecting up to 18 
different fluorochromes (http://www.bdbiosciences.com/index.shtml), most flow 
cytometers currently used in clinical immunology laboratories are limited to detection 
o f three fluorochromes. In the context o f the flow cytometry based assay for 
detection o f EBV immunity, this equates to CD8 FITC, IFN-y PE and CD3 Cy5.5.
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Therefore only one cytokine can be studied per sample. Although IFN-y production 
by CD8 T cells was found to be the most effective cytokine at detecting an EBV- 
specific T cell response in healthy individuals (Figure 3.2), a method which is able to 
detect several cytokines from one sample would have the advantage o f providing 
additional information regarding T cell functionality. Furthermore it would be 
advantageous to examine patterns o f cytokine production in EBV-driven malignancies 
such as HD and NPC where evidence indicates EBV exploits immune evasion 
strategies based on inducing aberrant cytokine profiles (Marshall et al., 2004; 
Skinnider and Mak, 2002; Kis et al., 2006; Hu et al., 2004; Budiani et al., 2002). 
Quantitative real-time PCR (qRT-PCR) is a highly sensitive molecular method for 
measuring the levels o f mRNA transcripts o f genes of interest. This technique detects 
gene expression from a very small number o f cells and multiple parameters can be 
studied for each sample. Therefore use o f this technique may circumvent the 
limitations o f ICS, however expensive instrumentation that is not routinely available 
in clinical immunology laboratories is required which may limit utility.
The principle o f qRT-PCR is that following the initial conversion o f RNA into cDNA 
template by an RNA-dependent DNA polymerase (reverse transcriptase), specific 
segments o f DNA encoding target genes o f interest are amplified by PCR and these 
products are then detected and quantified as they accumulate (i.e. in ‘real-time’) using 
fluorescent reporter molecules. This technology therefore enables reliable 
measurement o f target gene expression from small cell numbers. Two types of 
detection chemistries are used in qRT-PCR. The non-probe based method quantitates 
the production o f amplicon using a non-sequence specific fluorescent DNA dye such 
as SYBR green I. This dye exhibits little fluorescence in solution but emits a strong
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fluorescent signal upon binding to double-stranded DNA (Morrison et al., 1998). 
Fluorescence therefore increases as amplification proceeds. Disadvantages of this 
detection method however, are two-fold. Quantitation requires extensive optimisation 
using a melting point curve or dissociation analysis (Ririe et al., 1997) and secondly 
preferential binding o f SYBR Green to specific DNA sequences during amplification 
interferes with PCR kinetics rendering multiplexing (simultaneous analysis of 
multiple target genes from the same sample) problematic. Probe-based chemistries 
such as TaqMan™ probes use amplicon-specific fluorescent probes that only generate 
a fluorescent signal if  the probe hybridises with its complementary DNA sequence 
(F igure 2.4). This technique therefore has an advantage over the non-probe based 
method by introducing an additional level o f specificity. Furthermore, multiplex qRT- 
PCR is possible using probes labelled with different fluorophores (Grace et al., 2003). 
Given these advantages, a probe-based chemistry was chosen for the development of 
a qRT-PCR assay to measure EBV-specific immunity.
Another important consideration in the design of a qRT-PCR assay is the quantitation 
strategy. Absolute quantitation determines the copy numbers o f the transcript o f 
interest by relating the PCR signal from the test sample to a standard curve. While this 
method is useful for quantifying viral or tumour load in patient samples, it has the 
inherent disadvantage o f requiring production and accurate quantitation of cDNA to 
generate a standard curve which should be included in every experiment (Pfaffl and 
Hageleit, 2001). Relative quantitation however compares the changes in expression of 
a target gene relative to an internal reference gene. The advantage o f relative 
quantitation over absolute quantitation is that it eliminates the need for standard 
curves to be included into each experiment thus increasing throughput. Relative
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quantitation was chosen for the assessment of IFN-y mRNA expression by EBV- 
specific T cells because an absolute measurement was not required for interpretation 
o f results. The important parameter was the difference in IFN-y expression between 
the test sample (EBV stimulated PBMCs) and the appropriate negative control 
(unstimulated PBMCs or irrelevant antigen stimulated PBMCs). Calculations were 
performed using the comparative Ct method (AA Ct (Livak and Schmittgen, 2001)) 
and is detailed in Chapter 2, section 2.4.5.
Current clinical applications o f qRT-PCR exploit its ability to detect gene expression 
from small amounts o f material and is the method used to detect minimal residual 
disease (MRD) in a variety o f haematological malignancies (Marcucci et al., 1998; 
Elmaagacli et al., 2000; Hosier et al., 1999; Ladetto et al., 2001) and EBV viral load 
(Hochberg and Thorley-Lawson, 2005a; Stevens et al., 2005; Ryan et al., 2004). 
Therefore the technique o f qRT-PCR is increasingly being implemented in clinical 
diagnostic laboratories.
Recent research has also illustrated the potential use o f qRT-PCR in monitoring T cell 
mediated immune responses to tumour antigens. Kammula et al used qRT-PCR to 
detect increased melanoma-specific T cell responses in the peripheral blood of 
melanoma patients following vaccination with melanoma HLA class I-restricted 
peptides (Kammula et al., 1999; Kammula et al., 2000). PBMCs from vaccinated 
individuals were briefly stimulated in vitro with the peptides present in the vaccine 
and cytokine expression (IFN-y, TNF-a, IL-2, GM-CSF) or activation antigen 
expression (CD69 and CD25) assessed. Similar studies have also been used to detect 
low frequencies o f leukaemia-specific CD8+ T cells in patients with CML following 
HSCT (Rezvani et al., 2003) as well as endogenous tumour associated antigen
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(TAA)-specific T cells in breast cancer patients at the time of diagnosis (Rentzsch et 
al., 2003). Research studies have also taken advantage of the ability to detect gene 
expression by qRT-PCR from small amounts o f material to investigate immune 
interactions within the tumour microenvironment after vaccination (Ohnmacht et al.,
2001). Such studies are difficult with immunohistochemistry or flow cytometry due to 
the relatively large amounts o f material required. Analysis o f the immune response at 
the site o f pathology has the advantage o f examining the effector populations within 
the tumour which may be different from the circulating lymphocytes in PBMCs. 
Analysing cytokine expression within the tumour microenvironment by qRT-PCR has 
been used successfully to investigate the pathogenesis of both Hodgkin’s lymphoma 
(Malec et al., 2004) and melanoma (Kammula et al., 1999; Mocellin et al., 2001).
An important factor to consider with qRT-PCR assays is that it measures mRNA 
transcript expression and not protein. Therefore a concern with using qRT-PCR to 
measure cellular response to antigen is whether cytokine mRNA transcription 
correlates with the production o f cytokine protein. To address this concern, positive 
correlations have been made with the mRNA transcript levels o f IL-2, IL-4, TGF-Pi 
and IL-10, and concentrations o f the corresponding proteins detected by ELISA in 
PBMCs stimulated with anti-CD3 mAb (OKT3) (Mocellin et al., 2003), melanoma 
peptides (Kammula et al., 2000) and the purified protein derivative o f tuberculin 
(PPD, (Ekerfelt et al., 2002)). In experimental situations, Rezvani et al measured the 
CD8+ T cell response following stimulation with a CMV peptide and demonstrated a 
good correlation between mRNA IFN-y transcripts measured by qRT-PCR and the 
number o f CMV-specific CD8+ T cells detected by tetramer analysis (Rezvani et al.,
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2003). These studies show that cytokine mRNA expression can be used as an 
appropriate indicator o f functional cytokine producing cells.
The ability of qRT-PCR to reliably detect functional T cells has also been compared 
with that o f other assays. qRT-PCR has been shown to be capable o f detecting very 
low frequencies o f antigen specific T cells (range 1 in 50,000 to 1 in 100,000, 
(Kammula et al., 1999; Rezvani et al., 2003) compared to a detection limit o f 1 in 
10,000 cells for tetramer analysis (Rezvani et al., 2003; Klenerman et al., 2002). A 
comparison of ELISA, ELIspot, ICS and qRT-PCR to measure production o f IFN-y 
by CD8+ T cells specific for tetanus toxoid antigen in healthy individuals vaccinated 5 
years previously has been performed (Tassignon et al., 2005). The frequency of 
tetanus-specific T cells was low with each method used, however the probability of 
detecting a true positive response (sensitivity) by qRT-PCR was 71% compared to 
50% by ICS. The highest sensitivity was seen with ELIspot (93%). One explanation 
for the differences in sensitivity between ELIspot and qRT-PCR was the 20 hour 
period of stimulation used in this study prior to measuring the antigen-specific 
response. IFN-y mRNA transcription has been shown to increase rapidly after 
stimulation, peaking between 4 and 8 hours (Abdalla et al., 2003; Stordeur et al.,
2002). Transcription levels then decline due to translation into protein. Therefore 
although at 20 hours accumulation o f IFN-y producing T cells could be detected by 
ELIspot, mRNA transcript levels may have begun to decline leading to under­
estimation o f IFN-y production by qRT-PCR.
No studies to date have used qRT-PCR to measure EBV-specific T cell immunity. 
The aims o f the work described in this chapter were to develop an assay using qRT- 
PCR that could be used to quantify the cellular immune response to EBV in healthy
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individuals and patients with EBV-driven malignancies. Important points that were 
addressed were whether qRT-PCR could reliably measure IFN-y producing T cells 
using smaller numbers o f cells than required for ICS and whether the IFN-y mRNA 
expression correlated with the frequency o f IFN-y producing EBV-specific T cells 
measured by ICS. In addition, the sensitivity o f qRT-PCR compared to ICS was 
investigated by assessing whether qRT-PCR could improve differentiation of a 
positive signal from background in situations where a borderline response was 
obtained by ICS.
The assay was initially optimised with PBMCs from healthy individuals that had been 
stimulated with EBV HLA-restricted peptide pools. The number o f mRNA IFN-y 
transcripts after stimulation with EBV peptide pools or EBV-transformed LCLs were 
then directly compared to the frequency o f IFN-y producing CD8+ T cells detected by 
ICS in both healthy individuals and PTLD patients undergoing RIS therapy.
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5.2 RESULTS
5.2.1 Assessment of a qRT-PCR assay to detect and quantify IFN-y production 
by EBV-specific T cells from limited cell numbers
Initial experiments were performed to ascertain whether fewer numbers o f cells could 
be used to detect a positive EBV-specific T cell response by qRT-PCR than required 
for ICS analysis. The ability to discriminate between a positive response and a 
negative response by qRT-PCR and ICS was also assessed using combinations o f 
HLA class I-restricted EBV peptide pools.
5.2.1.1 Determination o f optimal duration o f antigen stimulation required for the 
detection o f  IFN-y mRNA expression by EB V-specific T cells
Previous studies have shown that the kinetics for cytokine mRNA expression differs 
with the cytokine measured and the antigen used to stimulate a response. Published 
studies using polyclonal activation of PBMCs with PHA have reported that IL-2 and 
IFN-y mRNA expression peaked 4 hours after stimulation and then rapidly fell to low 
levels by 16 hours (Kruse et al., 2001; Stordeur et al., 2002). Early induction o f IFN-y 
mRNA expression in CD8+ T cells was also seen after stimulation with tetanus toxoid 
and influenza antigens in healthy individuals (Kruse et al., 2001). The kinetics o f 
IFN-y mRNA expression in response to mycobacterial antigens, however, was slower 
to develop. IFN-y copy numbers peaked at 16-24 hours o f stimulation in patients with 
active M. tuberculosis and were still detected at 96 hours (Listvanova et al., 2003).
In order to characterise the kinetics o f IFN-y mRNA production in response to 
stimulation with EBV antigens, PBMCs from an EBV sero-positive HLA-A*0201
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individual were stimulated with a pool of HLA-A*0201 restricted EBV peptides and 
compared to stimulation with PHA (positive control) or an EBV peptide restricted 
through an irrelevant HLA class I allele (negative control). The results are shown in 
Figure 5.1 and represent the IFN-y mRNA expression relative to unstimulated 
PBMCs after normalisation to the internal reference gene, GAPDH.
In order for relative quantitation to be effective it is vital that the internal reference 
gene is expressed at a constant level in all test samples (Karge, III et al., 1998). (3- 
actin, GAPDH, 18S ribosomal RNA and hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) are typically used. However their expression has been shown to 
vary between individuals (Piechaczyk et al., 1984; Stout et al., 1985) and between 
different cell types within the same individual (Blomberg et al., 1987; Bustin, 2000). 
Experiments are therefore required to validate the choice of reference gene, by 
screening several different candidate genes and analysing variability between samples 
(Dheda et al., 2004).
Previous experiments performed in the laboratory (Dr K Matthews, unpublished data) 
compared the expression o f 18S ribosomal RNA, GAPDH, HPRT and CD8 in
CD3+CD8+ T cells that had been stimulated with PHA. Unstimulated CD3+CD8+ T
©cells were used as a negative control. Results were interpreted using the BestKeeper 
Software (http://www.gene-quantification.de/BestKeeper-1 .zip, (Pfaffl et al., 2004)), 
a statistical program which selects the least variable gene by comparing the Ct values 
and the geometric mean o f the expression o f several reference genes. This showed 
that GAPDH mRNA expression was the least variable gene for these in vitro assay 
conditions and was therefore chosen as the reference gene for development of this 
assay.
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Maximal induction of IFN-y mRNA expression occurred 6-8 hours after stimulation 
with PHA (Panel A) and 4 hours after EBV-specific stimulation with a HLA-A*0201 
peptide pool (Panel B). Therefore a 4 hour antigen stimulation period was used for all 
subsequent experiments.
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Figure 5.1: The kinetics of IFN-y mRNA expression following stimulation with HLA-A*0201- 
restricted EBV peptides in a healthy HLA-A*0201 individual
1 x 106 PBMCs from an HLA-A*0201 EBV sero-positive individual were stimulated with PHA (Panel 
A) or HLA-A*0201 restricted EBV peptide pools (Panel B) for different periods of time. After 
incubation, cells were harvested, and lysed. RNA extraction, generation of cDNA and qRT-PCR for 
IFN-y and GAPDH were performed as described in Chapter 2. Results are represented as IFN-y mRNA 
expression relative to unstimulated cells (unstim), after normalisation to corresponding GAPDH 
mRNA expression from the same sample, using the AACt method. Samples were performed in 
triplicate and presented as the mean totals. Error bars represent the sd.
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5.2.1.2 Assessm ent o f  the m inim um num ber o f  PBMCs required to detect IFN-y  
m RNA expression in EBV-specific Tcells  
Experiments were performed to determine the minimum number o f PBMCs from 
which IFN-y mRNA expression could be detected after stimulation with EBV peptide 
pools. Numbers o f PBMCs ranging from lxlO 6 to lxlO4 from a healthy EBV sero­
positive HLA-A*0201 individual were stimulated with HLA-A*0201 restricted EBV 
peptide pools for 4 hours. IFN-y mRNA expression from each sample was compared 
to unstimulated cells after normalisation to GAPDH. Stimulation using PHA and an 
EBV peptide restricted by an irrelevant HLA class I allele plus DMSO were used as 
positive and negative controls respectively. Figure 5.2 shows that an EBV-specific T 
cell response can be detected from as few as 5x l04 PBMCs using qRT-PCR. In 
contrast the ICS assay requires at least 5x l05 PBMCs per sample to detect a positive 
response (data not shown). A larger starting cell number is required for ICS because 
the assay incorporates many wash steps leading to cell loss. Therefore in order to 
acquire 2 x 105 live cells within the lymphocyte gate on the cytometer more PBMCs 
are required at the start o f the ICS assay to compensate for anticipated losses.
This result confirms the ability of qRT-PCR to detect cytokine expression from 
limited numbers o f cells. All subsequent experiments were performed using lxlO 5 
PBMCs.
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Figure 5.2: Assessment of the minimum number of PBMCs required to detect IFN-y mRNA 
expression following stimulation with HLA-A*0201 restricted EBV peptide pools
Decreasing numbers of PBMCs from an A*0201 healthy individual were stimulated for 4 hours with 
HLA-A*0201 restricted EBV peptide pools. After incubation, cells were harvested, and lysed. RNA 
extraction, generation of cDNA and qRT-PCR for IFN-y and GAPDH were performed as described in 
chapter 2. Results are represented as IFN-y mRNA expression relative to unstimulated cells (unstim), 
after normalisation to corresponding GAPDH mRNA expression from the same sample, using the 
AACt method. Samples were performed in triplicate and presented as the mean totals. Error bars 
represent the sd.
5.2.2 Com parison of ICS and qRT-PCR for m easuring IFN-y production from 
EBV-specific T cells after stimulation with peptides
Having established the optimal conditions for detecting a positive EBV-specific T cell 
response after stimulating PBMCs from healthy individuals with HLA class I- 
restricted EBV peptides by quantitation of cytokine mRNA expression using qRT- 
PCR, it was important to determine whether results obtained by qRT-PCR correlated 
with those obtained by ICS.
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PBMC's from two healthy EBV sero-positive individuals were stimulated with HLA- 
A*0201 restricted EBV peptide pools (Figure 5.3, Panels A and B) PBMCs were 
either stimulated for 16 hours at a concentration of lx l 06 per condition and analysed 
by ICS, or stimulated for 4 hours at lxlO5 per condition and analysed by qRT-PCR. 
The results for both individuals showed that positive EBV-specific T cell responses 
were detected after stimulation with HLA-A*0201 restricted peptide pools using both 
ICS and qRT-PCR assays despite using fewer PBMCs for the qRT-PCR assay. In 
addition, the magnitude o f the response above background (i.e. the difference between 
peptide stimulation and the negative peptide control) was consistently greater in the 
qRT-PCR assay compared to the ICS assay (35-fold increase by qRT-PCR compared 
to a 6-fold increase with ICS in individual A, and 69-fold increase by qRT-PCR 
compared to 4-fold increase by ICS in individual B).
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qRT-PCR
Figure 5.3: Comparison of ICS and qRT-PCR to measure IFN-y production by EBV-specific T 
cells using EBV peptides as stimulators
PBMCs from two healthy A*0201 individuals (Panel A and B) were stimulated with an HLA-A*0201 
restricted EBV peptide pool. PBMCs were either stimulated for 16 hours in the presence of Brefeldin A 
and analysed by ICS (■), or stimulated for 4 hours (■) and analysed by qRT-PCR. lxlO6 PBMCs were 
used per condition for ICS and 1x10s PBMCs were used per condition for qRT-PCR. Stimulation using 
an EBV peptide restricted to an irrelevant HLA class I allele plus DMSO (irrelevant peptide) and PHA 
were used as negative and positive controls respectively. Results for ICS were expressed as percentage 
IFN-y producing CD8+ T cells. Results for qRT-PCR were represented as IFN-y mRNA expression 
relative to unstimulated cells, after normalisation to GAPDH mRNA expression from the same sample. 
The stimulation index was calculated by dividing the results obtained by FACs or qRT-PCR for the test 
sample (EBV peptide) with negative control (irrelevant peptide). Samples were performed in triplicate 
and presented as the mean totals. Error bars represent the sd.
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5.2.3 Comparison of ICS and qRT-PCR for measuring IFN-y production from 
EBV-specific T cells after stimulation with LCLs
5.2.3.1 Preliminary experiments
Preliminary experiments show that EBV specific immunity can be detected using 
qRT-PCR following stimulation with HLA class I restricted peptides. However, the 
main problem with using EBV peptides as a source of antigen is that at present there 
is an inadequate knowledge o f epitopes for effective coverage o f the entire 
population. Therefore their use in a clinical assay to monitor EBV immunity in 
patients with EBV-driven malignancies is at present limited to patients with common 
HLA types. Autologous LCLs or partially HLA-matched LCLs represent alternative 
EBV antigens and could be used in patients with HLA class I alleles for which EBV 
peptide epitopes have yet to be identified. Therefore to develop a qRT-PCR assay that 
has a broader potential for clinical application it was important to investigate whether 
IFN-y mRNA expression could be detected following stimulation with autologous or 
partially HLA class I matched LCLs.
PBMCs from two healthy EBV sero-positive individuals were stimulated with 
autologous LCLs or HLA-mismatched LCLs (Figure 5.4, Panels A and B) at a ratio 
o f 1:1. PBMCs were either stimulated for 16 hours at a concentration o f lxlO 6 per 
condition and analysed by ICS, or stimulated for 4 hours at lx l0 5 per condition and 
analysed by qRT-PCR. IFN-y mRNA expression was normalised to GAPDH with 
each test sample compared to the sample stimulated with an HLA mismatched LCLs 
(negative control). Amplification curves for the internal reference gene GAPDH were 
identical for both the test sample and negative control sample as anticipated because
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input numbers o f PBMCs and LCLs were the same. Therefore any increase in 
expression o f IFN-y induced by stimulation with autologous LCLs relative to 
mismatched LCLs could be assessed by comparison o f IFN-y to expression of 
GAPDH which was constant in both samples. Unstimulated PBMCs alone could not 
be used as the comparator for experiments involving stimulation with LCLs because 
input numbers of cells (and therefore GAPDH levels) would be different.
The results in Figure 5.4 show that where the frequency o f IFN-y producing CD8f T 
cells detected by ICS was relatively high (4.5%, Panel A) the qRT-PCR assay was 
able to detect a clear positive response using autologous LCLs as stimulators and 
produced a greater stimulation ratio (differential between response obtained by 
stimulation with autologous LCLs and negative LCL control) than ICS (38.4 qRT- 
PCR vs 19.3 ICS). However, where the frequency o f IFN-y producing CD8+ T cells 
detected by ICS was lower (1.5%, Panel B) the qRT-PCR performed less well.
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Stimulation Index
38.44
Figure 5.4: Comparison of ICS and qRT-PCR to measure IFN-y production by EBV-specific T 
cells using EBV-transformed LCLs as stimulators
PBMCs from two healthy A*0201 individual (Panel A and B) were stimulated with EBV-transformed 
autologous LCLs (test sample). Results were compared to an HLA class I mismatched LCL (negative 
control). PBMCs were either stimulated for 16 hours in the presence of Brefeldin A and analysed by 
ICS (■), or stimulated for 4 hours (■) and analysed by qRT-PCR. lxlO6 PBMCs were used per 
condition for ICS and lxlO5 PBMCs were used per condition for qRT-PCR. Results for ICS were 
represented as the percentage of IFN-y producing CD8+ T cells. Results for qRT-PCR were represented 
as IFN-y mRNA expression relative to HLA class I mismatched LCLs after normalisation to GAPDH 
mRNA expression from the same sample. The stimulation index was calculated by dividing the results 
obtained by FACs or qRT-PCR for the test sample (autologous LCL) with negative control (HLA class 
I mismatched LCL). Samples were performed in triplicate and presented as the mean totals. Error bars 
represent the sd.
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5.2.3.2 Im proved detection o f  IFN-y mRNA expression by reducing the num ber o f  
LCLs used fo r  stimulation
The large amounts o f RNA produced as a result o f the rapid metabolism o f LCLs may 
physically impede the efficiency of the PCR and thus reduce the magnitude of the 
response detected. This phenomenon has been described in previous studies which 
show that the efficiency o f RT reaction is significantly reduced when target templates 
are rare (Karrer et al., 1995) or when large amounts of non-specific or background 
nucleic acids are present (Stahlberg et al., 2004; Curry et al., 2002). In order to 
maximise efficiency o f the reactions, it may be beneficial to reduce the number of 
LCLs used in the assay provided the antigen stimulation is not compromised.
PBMCs from a healthy EBV sero-positive individual were stimulated for 4 hours with 
autologous LCLs or HLA mismatched LCLs at various PBMC to LCL ratios. The 
number o f PBMCs was kept constant at lxlO5. At each ratio IFN-y mRNA 
expression relative to GAPDH from PBMCs stimulated by autologous LCLs (test 
sample) was compared to that from PBMCs stimulated by HLA-mismatched LCLs 
(negative control sample). For example at the 20:1 PBMC:LCL ratio, lxlO 5 PBMCs 
were stimulated with either 5x l0 3 autologous or 5x l03 HLA-mismatched LCLs. IFN-y 
mRNA expression is presented as the ratio o f autologous LCL stimulation: HLA- 
mismatch LCL stimulation (Figure 5.5).
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Figure 5.5: Comparison of IFN-y mRNA expression detected from EBV-specific T cells using 
different numbers of LCLs as stimulators
PBMCs from a healthy EBV sero-positive individual were stimulated for 4 hours with various ratios of 
autologous (test) or HLA class I mismatched LCLs (negative control). The number of PBMCs was kept 
constant at lxlO5 per condition. After stimulation, cells were harvested and lysed. RNA extraction, 
generation of cDNA and qRT-PCR for IFN-y and GAPDH mRNA expression was performed as 
described in Chapter 2. At each ratio IFN-y mRNA expression normalised to GAPDH is represented 
relative to the HLA-mismatch negative LCL control. All samples were performed in triplicate. Error 
bars represent the sd.
The results shown in Figure 5.5 demonstrate that the qRT-PCR assay was able to 
detect a positive EBV-specific response from stimulation with autologous LCLs at all 
responder: stimulator ratios tested. The largest signal was obtained from stimulating at 
20:1 ratio, with similar results obtained from ratios of 2:1 and 10:1. The signal using a 
1:1 ratio however was significantly lower, consistent with inefficient PCR 
amplification at high template concentrations. The reduced signal at the 50:1 and 
100:1 ratios is likely due to inadequate antigen stimulation with the lower numbers of
231
Chapter 5
LCLs. For subsequent experiments, PBMCs were stimulated with LCLs at a 20:1 
ratio.
5.2.4 Comparison of ICS and qRT-PCR for measuring IFN-y production by 
EBV-specific T cells in patients with PTLD
A drawback to using ICS as the platform for analysis is that the number of viable 
PBMCs required for appropriately controlled results often exceeds the number 
available from patient samples. qRT-PCR can detect EBV-specific T cell responses 
from healthy individuals using 10-fold fewer PBMCs than required for ICS analysis 
(Figure 5.2). Therefore, in order to establish whether qRT-PCR could provide an 
alternative means o f measuring EBV-specific T cell responses in patients with EBV- 
driven malignancies, the responses obtained from ICS were compared to those 
obtained by qRT-PCR.
Samples from two PTLD patients were analysed by both methods. Patient EBV+ 5 
(Chapter 4, section 4.1.3) developed an EBV-positive PTLD and was treated with 
RIS and infusion o f EBV-specific T cells. The sample used to compare the assays was 
collected 2.6 months after diagnosis at a time point where EBV-specific T cell 
immunity was rising rapidly in response to therapy (Figure 5.6, Panel A). Patient 
EBV+ 4 (Chapter 4, section 4.1.3) also developed an EBV-positive PTLD and 
responded clinically to treatment with RIS alone. The PBMC sample used to compare 
ICS with qRT-PCR was collected 9.6 months after diagnosis. At this time point a 
clinical response to RIS treatment had been achieved and the EBV-specific response
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detected by ICS in response to both EBV peptide and autologous LCL stimulation had 
begun to decline in response to tumour control (Figure 5.7, Panel A).
PBMCs from both patients were stimulated with HLA-restricted EBV peptide pools 
or autologous LCLs and compared with either an EBV peptide restricted through an 
irrelevant HLA allele plus DMSO or an HLA-mismatched LCL respectively. The ICS 
assay used lxlO 6 PBMCs per condition and LCLs at a 1:1 responder to stimulator 
ratio whereas the qRT-PCR assay used lxlO5 PBMCs per condition and LCLs at a 
20:1 ratio. EBV-specific T cell responses from both ICS and qRT-PCR were 
represented as a stimulation ratio of a specific response compared to the relevant 
negative control.
Results showed that the qRT-PCR assay was able to demonstrate a positive EBV- 
specific T cell response above background in both patients despite using lOx fewer 
PBMCs than the ICS assay. This was achieved both in a patient where there were high 
numbers o f circulating EBV-specific T cells detected by ICS (Patient EBV4 5, Figure 
5.6) and also in the more challenging situation of a patient whose EBV immunity had 
fallen to low levels in response to tumour control (Patient EBV+ 4, Figure 5.7). 
Comparison of stimulation ratios, however, showed that in both patients the 
differentiation o f a positive EBV-specific response from background was better with 
ICS.
These preliminary results therefore suggest that qRT-PCR can be used to detect an 
EBV-specific T cell response in patients with PTLD using low numbers of cells.
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Figure 5.6: Comparison of ICS with qRT-PCR for measuring EBV-specific T cell immunity in a 
PTLD patient with high numbers of IFN-y producing EBV-specific T cells
PBMCs from a PTLD patient (EBV+ 5) being treated with RIS and infusion of EBV-specific T cells 
were taken 2.6 months after diagnosis and analysed for an EBV-specific T cell response using ICS (■) 
and qRT-PCR (■). Serial EBV responses throughout treatment measured by ICS are shown in Panel A. 
1 x 105 PBMCs were stimulated for 4 hours and analysed by qRT-PCR and lx 106 PBMCs were 
stimulated for 16 hours and analysed by ICS. Panel B shows results from PBMCs stimulated with a 
pool of HLA class I-restricted EBV peptides. Stimulation with an EBV peptide restricted to an 
irrelevant HLA class I allele plus DMSO (irrelevant peptide) was used as the negative control. Results 
are represented as a ratio of HLA class I-restricted EBV peptide stimulation compared to an EBV 
peptide restricted through an irrelevant HLA class I allele plus DMSO (peptide pool/Irrel peptide + 
DMSO ratio). Panel C shows results using PBMCs stimulated with autologous LCLs. Stimulation with 
an HLA-mismatched LCL was used as the negative control. LCLs were used at a 20:1 and a 1:1 
responder to stimulator ratio for qRT-PCR and ICS respectively. Results are represented as a ratio of 
autologous LCL stimulation compared to HLA-mismatched LCL stimulation (auto LCL/Mismatch 
LCL ratio).
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Figure 5.7: Comparison of ICS with qRT-PCR for measuring EBV-specific T cell immunity in a 
PTLD patient with low numbers of EFN-y producing EBV-specific T cells
PBMCs from a PTLD patient (EBV* 4) treated with RIS were taken 9.6 months after diagnosis and 
analysed for an EBV-specific T cell response using ICS (■) and qRT-PCR (■). See Legend 5.6
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5.3 DISCUSSION
Results presented in chapters 3 and 4 show that ICS is a rapid and effective method 
for measuring functional EBV-specific T cell responses in healthy individuals and 
patients with EBV-driven malignancies. The main disadvantage with this technique, 
however, was that the number of PBMCs required for consistent results often 
necessitated taking large amounts o f blood, especially in PTLD patients where the 
yield o f viable PBMCs was low due to immunosuppression. qRT-PCR represents an 
alternative method o f measuring EBV cellular immunity by analysing mRNA 
cytokine expression in response to EBV antigen stimulation. Already widely used in 
the clinical setting to monitor viral copy number and minimal residual disease, recent 
studies also suggest the potential application of qRT-PCR for measuring functional 
immunity, especially in situations where sample material is limited. Experiments 
presented in this chapter assessed the advantages and disadvantages of this technique 
and directly compared results obtained from qRT-PCR and ICS using samples from 
healthy EBV sero-positive individuals and patients with PTLD.
Functional EBV-specific T cell immunity was shown to be reliably detected using 
qRT-PCR from 10-fold less PBMCs than required for ICS analysis in both healthy 
individuals and patients with PTLD and highlights the attraction o f this method in 
situations where samples are limited in the number o f viable cells. An important 
consideration however, is that the qRT-PCR assay detected IFN-y production from all 
cells within the PBMC sample, whereas the ICS assay was able to target IFN-y 
production from CD3+CD8+ T cells within the PBMC sample using the gating 
strategies described in Chapter 2. In order to target this cell subset using the qRT-PCR
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assay, it would have been necessary to purify CD3 CD8 T cells from the PBMC 
sample prior to the stimulation experiments. Cell losses are expected with any 
purification process and therefore had this approach been used for the qRT-PCR assay 
it is probable that more PBMCs would have been required.
Unlike the ICS assay where each sample is entirely committed to analysis of IFN-y 
production, only a fraction o f the cDNA obtained from each test sample 
(approximately 1/100th) is used for a single qRT-PCR reaction. Both RNA and cDNA 
can be stored for several months and therefore a sample can be tested on multiple 
occasions and analysed for a wide spectrum of different genes of interest.
In patients with PTLD the EBV-specific T cell response can be effectively monitored 
with IFN-y production from CD 8+ T cells. However, assessment o f several cytokines 
from the same sample would be useful for analysis o f the EBV cellular immune 
response in EBV-positive malignancies such as PTLD, HD and NPC. For example, 
the predominance o f CD44 cells in the lymph nodes o f EBV-positive HD suggests 
that a T-helper response plays a major role in the pathogenesis o f this disease. In 
addition, the cellular immune response to EBV in HD patients is weak due to the virus 
displaying a limited set o f weakly antigenic viral proteins (LMP-1 and 2) as well as 
the immunosuppressive environment created within the lymph node rendering EBV- 
specific T cells anergic (discussed in Chapter 4). Therefore in order to effectively 
monitor the cellular response to EBV in HD several cytokines from the ThI and the 
T»2 response may need to be evaluated.
Results from Chapter 4 suggested an increased EBV-specific CD4+ T cell response in 
patients with EBV-positive HD compared to patients with EBV-negative HD and 
reactive lymphadenopathy measured by ICS. However, due to low cell numbers the
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analysis was restricted to IFN-y production as a measure of functionality and it was 
not practical to determine whether this represented an increased T hI response or an 
increased antigen-induced T regulatory response or a combination of both. The 
advantage o f using qRT-PCR in this context is that mRNA expression of multiple 
cytokines could be evaluated from the same sample without the need for large 
amounts o f patient material.
Initial qRT-PCR experiments showed that maximal mRNA expression of IFN-y 
occurred after PBMCs had been stimulated with HLA class I-restricted EBV peptide 
pools for only 4 hours. RNA extraction, generation of cDNA and analysis of IFN-y 
mRNA expression takes approximately 4-6 hours and therefore results for PTLD 
patients can be analysed and reported back to the clinician within 8-10 hours of 
receiving the blood sample. An overnight (16 hour) antigen stimulation period was 
chosen for the ICS assay for practical considerations; however this can be effectively 
reduced to 6 hours (data not shown). The assay then requires approximately 2 hours to 
acquire and analyse IFN-y production from stimulated T cells. The turnaround time to 
process a sample for both assays is therefore equivalent. qRT-PCR however, offers 
the advantage that test samples do not need to be analysed fresh once the PBMCs 
have been stimulated, and can be lysed and stored at -80°C for several months. 
Previous studies have demonstrated that IFN-y mRNA transcript expression measured 
by qRT-PCR are good indicators o f antigen T cell specificity by showing strong 
correlation with IFN-y protein production from antigen-specific cells (Mocellin et al., 
2003; Nielsen et al., 2000; Ekerfelt et al., 2002; Rentzsch et al., 2003; Rezvani et al., 
2003). Similar comparisons have not been performed using EBV antigens and it was 
therefore important to compare IFN-y mRNA expression from PBMCs stimulated
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with HLA-restricted EBV peptide pools and autologous LCLs obtained by qRT-PCR 
analysis with the frequency o f CDS'IFN-y' T cells determined by ICS analysis.
Results from the preliminary comparisons between the two methods o f analysing the 
EBV-specific T cell response showed that the results from qRT-PCR analysis 
consistently correlated with the results obtained from ICS in both healthy individuals 
and patients with PTLD. Results however did not show a consistent advantage with 
qRT-PCR in terms o f differentiating a positive EBV-specific T cell response from 
background compared to ICS. Differentiation o f a positive response from background 
by the qRT-PCR assay compared to ICS was larger in healthy individuals but smaller 
in the PTLD patients. Reasons for this are unclear and require further investigation 
with serial comparisons o f both qRT-PCR and ICS using healthy individuals and 
PTLD patients.
In conclusion, results from this chapter demonstrate that qRT-PCR can be used to 
detect functional EBV-specific T cells in healthy individuals and patients with PTLD. 
The advantages o f  the qRT-PCR technique are the ability to accurately detect a 
response from samples where cell numbers are limited, and the option to test for 
multiple cytokines involved in the EBV cellular immune response for each sample. A 
disadvantage however is that qRT-PCR instrumentation and the technical skills 
required are not common in clinical immunology laboratories as yet. However qRT- 
PCR is a clinical tool that is increasingly being used in virology and haematology 
laboratories. Therefore qRT-PCR may represent the future for monitoring T cell 
mediated antigen- specific immunity.
239
Chapter 6
Chapter 6
Detection of all patterns of EBV latency in human 
cells and tissues using a novel monoclonal antibody,
RFD3.
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6.1 INTRODUCTION
The work described in the preceding chapters showed how functional CD8 T cell 
immunity to EBV can be assessed in both healthy individuals and patients with 
EBV-driven malignancies, and how the response to treatment varied according to 
whether the tumour expressed EBV antigens. In patients with PTLD the presence of 
EBV antigens stimulated an EBV-specific CD8' T cell response which increased as 
immunosuppression was withdrawn. This response was also shown to correlate with 
a clinical response to treatment. In contrast, although EBV immunity was detected in 
patients with EBV-negative PTLD tumours, no correlation with clinical response 
was observed. Accurate assessment o f the presence of EBV antigens on PTLD 
tumours can therefore provide important prognostic information and influence 
clinical management.
In EBV-transformed LCLs and EBV-driven malignancies the virus is present 
latently and is transcriptionally active. Three defined types o f latency have been 
described in which varying degrees o f expression o f the latent genes occur (Table
1.2). Latency III occurs in IM with expression o f many EBV genes (EBNA-LP, 
EBNA2, 3A, B, C). Latency II shows a more restricted expression (EBNA1, LMP1 
and 2) in malignancies such as Hodgkin’s disease or nasopharyngeal carcinoma and 
Latency I expression is restricted to EBNA 1 occurring in Burkitt’s lymphoma 
(Klein, 1989). This variability in expression of EBV antigens causes problems in 
detecting EBV in pathological samples o f malignant disease and makes diagnosis 
difficult.
For formalin-fixed and paraffin embedded tissues an in-situ hybridisation technique 
has to be used to detect EBV encoded RNAs (EBER1 and 2) which are the most 
widely expressed antigens present in all stages o f Latency (Howe and Steitz, 1986).
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On fresh tissues, staining of EBNA1 can only be achieved by immunofluorescence 
or immunoperoxidase staining using immune sera from EBV seropositive 
individuals and employing complement fixation to amplify the signal sufficiently to 
detect all stages o f Latency (Ohno et al., 1977). Established monoclonal antibodies 
specific for LMP 1 and 2, EBNA 2 and BFLZ 1 are available to detect EBV but 
these are generally inadequate to identify all types of EBV related malignancies and 
frequently underestimate or are negative for malignancies that stain positively for 
EBER or EBNA1 (Thomas et al., 1995). There is currently no monoclonal antibody 
which is capable o f identifying all EBV positive transformed cells. Monoclonal 
antibodies to EBNA 1 have been described but these have failed to reproduce results 
reliably enough to support commercial development (Grasser et al., 1994; Oudejans 
et a l., 1996).
During immunohistological staining o f fresh frozen tissues, nuclear reactivity o f a 
murine monoclonal antibody, RFD3, was observed in EBV-driven 
lymphoproliferation. RFD3 is an IgG2 antibody that stains follicular dendritic cells 
(FDCs) and collagen (particularly associated with basement membranes) strongly 
and mesangial cells weakly (Bofill et al., 2000).
The aim of the work described in this chapter was to explore whether RFD3 
represents a reagent capable o f detecting all patterns o f EBV latency. IP staining 
using RFD3 was carried out on a range o f EBV-positive and -negative cell lines and 
tissues, and compared to current methods o f EBV detection. Two HHV-8-positive, 
EBV-negative cell lines, one CMV-positive, EBV-negative cell line and malignant 
tissues were investigated to determine the cross-reactivity o f RFD3 with other 
herpes viruses. In addition the efficacy o f RFD3 in detecting EBV in cytospins and 
fresh or formaldehyde-fixed tissues was assessed.
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6.2 RESULTS
6.2.1 Nuclear staining of fresh frozen cryostat sections of lymph node and 
tumour tissues by RFD3.
The monoclonal antibody RFD3 is known to bind to unidentified collagen-like 
material which is expressed on mature follicular dendritic cells and identifies 
networks within lymphoid follicles and germinal centres (Bofill et al., 2000). RFD3 
also binds to the basement membranes o f blood vessels and intercellular material 
that is markedly accentuated in fibrotic conditions. In addition to this staining 
pattern, it was observed that speckled nuclear staining occurred occasionally in 
pathological tissues of EBV-driven malignancies. Examples are shown in Figure 
6. 1.
In order to examine the association between the presence o f RFD3 nuclear staining 
and the EBV status o f a tumour, several non-malignant reactive LNs and malignant 
B cell lymphoma (ML-B) LN sections were stained using the mAb RFD3. All 
samples from diseases with known EBV association were screened for presence of 
EBV by EBER in situ hybridisation (EBER ISH) or EBNA Complement Fixation 
staining (EBNA-CFT) to confirm their EBV status. Formal identification o f EBV 
negative status was performed for representative samples o f the diseases that are not 
known to be associated with EBV. The results are summarised in Table 6.1 and 
show a strong agreement between EBV and RFD3 nuclear staining. O f note, tissues 
from 2 patients with ML-B: diffuse large cell type (ML-B:DLC) stained positive 
with RFD3, a result which was confirmed by EBNA-CFT analysis. This disease is 
not typically associated with EBV; however both ML-B DLC samples that stained
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positive with RFD3 were from patients that also had coexisting immunodeficiencies 
that are known to confer an increased risk of EBV associated lymphomas.
Table 6.2 details the percentage of positive nuclei in EBV positive pathologies as 
examined by the three methods of EBV detection. Statistical analysis of this table 
showed a strong correlation between RFD3 nuclear staining and EBER-ISH staining 
(r = 0.909) or EBNA-CFT (r = 0.937). Correlation coefficients were calculated using 
the Pearson’s method.
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Figure 6.1: RFD3 nuclear staining of EBV-positive tissues
EBV-positive HD (Panels a-c) and malignant lymphoma B cell type: diffuse large B cell (Panels d-f) 
were stained using the following techniques. Haematoxylin and Eosin (H&E) stain: Panels a,d; 
RFD3 mAh: Panels b, e; LMP mAb: Panel c; EBNA Complement Fixation staining (EBNA-CFT): 
Panel f.
Unstained nuclei are counterstained with Fast Red and show as pale pink.
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D isease N o E B V
status
Pre-ID R F D 3n
ML-B PTLD 12 1 1 positive 
1 nd
12 12
M L-HD 8 1 positive 0 1
M L-NK LC 1 1 positive 0 1
RH/RFH 20 3 negative 
17 nd
0 0
N on-m alignant reactive lymph 
nodes
6 2 negative 
4 nd
2 0
M L-B B/BL 2 2 negative 1 0
M L-B F 16 1 negative 
15 nd
0 0
M L-B MZ 4 nd 0 0
M L-B CLL 4 nd 0 0
M L-B DLC 26 17
negative 
2 positive 
7 nd
3 2
M L-ALC 3 1 positive 0 1
Kaposi sarcom a 3 3 negative 3 0
Carcinom a 2 nd 0 0
Table 6.1: RFD3 nuclear staining in reactive, malignant and lymphoma tissues in relation to 
EBV associated pathologies
No: Number of lymph nodes or tissues examined. EBV status: Presence of EBV in tissue was 
assessed by EBER or EBNA CFT staining. Pre-ID: Pre-existing immunodeficiency or intensive 
immunosuppression. Two patients in the non-malignant group had Common Variable 
Immunodeficiency (CVID) and 1 ML-B: B/BL patient had HIV. All 12 ML-B PTLD patients were 
on long-term immunosuppression for solid organ transplants and all patients with Kaposi’s sarcoma 
were immunosuppressed due to HIV. O f the 26 ML-B: DLC patients, 3 had immunodeficiency; 1 
secondary to CVID, 1 secondary to HIV and 1 secondary to chronic active hepatitis. RFD3n: 
Number of samples positive by RFD3 nuclear staining. RH/RFH: Reactive hyperplasia or reactive 
follicular hyperplasia of unknown cause. Non-malignant: Castlemann’s disease 1, Granulomatous 
disease 2, Histiocytic reaction 1, Common Variable Immunodeficiency 2. ML-B Malignant 
lymphoma B cell type: ALC -  Anaplastic Large Cell, B/BL -  Burkitf s or Burkitt-like, F - follicular, 
MZ - marginal zone, DLC - diffuse large cell, CLL - chronic lymphocytic leukaemia, HD - 
Hodgkin’s disease, NK LC -  Natural killer large cell, PTLD -  Post transplant Lymphoproliferative 
Disease. Nd: Not done
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L ym phom a R F D 3n E B E R -IS H E B N A -C F T R F D 3-F D C Pre-ID
M L-B ALC 10 10 10 - 0
M L-B DLC 80 50 - CAH + HD
M L-B DLC 30 20 - HIV
M L-H D 7 7 - 0
M L-NK  LC 20 30 - 0
M L-B PTLD 30 35 - IS/RT
M L-B PTLD 1 0 0 - IS/RT
M L-B PLTD 30 40 35 - IS/RT
M L-B PT L D 1 75 60 60 + IS/RT
M L-B PTLD 2 75 40 55 +
M L-B PTLD 3 7 0 -
M L-B PTLD 35 40 - IS/OLT
M L-B PTLD 70 60 65 - IS/RT
M L-B PTLD 70 80 - IS/RT
M L-B PTLD* 15 10 + IS/RT
M L-B PTLD 2 10 10 7 +
M L-B PTLD 12 12 12 - IS/RT
Table 6.2: Percentage of nuclei staining by RFD3, EBER and EBNA CFT in EBV positive 
pathologies
Key: As for Table 1.
RFD3-FDC: Staining positive for follicular dendritic cells by RFD3 
CAH + HD: Chronic active hepatitis and previous Hodgkin’s disease 
HIV: Human immunodeficiency virus positive 
IS/RT: Immunosuppression for a renal transplant 
IS/OLT: Immunosuppression fora liver transplant
Superscripts 1, 2 & 3 indicate sequential tissue biopsies on the same patient.
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In order to assess whether RFD3 could be employed on formalin-fixed tissues, 
several EBV-positive samples were tested (Ms R Sims, department of 
Histopathology, Royal Free Hospital). Despite trialling a range of preparation 
techniques prior to staining (See Materials and Methods 2.5.3) all results were 
negative (data not shown), confirming the use of RFD3 in detecting EBV in fresh 
tissue samples only.
6.2.2 Comparison of the efficacy of RJFD3 versus LMP/EBNA-2 (IP) and 
EBNA CFT staining, using a range of EBV positive and negative cell 
lines
To confirm the immuno-histological findings using tissue that RFD3 stains nuclei of 
EBV positive cells, cell lines o f known EBV status were examined using the 
monoclonal antibodies RFD3, anti-EBNA-2, anti-LMP-1 and -2 and EBNA-CFT. 
Only nuclear staining was evaluated. Some cell lines gave variable amounts of 
cytoplasmic staining, particularly with EBNA-CFT. Since EBNA-CFT uses EBV 
positive human sera as a source o f anti-EBNAl antibody, cytoplasmic staining is 
often found and is not o f EBV-related significance.
Figure 6.2 shows the pattern o f staining obtained from EBV-positive cell lines and 
shows consistent nuclear staining between all three mAbs tested.
The proportion o f cells correctly identified by nuclear staining from RFD3, anti- 
EBNA-2 and anti-LMP was analysed and compared to results obtained by EBNA- 
CFT (Table 6.3). RFD3 was effective in identifying EBV positive cell lines and 
there was concordance with EBNA-CFT staining on all human EBV-transformed 
LCLs except for LCL 4 where only a low percentage o f cells was detected by RFD3. 
The number o f cells stained positive by RFD3 was similar or a little above the
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proportion stained by anti-EBNA-2 mAb using the IP method and always more than 
the number stained positive by anti-LMP mAbs. When staining EBV-positive 
human Burkitt’s lymphoma cell lines, EBNA-CFT and IP staining with RFD3 
yielded similar results, with the proportion of cells stained positive always higher 
than those detected using anti-EBNA-2 and anti-LMP mAbs. This was also the case 
with the EBV-positive acute lymphoblastic leukaemia (ALL) cell line, HPB-Null 
and the unidentified EBV-positive cell line Ramal. RFD3 however, detected a much 
higher level o f positivity (90%) in a second ALL cell line, KM-3 compared to 
detection by EBNA-CFT (4%).
Overall correlations between the positive results obtained by RFD3 nuclear staining 
compared to EBNA-CFT and EBNA2 were strong (r=0.701 and r=0.795, 
respectively, using the Pearson’s method), confirming the ability o f RFD3 to detect 
the presence o f EBV. The correlation between RFD3 and LMP however, was less 
(r=0.335) reflecting the previously described inconsistent results obtained with 
established mAb staining (Thomas et al., 1995).
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Figure 6.2: Staining of EBV-positive cell lines with RFD3, EBNA2 and LMP mAbs
EBV-positive cell lines were stained with RFD3 (Panels a, d, e), EBNA2 (Panels b, e, h) and LMP 
(Panels c, f, i). The cell lines used were EBV-transformed LCLs (Panels a-c) and EBV-positive 
Burkitt’s cell lines, Raji (Panels d-f) and KM-3 (Panels g-i).
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Cell Line RFD3 Negative
control
LM P EBNA-2 EBNA-
C FT
Negative
control
LCL 1 80 0 1 75 80 0
LCL 2 75 0 60 65 80 0
LCL 3 7 0 0 0 2 0
LCL 4 5 0 0 0 90 0
LCL 5 85 0 7 75 90 0
LICR(-LO N - 90 0 7 90 95 3
HMy2)
DAUDI 95 1 1 5 95 0
EB-3 30 0 5 0 25 0
Nam alwa 85 0 0 65 90 0
R A JI 90 0 3 70 95 0
HPB Null 90 0 15 80 90 0
KM-3 90 0 0 3 4 0
Ram al 95 0 0 40 95 0
Table 6.3: RFD3 staining of EBV-positive cell lines compared to other methods 
Cell lines: LCL 1-5: Human EBV transformed B lymphoblastoid cell lines; LICR(-LON-HMy2): 
plasmacytoma cell line; Daudi, EB-3, Namalwa and Raji: Burkitt’s cell lines; HPB Null: Pre-B 
ALL line; KM-3: Pro-B ALL line; Ramal: unidentified EBV-positive cell line.
Almost all EBV-negative cell lines were negative when tested with the range of 
antibodies used to detect EBV (Table 6.4). There was some cytoplasmic staining of 
the human acute T cell lymphoblastic leukaemia cell lines, C8166 and U937 cells 
and extremely weak speckled staining o f the small cell lung carcinoma cell line, H69 
(5-10%) using RFD3. Correspondingly, when using the EBNA-CFT method, there 
was cytoplasmic staining o f the cell lines, C8166, CCRF-CEM, HL-60 and U937 
using the anti-EBNA antibody or the mouse serum (negative control). Speckled
250
Chapter 6
staining occurred in the cell lines HPB ALL and H69, however this was too weak to 
have led to a positive designation.
Cell line RFD3 M ouse
serum
IM P EBNA-2 EBN A-
C FT
Negative
control
C8166 0 0 0 0 0 0
CCRF-CEM 0 0 0 0 0 0
HPB ALL 0 0 0 0 90 0
Jurkat 0 0 0 0 0 0
MOLT-3 0 0 0 0 0 0
HL60 0 0 0 0 0 0
K562 0 0 0 0 0 0
Ramos 0 0 0 0 20 40
U937 0 0 0 0 0 0
MWHDL 0 0 0 0 0 0
H69 7 0 0 0 70 0
Table 6.4: RFD3 staining of EBV-negative cell lines compared to other methods 
Cell lines: C8I66, CCRF-CEM, HPB-ALL, Jurkat, MOLT-3: Human acute T lymphoblastic 
leukaemia; HL60: human promyelocytic leukaemia; K562: human chronic myelogenous leukaemia; 
Ramos: Burkitt lymphoma; U937: Histiocytic cell line; MWHDL: Mesothelioma cell line; H69: 
human small cell lung carcinoma. Normal mouse serum was used as a negative control for the mAb 
staining. Human serum from an EBV sero-negative individual was used as the negative control for 
detection of EBV using EBNA-CFT.
6.2.3 Determining the ability of RFD3 to identify cells infected with other 
members of the herpes virus family, namely HHV-8 and CMV
In order to determine whether RFD3 cross-reacted with antigen from other herpes
viruses, RFD3 was used to stain HHV-8 and CMV positive cell lines. Staining
HHV-8-positive, EBV-negative cell lines with RFD3 gave consistently positive
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results. Negative results however were seen using the LMP and EBNA2 antibodies 
as well as normal mouse serum.. In contrast RFD3 did not show any positive 
staining in the cells o f a CMV-positive, EBV-negative cell line. Negative staining 
was also seen with the LMP and EBNA2 antibodies and the negative control (Table 
6.5).
Cell
line
R F D 3 M o u se
serum
L M P E B N A -2 LN 53 C M V E B N A -
C F T
N egative
control
BC-3 95 0 0 0 50 nd 0 0
BCP-1 IS 0 0 0 95 nd 0 0
BJ1 0 0 0 0 nd 90 0 0
Table 6.5: RFD3 staining of different Herpes virus positive cell lines compared to other 
methods
Cell lines: BC-3 and BCP-1: HHV-8-positive, EBV-negative cell lines; BJ1: CMV-positive, EBV- 
negative fibroblast cell line (AD 169 strain). Normal mouse serum was used as a negative control for 
the mAb staining. Human serum from an EBV sero-negative individual was used as the negative 
control for detection of EBV using EBNA-CFT.
The pattern o f staining o f HHV-8-positive cell lines observed with RFD3 however, 
yielded an atypical pattern in comparison to that seen with the EBV-positive cell 
lines. In addition, both pattern and percentage of cells detected differed from the 
nuclear staining seen with the monoclonal antibody LN53, currently used to detect 
the latent nuclear antigen-1 (LTA-1) expressed in all HHV-8 positive cells (Dupin et 
al., 1999). It must be noted that LN53 also appeared to detect linear structures 
within the nucleus o f Raji (EBV-positive, HHV-8-negative) cells (Figure 6.3).
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Figure 6.3: Staining of herpes virus-positive cell lines with RFD3 and LN53 mAbs
Cell lines were stained with RFD3 (Panels a, c, e), and LN53 (Panels b, d, f). The cell lines used 
were HHV-8-positive, EBV-negative BC3 (Panels a-b) and BCP (Panels c-d) as well as the HHV-8- 
negative, EBV-positive Burkitt’s cell line, Raji (Panels e-f).
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6.2.4 Attempting to separate staining of EBV positive nuclei and staining of 
FDCs
Immunoperoxidase staining of fresh tonsil sections containing follicular dendritic 
cells (FDC), or skin sections containing collagen, was carried out using RFD3 mAb- 
containing supernatants taken from 47 RFD3 monoclonal cell lines established by 
limiting dilution. All tissue sections stained positive for FDCs or collagen (data not 
shown), therefore staining o f EBV-positive nuclei and FDCs/collagen could not be 
separated. However the pattern of staining was such that the three cellular 
components could be differentiated.
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6.3 DISCUSSION
The detection of EBV in pathological sections of EBV-driven malignancies is 
currently determined by an in situ hybridisation technique used to identify the 
presence o f EBV encoded RNA (EBER). The expression of EBER is seen across all 
latency patterns o f EBV and therefore identifies all EBV-positive cells. This method 
however is cumbersome and only possible on formalin-fixed samples. IP staining 
with monoclonal antibodies offers a quicker alternative but to date antibodies to 
EBV antigens have produced unreliable results. In addition, a panel of antibodies is 
required to ensure adequate identification of EBV positive cells across all stages of 
EBV latency. The results presented in this chapter provide evidence that the mouse 
monoclonal antibody, RFD3 is able to detect an unidentified nuclear antigen present 
in all latency patterns o f EBV-positive cells and therefore has potential as a useful 
diagnostic and research tool.
O f the 107 samples from patients with EBV associated pathologies, a positive EBV 
diagnosis as predicted by RFD3 was confirmed by EBER-ISH or EBNA-CFT in 16 
samples. One PTLD sample was weakly positive with RFD3 but was determined 
EBV negative according to EBNA-CFT (Tables 6.1 and 6.2). Overall, there was 
strong correlation in the number o f positive nuclei when RFD3 staining was 
compared to the current diagnostic methods used to detect EBV (r = 0.9168 with 
EBER-ISH and r = 0.9323 with EBNA-CFT).
To confirm and elaborate on the above-described results, 24 cell lines were
investigated with the monoclonal antibodies, RFD3, anti-LMP 1, anti-LMP 2 and
anti-EBNA-2. EBV was also detected using EBNA-CFT. O f the 11 assumed EBV
negative cell lines, one consistently stained weakly positive with RFD3. Weakly
positive staining was also observed in this cell line using EBNA-CFT. 11 o f the 13
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cell lines assumed to be EBV positive were confirmed unequivocally positive by 
RFD3 staining. O f the two cell lines that stained weakly by RFD3, one was also 
weakly positive by EBNA-CFT staining and the other was strongly positive (Table
6.3). Overall correlation between the number of EBV positive nuclei determined by 
EBNA-CFT and RFD3 remained high (r = 0.701) confirming the clinical utility of 
RFD3 as a diagnostic tool for detecting EBV in pathological samples.
Despite the observation that gene expression in EBV positive Burkitt's lymphoma 
cell lines can, with increasing passage number, be more strongly related to latency 
III than latency I (Gregory et al., 1990), the results obtained with LMP and EBNA-2 
(Table 6.3) suggest that at least two o f the BL lines, DAUDI and EB-3, have a 
latency I expression pattern. Thus, the cell lines used in these experiments were 
representative o f expression patterns associated with all three malignancy-related 
latency types (Klein, 1989).
The possibility that RFD3 detected other herpes virus-positive cells was investigated 
using HHV-8-positive and CMV-positive cell lines. Although CMV-positive, EBV- 
negative cells showed negative staining by RFD3, in cells of HHV-8-positive, EBV- 
negative lines RFD3 detected small round structures that appeared to border the 
nucleus (F igure 6.3). Likewise, there was staining o f the EBV-positive, HHV-8- 
negative Raji cells with the established anti-HHV-8 antibody. Explanations for this 
include homology between the nuclear antigens present in HHV-8 and HHV-4 
infected cells. However, although similarities have been described between HHV-8 
genes and EBV genes encoding the nuclear antigens, LMP 1 and 2 (Glenn et al., 
1999) and the membrane antigen p i40 (Cesarman et al., 1996), no homology has 
been described between HHV-8 genes and the other EBV nuclear antigens 
expressed in different latency patterns, all o f which RFD3 has been shown to
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positively identify. Additional staining with RFD3 on 1 lHV-8-positive Kaposi’s 
sarcoma (KS) samples yielded negative results (results not shown), suggesting that 
RFD3 is exclusively associated with EBV in pathological tissue sections. Possible 
reasons for the presence o f confounding staining with RFD3 in cell lines but not 
tissue samples include different patterns of HFIV8 gene expression in the cell lines 
compared to the KS samples.
The results obtained thus far are insufficient to ascertain the identity o f the nuclear 
antigen detected by RFD3 monoclonal antibody. O f the known EBV antigens, only 
EBNA 1 is present in all three forms o f malignancy-related latency (Klein, 1989), 
however there is also evidence for the maintained expression o f the family of 
alternatively spliced BamUl A fragment transcripts in EBV-transformed cells 
(Brooks et al., 1993). Three open reading frames have been investigated in detail, 
and there is some data suggesting the putative protein products of two of these, 
RPMS1 and RK-BARFO may be nuclear (Kienzle et al., 1999; Smith et al., 2000; 
Sun et al., 1998). Finally, the antigen detected could be EBV-induced of host origin. 
Further investigation is required to determine the antigen's function as related to 
EBV latency; however its presence across all latencies suggests the possibility of 
using RFD3 in the diagnosis o f EBV-related malignancies.
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7.1 GENERAL CONCLUSIONS
Work detailed in this thesis describes the development of a flow cytometry based 
assay to measure functional IFN-y producing EBV-specific T cells, and assesses its 
role in the clinical management of EBV-driven malignancies.
The rationale for developing this assay was primarily directed at PTLD patients 
where uncontrolled EBV-driven B cell proliferation is caused by suppression of the 
host’s natural EBV immunity secondary to immunosuppressive drugs used post 
transplant to control alloreactivity and prevent graft rejection. In these patients 
gradual withdrawal o f these drugs allows immune recovery and the re-emergence of 
functional EBV-specific T cells which in turn leads to effective tumour control and 
resolution o f the disease. At present the emergence of this EBV response is 
monitored using an immunophenotyping assay which identifies increases in 
activation markers such as MHC Class II and CD69 (Amlot et a l., 1996). Using 
serial data from the point o f diagnosis the rate of withdrawal o f immunosuppression 
can be tailored to each individual PTLD patient (Amlot et al., 2007). Although this 
approach is effective, it measures the recovery of all activated T cells following RIS 
but does not provide information on their antigen specificity.
Measurement o f IFN-y producing CD8+ T cells was shown to consistently 
demonstrate functional EBV immunity in healthy individuals and patients with 
PTLD or HD. Further, in PTLD patients a temporal relationship was observed 
between the emergence o f IFN-y producing EBV-specific CD8+ T cells and 
regression o f the EBV-associated tumours in response to RIS treatment. These 
findings confirm the crucial role of these cells in the elimination o f malignant cells 
transformed by EBV and supports previous indications that IFN-y producing CD8+ 
T cells provide protective immunity in healthy individuals (Hislop et al., 2001) and
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in patients with IM (Callan et al., 2000; Hoshino et al., 1999). IFN-y producing 
CDS' T cells have also been recently shown to be specific for EBNA-1, an EBV 
antigen previously thought not to be recognised by CD8 T cells because responses 
could not be detected by traditional cytotoxicity assays (Lee et al., 2004). IFN-y 
production may therefore represent a more effective indicator o f target cell 
recognition in the context o f EBV.
Intracellular staining for cytokine production was shown to be a rapid and effective 
means of detecting functional EBV-specific CD8' T cells and therefore amenable to 
routine diagnostic use. The T cell mediated immune response to EBV has been 
characterised in healthy individuals and patients with primary EBV infection using a 
variety o f techniques including LDAs, cytotoxicity assays, ELIspot assays and 
fluorochrome-labelled HLA class Epeptide tetramers (detailed in chapter 3). 
However, while each o f these assays is commonly used in the context o f research, 
each has limitations prohibiting their use as a clinical assay (Table 3.1). ICS 
however, has the advantage over the above techniques of generating results rapidly 
as well as using a flow cytometer and thus equipment universal to all clinical 
immunology laboratories. Kuzushima et al described use o f this technique to 
enumerate EBV-specific T cells in healthy individuals and showed superior 
sensitivity compared to assessment o f cytotoxic T cell precursor frequencies by the 
LDA or detection of IFN-y producing T cells by the ELIspot assay (Kuzushima et 
al., 1999). The ICS assay was subsequently shown to effectively illustrate the 
dynamics o f EBV-specific CD8+ T cells in a single patient with PTLD following 
HSCT (Kuzushima et al., 2000).
Assessment o f cytokine gene expression by qRT-PCR was shown to be an 
alternative method o f detecting EBV-specific T cells in both healthy individuals and
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patients with PTLD. This is the first report of use of qRT-PCR to examine LBV 
immunity, and preliminary results showed a consistent correlation with those 
obtained by ICS, supporting previous studies suggesting that IFN-y mRNA 
transcript expression is an effective surrogate for cytokine production by antigen 
specific T cells (Ekerfelt et al., 2002; Mocellin et al., 2003; Nielsen et al., 2000; 
Rentzsch et al., 2003; Rezvani et al., 2003). It was also shown that qRT-PCR 
requires fewer PBMCs to elicit a positive result, making this an attractive alternative 
method o f detecting the cellular immune response to EBV in paediatric or severely 
lymphocytopenic PTLD patients where cell numbers are limited. A caveat however 
is that the qRT-PCR experiments performed with PBMCs did not allow 
identification o f the cell population producing IFN-y, whereas ICS facilitates 
visualization o f the CD8+ T cells within the PBMC population and therefore targets 
detection to a specific cell subset. A direct comparison of cell numbers required in 
qRT-PCR and ICS for measurement of IFN-y production by CD8+ T cells therefore 
requires further experiments using a cell sorting technique to isolate CD8+ T cells 
prior to analysis by qRT-PCR.
Autologous LCLs provided an excellent source o f EBV antigen as they 
constitutively express the complete range o f EBV latent cycle antigens (latency 
pattern type III) which is the predominant expression pattern in EBV associated 
PTLD. In patients where it was not possible to transform their B cells, LCLs 
matched on multiple HLA class I alleles were used as an effective alternative 
stimulator. Due to the phenomenon of immunodominance, LCLs matched for only 
one HLA-A or HLA-B allele did not give consistently positive results. Pools of 
HLA class I restricted EBV peptides were also effective at stimulating an EBV- 
specific CD8+ T cell response, but this approach is hindered by the limited number
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of EBV epitopes described to date. Epitopes presented by rarer HLA class I alleles 
and HLA types in non-Caucasoid populations have yet to be characterised.
The emergence o f IFN-y producing CDS4 T cells detected by serial monitoring of 
PTLD patients treated with RIS mirrored the rise in MHC class II expression by 
CD8' T cells during step-wise withdrawal of immunosuppression. This assay is used 
in conjunction with the disease and performance status of the patient to provide an 
effective and individually tailored approach to RIS and has been shown to limit the 
incidence o f graft rejection caused by arbitary or too rapid withdrawal of 
immunosuppressive drugs (Amlot et a l., 2007). Advantages o f this technique 
include its speed; results can be generated within 1-2 hours o f receiving a sample 
and its low cost; analysis o f surface activation markers can be obtained with a panel 
o f 15 monoclonal antibodies using a three-colour flow cytometer. Cost would be 
further reduced however, if the immunophenotyping assay was simplified to 
measure MHC class II surface expression on CD8+ T cells alone. The good 
correlation observed between rise in functional EBV specific T cell immunity with 
the increase in numbers o f CD8+ T cells expressing surface activation markers 
supports the view that the immunophenotyping assay is sufficient for guiding RIS. 
However, this assay does not show which antigen is stimulating the rise in activated 
T cells and is limited to evaluating the capability o f the immune response to 
infection in the context o f RIS. In addition, changes in the frequency o f CD8+ T cells 
expressing MHC class II can be seen with alloreactivity occuring in bowel 
transplants. This has not been demonstrated in renal or liver transplantation, 
however (P. Amlot, personal communication). In contrast an assessment o f cytokine 
production in response to EBV antigen stimulation has the advantage of providing a 
specific measure o f EBV immunity. A potential draw-back o f switching from the
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immunophenotyping assay to the ICS assay is that a source o f EBV antigen needs to 
be readily available for each PTLD patient, either in the form of an autologous LCLs 
or a LCLs matched on multiple HLA class I alleles. Facilities for cell 
cryopreservation are therefore necessary. In addition, although it is assumed that 
PTLD tumours express the full range o f EBV antigens, many studies have shown 
that this is an oversimplification and that EBV antigen expression is variable. 
Therefore, it is possible that the EBV-specific T cell response may be missed in 
some PTLD patients with tumours that express a limited pattern of EBV antigens, 
such as Burkitt’s-like PTLD and HD-like PTLD tumours which express antigens 
known to be weakly immunogenic. An important additional step would therefore be 
to evaluate the expression o f EBV antigens present on each tumour using 
immunohistochemical methods. This could involve use o f the novel monoclonal 
antibody RFD3 shown in this study (Chapter 6) to detect the presence o f EBV in all 
forms o f latent infection.
Prospective assessment o f a larger cohort of PTLD patients is required to fully 
evaluate ability o f the ICS assay to detect functional EBV immunity in all 
permutations of PTLD encountered in patients. Study o f a larger patient cohort may 
also allow determination o f a critical threshold number o f IFN-y producing EBV- 
specific CD8+ T cells required to control PTLD.
Detection o f functional EBV-specific T cells by intracellular staining for cytokine 
production also has wider clinical applications. Experiments described in this thesis 
have suggested that detection o f IFN-y producing EBV-specific T cells after 
stimulation with EBV antigen is also possible in TILs and PBMC samples from 
EBV-positive HD patients. Comparison o f results from reactive and EBV-negative 
HD LNs revealed presence o f EBV-specific CD4+ T cells and CD8+ T cells in the
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LNs expressing EBV antigens, showing that functional EBV-specific T cells are 
recruited to EBV-positive HD tumours. In order to elucidate the role of these cells, 
further experiments are required to examine the precise EBV antigen specificity of 
the T cells and whether they represent a protective immune response with potential 
to eradicate tumour cells or if  infiltrating cells include T cells that suppress anti­
tumour immunity, as has been described (Alvaro et al., 2005; Marshall et al., 2004). 
Detailed assessment o f the range of cytokines produced from the EBV-specific T 
cells found in HD TILs by the flow cytometry based assay or qRT-PCR could be 
used to address these questions Further research into the pathogenesis o f EBV- 
driven HD and the precise function of the EBV-specific T cells present in TILs is 
particularly important for the future role of adoptive transfer o f EBV-specific T cells 
as a treatment for EBV-positive HD (Bollard et al., 2004; Lucas et al., 2004). 
Clearly if functional regulatory T cells are present, infused T cells entering the 
tumour could quickly be suppressed.
Another potential clinical application of ICS for detecting functional antigen specific 
T cells is in the treatment of HHV8-driven KS. This tumour occurs post 
transplantation and, analogous to EBV-driven PTLD, is thought to be caused by 
viral reactivation secondary to suppression o f the host’s natural immunity (Cattani et 
al., 2001; Allen, 2002). Post transplant KS is treated effectively with RIS with 
complete clinical responses in the majority o f patients (Euvrard et al., 2003). The 
immune response to HHV8 has been well characterised in both healthy sero-positive 
individuals (Osman et al., 1999) and primary infection (Wang et al., 2001) and 
several HLA class I restricted epitopes have been identified (Ribechini et al., 2006; 
Micheletti et al., 2002; Wilkinson et al., 2002). Stimulation of PBMCs with HHV8 
antigens and the detection o f IFN-y producing HHV8-specific CD8+ T cells by ICS
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could be used to tailor RIS in KS patients. Although EBV and HHV8 are both y- 
herpes viruses and share similar patterns of gene expression, HHV8 is unable to 
immortalise cells in vitro, in the absence of EBV (Kliche et a l., 1998). Therefore 
HLA class I restricted HHV8 peptide pools would have to be used as the antigen 
source, limiting the assay to patients with HLA types for which epitopes are known. 
Another factor that would also need to be considered is that the efficiency o f peptide 
presentation by APCs from HHV8-positive patients may be compromised because 
the virus is known to suppress cell surface expression of HLA class I molecules by 
reducing TAP expression (Brander et al., 2000; Guihot et al., 2006).
In summary the work described in this thesis has shown that a simple intracellular 
assay to detect IFN-y producing EBV-specific T cells is able to measure EBV 
immunity in healthy individuals and patients with EBV-driven malignancies, and 
that it could be applied clinically to assist with treatment related decisions.
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Appendix 1.1
Clinical Staging of Hodgkin’s and Non-Hodgkin’s Lymphomas (Ann Arbor 
Classification)
Stage Distribution o f  Disease
I Involvement o f a single lymph node region (I) or involvement o f a 
single extra lymphatic organ or site (IE)
II Involvement of 2 or more lymph node regions on the same side of 
the diaphragm alone (II) or with involvement o f limited contiguous 
extra lymphatic organ or site (IIE)
III Involvement of lymph node regions on both sides o f the diaphragm 
(III), which may include the spleen (IIIS) and/or limited contiguous 
extra lymphatic organ or site (IIIE, HIES)
IV Multiple or disseminated foci of involvement o f one or more extra 
lymphatic organ or site (IIIE, HIES)
All stages are further divided on the basis o f the absence (A) or presence (B) o f the 
following systemic symptoms: fever (>38°C), night sweats, or weight loss o f greater 
than 10% o f body weight.
Adapted from (Carbone et al., 1971).
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Appendix 1.2
Karnofsky Scale
Scale (%) Description
100 No complaints; no evidence of disease
90 Able to carry on with normal activity; minor signs or 
symptoms o f disease
80 Some signs or symptoms of disease with effort
70 Cares for self; unable to carry on with normal activity or to 
do active work
60 Requires occasional assistance but is able to care for most 
personal needs
50 Requires considerable assistance and frequent medical care
40 Disabled; requires special care and assistance
30 Severely disabled; hospitalisation indicated, although death 
not imminent
20 Very sick; hospitalisation necessary; requires active 
supportive treatment
10 Moribund; fatal processes progressing rapidly
0 Dead
Adapted from (Karnofsky and Burchenal, 1949)
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Appendix 1.3
Response evaluation criteria in solid tumours: RECIST criteria
Response
Complete response (CR) 
Partial response (PR)
Stable disease (SD) 
Progressive disease (PD)
Disappearance of all target lesions; 
confirmed at 4 weeks.
At least 30% reduction in the longest 
diameter (LD) of a single tumour or the 
sum of the LD o f multiple lesions, 
taking as reference the baseline study; 
confirmed at 4 weeks.
Neither PR or PD criteria are met.
At least 20% increase in the LD of a 
single lesion or the sum of the LD of 
multiple lesions, taking as reference the 
smallest LD or the sum of the LDs 
recorded since treatment started, or 
appearance of new lesions.
Adapted from (Therasse et al., 2000).
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Appendix 1.4
GAPDH Primers
Forward primer: gtc aga cgc ate ttc ttt t
Reverse primer: ate gee cca ctt gat ttt
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Appendix 1.5
Serial m easurem ent of EBV-specific T cell responses in EBV-positive and EBV- 
negative PTLD patients
EBV +1
T cell analysis 
(upper panel)
•  HLA class II
▼ Autologous B-LCL
Multiple HLA matched B-LCL
♦  HLA mismatched B-LCL 
■  Peptide pool
A  Irrelevant peptide
PTLD treatment regime 
(lower panel)
□  Creatinine 
▼ Cyclosporin A 
A  Azathioprine 
0  Prednisolone 
♦  Mycophenolate mofetil 
■  Tacrolimus
Time from diagnosis (months)
Serial EBV-specific T cell responses in Patient EBV* 1.
Patient EBV* 1 presented with an EBV-positive tumour 129 months following renal transplant. He 
was treated with surgery and RIS and had a complete response to treatment. Figure A shows a rise in 
the number of EBV-specific T cells on stimulation with an multiple HLA-matched LCL compared to 
an HLA-mismatched LCL during treatment The response to stimulation with an HLA class I 
restricted EBV peptide pool also increased during treatment compared to an EBV peptide restricted 
through an irrelevant HLA allele (irrelevant peptide), but this was less than the response seen after 
stimulation with autologous LCLs. Cell surface expression of the lymphocyte activation marker 
MHC class II also increased during treatment. Figure B shows the RIS schedule and serial creatinine 
measurements.
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Serial EBV-specific T cell responses in Patient EBV+ 2
Patient EBV+ 2 presented with an EBV-positive tumour 4 months after renal transplant. He was 
treated with RIS followed by rituximab and chemotherapy, but died on treatment before a clinical 
response could be achieved. Figure A shows high numbers of EBV-specific T cells on stimulation 
with a multiple HLA-matched LCL compared to a HLA-mismatched LCL following treatment with 
RIS. The absolute cell numbers of CD8+ T cells expressing MHC class II also increased during 
treatment
RIS data was not available for this patient.
271
Appendices
.i’ d!»o3 X
-0.20
ro.15
-0.10
-0.05 l
xo
0.00
T cell analysis 
(upper panel)
•  HLA class II
▼ Autologous B-LCL
♦  HLA mismatched B-LCL 
■  Peptide pool
A Irrelevant peptide
13
B Radiotherapy
175-1 r700
-600125-
-500
75-
-400
25-
10-r
-300
-200
-100
0 5 5 6 7 8 9 10 11 12 13
PTLD treatment regime 
(lower panel)
□
▼
▲
Creatinine 
Cyclosporin A 
Azathioprine 
Prednisolone
Time from diagnosis (months)
Serial EBV-specific T cell responses in Patient EBV+6.
Patient EBV+6 presented with an EBV-positive tumour 216 months following renal transplant. He 
was treated with RIS and radiotherapy and had a partial response to treatment. Following this he 
developed hydronephrosis and renal failure, and died 12 months after PTLD diagnosis. Figure A 
shows a rise in the absolute number of EBV-specific T cells on stimulation with an autologous LCL 
compared to an HLA-mismatched LCL during treatment with RIS. This trend was mirrored by the 
response obtained after stimulation with HLA class I restricted EBV peptide pools. The magnitude of 
the response using peptides however was less than that with autologous LCLs. The number of CD8+ 
T cells expressing the lymphocyte activation marker MHC class II remained the same for the first 
nine months after diagnosis during treatment with RIS and then fell in conjunction with the number 
of EBV-specific T cells prior to death. Figure B shows the RIS schedule and serial creatinine 
measurements.
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Serial EBV-specific T cell responses in Patient EBV* 7.
Patient EBV* 7 presented with an EBV-positive tumour 39 months following renal transplant. He was 
treated with RIS followed by cytotoxic chemotherapy and had a partial response to treatment. Figure 
A shows a fall in the absolute number of EBV-specific T cells on stimulation with a 3 allele HLA 
class I matched LCL and an HLA class I restricted EBV peptide pool during treatment compared to 
the relevant negative controls. The magnitude of the response using the peptide pool was however 
less than that with the autologous LCL. The number of CD8* T cells expressing the lymphocyte 
activation marker MHC class II also fell during treatment. Figure B shows the RIS schedule and 
serial creatinine measurements.
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Serial EBV-specific T cell responses in Patient EBV + 8.
Patient EBV + 8 presented with a PTLD tumour 58 months following renal transplant. He was treated 
with RIS followed by cytotoxic chemotherapy and had a partial response treatment but died due to 
neutropenic sepsis. Figure A shows an increase in the absolute number of EBV-specific T cells on 
stimulation with a multiple HLA-matched LCL compared to an HLA-mismatched LCL during 
treatment with RIS. The number of CD8+ T cells expressing the lymphocyte activation marker MHC 
class II also increased during treatment. Figure B shows the RIS schedule. Serial creatinine 
measurements were unavailable.
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Serial EBV-specific T cell responses in Patient EBV  a.
Patient EBV a presented with an EBV-negative tumour 150 months following renal transplant. She 
was treated with RIS and rituximab and had a complete response to treatment. Figure A shows no 
rise in the number of EB V-specific T cells on stimulation with an autologous LCL or a multiple 
HLA-matched LCL compared to an HLA-mismatched LCL during treatment with RIS. The number 
of CD8+ T cells expressing the lymphocyte activation marker MHC class II was also unchanged. 
Figure B shows the RIS schedule and serial creatinine measurements.
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Serial EBV-speciflc T cell responses in Patient EB V 'd
Patient E B V 'd  presented with an EBV-negative tumour 143 months following renal transplant. He 
was initially treated with RIS but had no clinical response. He was then treated with 6 cycles of 
chemotherapy and had a complete clinical response. Figure A shows no consistent rise in the number 
of EBV-specific T cells on stimulation with an autologous LCL and a 3 allele HLA class I matched 
LCL compared to an HLA-mismatched LCL during treatment with RIS. There was also no consistent 
rise in the number of CD8+ T cells expressing the lymphocyte activation marker MHC class II. 
Figure B shows the RIS schedule and serial creatinine measurements.
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